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ABSTRACT 
Structure-Activity Relationships of Retinoids 
in Developmental Toxicology 
by 
W. Brian Howard, Doctor of Philosophy 
Utah State University, 1988 
Major Professor: Dr. Raghubir Sharma 
Department: Toxicology 
The teratogenic potency of retinoid analogs was determined in Syrian 
hamsters and compared to the teratogenic potency of all-tmru.-retinoic acid 
(all-tmru.-RA, ED5o = 10.5 mg/kg). A total of 15 analogs having variations in 
the cyclohexene ring were evaluated following various amounts of single oral 
doses on day 8 of gestation. Retinoids containing a five- or six-membered 
ring were as teratogenic as all-tmru.-RA, provided they had sufficient lipophilic 
substituents on the ring. The same pattern emerged for retinoids that had 
six-membered aromatic ring substitution for the natural cyclohexene ring of 
vitamin A. Incorporation of a supplementary aromatic ring in the side-chain 
adjacent to a gem-dimethyl-hexene ring resulted in an increase in 
teratogenicity by IS-fold compared to all-tmru.-RA. Major modifications of the 
cyclohexene ring can be made without altering teratogenic activity. The ring 
need not be six-membered and can have decreased lipophilicity through the 
incorporation of polar groups compared to all-tmru.-RA, but must have 
sufficient lipophilic substituents to provide the necessary mass for interaction 
with the retinoid receptor. Incorporation of a supplementary aromatic ring 
xii 
adjacent to a gem-dimethyl-hexene ring facilitated 11-electron delocalization 
and restricts side-chain flexibility , thereby increasing teratogenic potency. 
The pharmacokinetic disposition of 8 retinoids was investigated. Pregnant 
hamsters were dosed orally with all-trans-RA, 13-ill-retinoic acid, all-!mru.-4-
oxoretinoic acid, 9-ill-retinal , all-!mru.-retinyl acetate, ]::i-ethyl-all-!mru.-
retinamide, ]::i-ethyl-13-ill-retinamide, and arotinoid. 
retinamides was one-tenth that of the free acid 
The bioavailability of the 
retinoids . The plasma 
elimination half-life for all-!mru.-RA was 0.5 h. For 13-ill-retinoic acid and 
all-!mru.-4-oxoretinoic acid the elimination half-lives were 4.4 and 5.7 h, 
respectively. 
The binding affinity of various retinoids to cellular retinoic acid-binding 
protein (cRABP) was determined in day-12 hamster fetuses. Fetal supernatants 
from the 105,000x g fraction were incubated with high specific-activity [3H)-
all-!mru.-RA in the presence of various concentration of unlabeled retinoids 
with subsequent isolation of cRABP by size-exclusion HPLC. Teratogenic 
retinoids, or acidic metabolites of teratogenic retinoids bound to cRABP 
whereas nonteratogenic retinoids failed to bind. 
(181 pages) 
xiii 
CHAPTER I 
STATEMENT OF PROBLEM 
The retinoids constitute a large group of synthetic and naturally 
occurring compounds similar in structure to retinol (vitamin A). Several 
retinoids are used clinically for treatment of recalcitrant cystic and conglobate 
acne, Darier's disease, pustular psoriasis , lichen ruber planus, basal cell 
carcinoma, keratoacanthoma and melanoma (Peck, 1982; Orfanos, 1980). In 
mice certain retinoids exert a therapeutic influence on chemically-induced 
papillomas and carcinomas of the skin (Bollag, 1975), and in rats certain 
retinoids prevent cancer of the urinary bladder (Sporn et al. , 1977) and 
mammary gland (Moon and McCormick, 1982; Hartmann and Bollag, 1985). 
The toxicology of the retinoids in humans and animals has been reviewed 
(Howard and Willhite, 1986). Adverse effects of retinoids are usually limited 
to such dermatologic disorders as alopecia, chelitis, exfoliation, dermatitis, 
conjunctivitis, paronichia, pruritis, and xerosis. However, when certain 
retinoids are administered at therapeutic dose levels to women in the first 
trimester of gestation, the developing embryo can be severely damaged 
(Willhite et al., 1986). Isotretinoin (AccutanP; 13-m-retinoic acid; 13-ill-RA) 
and etretinate (Ro 10-9359, Tigasod&) can induce severe malformations in 
human infants, including dysmorphia of the face, of the central nervous 
system, of the urogenital system, of the cardiovascular system, and of the 
axial and appendicular skeleton (Willhite et al., 1986; Happle et al., 1984). The 
teratogenic effects of retinoids in Syrian golden hamsters have features in 
common with those observed in humans, who are approximately 16 times more 
sensitive (on a mg/ kg basis) to the teratogenic effects of 13-ill-RA than 
hamsters (Willhite et al. , 1986). 
The retinoids exhibit large variations in their teratogenic potencies in 
animals. Such conformationally restricted retinoids as the retinoidal benzoic 
acid derivative Ro 13-6298, containing one or two supplementary rings in their 
side chains, are 10-1,000 times more potent teratogens in hamsters than all-
lrillli-retinoic acid (all-lrillli-RA) (Flanagan et a!., 1987). Ro 13-6298 is 1,000 
times more potent at induction of cartilage resorption in rat embryonic limb 
buds than tetraene retinoids (Kistler, 1985), and it is at least 130 times as 
embryolethal as all-lrillli-RA in hamsters (Flanagan et a!., 1987). Retinamides 
and retinylidene 1 ,3-diketones contain modifications of the polar terminus of 
the vitamin A molecule, and these retinoids are devoid of teratogenic activity 
in hamsters (Willhite et a!., 1984). These differences may be related to 
absorption from the gut, biotransformation patterns, pharmacokinetic or 
disposition differences, differential placental permeabilities, or differential 
binding affinities with embryonic cellular retinoic acid-binding protein (cRABP). 
Proposed mechanisms of retinoid action have included amphipathic 
membrane alterations via non-specific, detergent-like disruption (Fell and 
Dingle, 1963), glycosylation of cell surface glycoproteins via formation of 
retinyl mannose phosphate intermediates (De Luca et a!., 1979), and activation 
and suppression of the genome (Sporn and Roberts, 1983). Retinoid-induced 
teratogenicity cannot be due to non-specific membrane disruption, because 
retinoids containing a hydrophilic carboxyl terminus, a 9-carbon flexible side 
chain, and a B-cyclogeranylidene ring failed to induce terata (Willhite, 1986). 
Nor can retinoid toxicities be attributed to involvement in sugar transfer 
reactions, as the retinoidal benzoic acid derivative Ro 13-6298 does not 
participate in retinyl phosphate mannose pathways (Sporn and Roberts, 1983). 
Several research groups have provided biochemical data on retinoid 
control of cellular proliferation. When retinoic acid was used to induce 
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differentiation in cultured HL-60 cells, it suppressed expression of the !!!.Y£ 
oncogene, a nucleotide sequence considered to be involved in excessive 
proliferation of HL60 cells (Sporn and Roberts, 1983 ). Omori and Chytil ( 1982) 
demonstrated that feeding retinyl acetate, retinoic acid, or 3, 7,11,15-
tetramethyl-2,4,6, 10, 14-hexadecapentaenoic acid (a synthetic retinoid) to 
retinol-deficient rats suppressed production of a 22 kDa protein; whereas 
retinoic acid and the synthetic retinoid both induced production of a 55 kDa 
protein. It appears from these results that retinoids modify cellular gene 
expression (Sporn and Roberts, 1983; Omori and Chytil, 1982). Chytil and Ong 
(1979) have put forth the hypothesis that retinoids are bound in the cytosol by 
either cellular retinol-binding protein (cRBP)(if an alcohol) or cRABP (if an 
acid) and are subsequently transported into the nucleus where they can modify 
gene expression. 
Cellular retinoic acid- binding protein has been identified in all fetal rat 
tissues (except in serum, where all-trans-RA is transported bound to plasma 
albumin), in the intestine, brain, and kidney of the fetal rabbit, in limb buds 
of the mouse, and in embryonic. chick skin (Chytil and Ong, 1983; Rainier et 
al., 1983; Kwarta et al., 1985). In the mouse limb bud, all-lli!lli.-RA has a 315-
fold greater affinity for cRABP than 13-ili-RA (Kwarta et al., 1985). Because 
the teratogenic effective dose 50 (ED 5o) is 22.3 and 10.5 mg/kg for isotretinoin 
(13-ili-RA) and all-!rlllli.-RA, respectively, and because the dose-response 
curves are parallel, it can be concluded the 13-ili-RA is approximately one-
half as potent a teratogen as all-t.mM-RA in hamsters (Willhite and Shealy, 
1984). And 13-ili-RA is four to eight times less embryopathic than all-lli!lli.-
RA in the mouse (Kochhar et al., 1984b). However, it is unknown if binding 
to cRABP is obligatory for teratogenic activity. The dose-response curves for 
induction of terata by retinoids in the hamster are parallel, suggesting a 
common embryotoxic mechanism of action . The structural requirements for 
teratogenic activity of retinoids in hamsters were primarily dependent upon the 
presence of, or biotransformation to, a free carboxyl or other moiety with an 
equivalent pKa at C 15 for the polar terminus , not upon the stereochemistry 
about Cl3, or C9, nor upon the size of the molecular substituent at Cl5. For 
the polyene side-chain, retinoid activity was dependent upon a carbon side-
chain of more than 5-carbon atoms, upon conservation of the curved, 
hydrophobic plane and upon preservation of 7T -electron delocalization across 
the polyene chain (Willhite et at., 1 984; Willhite, 1986). 
SPECIFIC AIMS 
This research was designed to determine some of the structural 
requirements of the vitamin A molecule for induction of terata in hamsters. 
The project also focused upon the contribution of some of the maternal and 
embryonic factors (i.e . pharmacokinetics, placental permeability, distribution, 
and disposition) in retinoid-induced teratogenesis. In addition, a study 
clarifying the possible role of cRABP as it pertains to the differences in the 
potencies of retinoid-induced terata is presented. 
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CHAPTER II 
TOXICITY OF RETINOIDS IN HUMANS AND ANIMALS: 
A LITERATURE REVIEW 
INTRODUCTION 
As early as ancient Egypt it was recognized that poor nutrition caused 
night blindness, and as a result vitamin A was the first vitamin identified. 
Today retinoids are useful in treatment of punctate keratopathy, corneal 
xerosis, refractory cystic and conglobate acne, xerophthalmia, psoriasis, and 
keratomalacia (Ubels and Edelhauser, 1982; Ubels et al., 1983). Large scale 
administration of massive doses (200,000-300,000 I.U.) of vitamin A has been 
carried out in prophylaxis of nutritional blindness secondary to corneal 
xerophthalmia and keratomalacia (Vijayaraghaven et al., 1984). The history, 
industrial synthesis, metabolism, physiologic roles, transport mechanisms, 
characteristics, functions of extra-and intra-cellular binding proteins, and the 
possible mechanisms of action of retinol, the retinyl esters, retinoic acid, and 
their analogs have been the subjects of numerous reviews (Lotan, 1980; Wolf, 
1984; Sporn et al. , 1984; Goodman, 1984). The present work is a summary of 
the acute and chronic toxicity of vitamin A and its synthetic congeners, 
collectively termed the retinoids. 
The retinoids comprise a large group of synthetic and naturally occurring 
compounds, similar in structure to retinol (vitamin A) . Retinol is an essential 
nutrient for visual dark adaptation, bone growth, reproduction, embryonic 
development, and differentiation of epithelial tissues. The importance of 
vitamin A in the development of cancer was recognized as early as 1926, when 
Fujimaki ( 1926) reported that rats fed a diet deficient in vitamin A developed 
stomach carcinomas. However, it was not until 1963 that Lasnitzki showed 
that vitamin A could prevent or revert the transformation of prostate 
secretory cylindrical epithelium into dysplastic, hyperplastic, and metaplastic 
tissues produced by carcinogenic hydrocarbons. 
These findings led others to investigate the role of vitamin A in 
dermatology and oncology (Bollag, 1970; Mayer et al. , 1978; Sporn and Newton, 
1979). Due to the highly toxic side effects of naturally occurring forms of 
vitamin A (hypervitaminosis A) at therapeutic dose levels, their clinical use has 
been limited. In an effort to divorce the toxic side effects from clinical 
effectiveness, over 1,500 retinoids have been synthesized (Lucek and Colburn, 
1985). Some of these are in clinical use for treatment of recalcitrant cystic 
acne, Darier's disease, pustular psoriasis, lichen ruber planus, basal cell 
carcinomas, keratoacanthomas, and melanomas. Certain retinoids exert a 
therapeutic influence on chemically induced papillomas and carcinomas of the 
skin of mice (Bollag, 1975) and prevent carcinogenesis in the urinary bladder 
(Sporn et al., 1977) and mammary gland (Moon and McCormick, 1982; Hartman 
and Bollag, 1985) of rats. The use of retinoids in anticancer and dermatologic 
therapy has been reviewed (Bollag, 1979; Cunningham and Ehmann, 1983; Hill 
and Grubbs , 1982; Lauharanta, 1980; 1982; Meyskens, 1983; Orfanos, 1980; Peck, 
1981; Peck, 1982; Sporn and Roberts, 1983). 
HUMAN TOXICITY 
Vitamin A Acute Subchronic 
and Chronic 
The toxicity of naturally occurring retinoids was reviewed as early as 
1953 by Knudson and Rothman. Other than ingestion of bear, halibut, cod 
liver or their oils, vitamin A toxicity (hypervitaminosis A) due to foodstuffs is 
rare. However, self medication or consumption of vitamin A supplements can 
6 
lead to dizziness, anorexia, headache, weight loss, increased cerebrospinal fluid 
(CSF) pressure, and skin peeling. The required dail y amount is 5,000 I.U . and 
signs of toxicity occur at 25,000-100,000 I.U./ d. Excessive intake also causes 
gastrointestinal distress, fatigue , insomnia, menstrual disorders, and bone and 
joint pain. Bone resorption, periosteal calcification with osteocytic osteolysis, 
and hypermineralization have occurred (Eaton, 1978; Jowsey and Riggs, 1968; 
Gerber eta!., 1954). 
The toxicity is dose-related , and chronic toxicity often has more profound 
effects than a single bolus dose. 
severe than in adults given an 
The toxicity in children is generally more 
equivalent dose . Acute ingestion of 
300,000-350,000 I.U. of vitamin A by children induced acute hyd rocephalus with 
obvious bulging of the fontanel within 12 h (Ehrengut , 1955; Marie and See, 
1954). Additional signs of intoxication include vomiting, restlessness, diarrhea, 
and insomnia. Cerebrospinal fluid hypertension may underlie acute 
hydrocephalus, as removing a small amount of CSF decreased the intensi ty of 
the hydrocephalus (Marie and See, 1954). Some cases of idiopathic benign 
intracranial hypertension (pseudotumor cerebri) have been attributed to retinoid 
intoxication, especially in children (Farris and Erdman, 1982). Acute 
intraventricular hemorrhage could be a consequence of retinoid-induced 
hydrocephalus (Ehrengut, 1955). 
In adults, toxicity is most often manifest in dermatologic changes, 
alopecia, migratory bone and joint pain, headache, and such ps yc hic changes as 
nervousness and irritability. Symptoms abate as ingestion of the retinoid is 
reduced or discontinued. Krause (1965) found elevated circulating trigl yceride 
levels, but no signs of overt retinoid poisoning in an elderly male who ingested 
50,000 I.U. vitamin A/ d for 17 years. At autopsy, the liver contained 5.4 g of 
retinol. Chronic hypervitaminosis A in humans also causes elevated plasma 
alkaline phosphatase acti vi ty (Smith and Goodman, 1976), a pathologic condition 
indicative of bone toxicity. Class ic signs of vi tamin A intoxication appeared in 
20-year-old woman who ingested 50,000 I.U. vitamin A/ d for 2 years. 
Hepatomegaly, parenchymal disease , portal hypertension, elevated CSF pressure, 
headache, enhanced alkaline phosphatase and glutamic oxalacetic transaminase, 
and increased prothrombin time were associated with a circulating retinol 
concentration of 12.8 pg/ ml (normal 5 ± 1.5 pg/ ml). Mucocutaneo us side 
effects included a diffuse scaling erythematous dermatitis and soft palate 
petechiae (Anonymous, 1982). 
Hepatic degeneration and alterations in fat metabolism occur in retinoid 
intoxication. Hepatic fibrosis and fatty liver accompanied elevations in total 
serum lipids in women ingesting 100,000-300,000 I.U. vitamin A/ d for up to 9 
years (Muenter et al., 1971 ). After 8 days, serum triglyceride concentrations 
doubled , and these elevations persisted for 9 weeks after cessation of oral 1.0 
x 106 I.U. vitamin A/ d (Dicken, 1981). Retinoids do not appear to elic it 
systemic toxicity following topical application, but the limiting factor is 
retinoid-induced skin irritation (Grice et al. , 1973; Ashton et al., 1971). 
Synthetic Retinoids Acute 
Subchronic and Chronic 
The synthetic retinoids share similar side effects with those induced by 
hypervitaminosis A, and toxicity depends upon the structure of the retinoid 
and its dose. Acute toxicity is relatively rare; in one instance, a young man 
(82 kg) ingested 2.04 kg of 13-lli-retinoic acid (13-cis-RA, isotretinoin , 
Accutan~) over a 2-day period (Sutton, 1983). The only signs of retinoid 
intoxication reported were dry lips and scattered areas of dry skin. Routine 
liver function tests, hematology, and urinalysis failed to reveal abnormalities 
(Sutton, 1983). The most common side effects observed after prolonged 
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treatment with oral 13-lli-RA were mucocutaneous dryness (chelitis), cutaneous 
desquamation, alopecia, epistaxis , and conjunctivitis (Pawson et al., 1982). 
Gastrointest inal distress was reported by 20% of the patients; 15% reported 
musculoskeletal signs; 10% felt lethargic; and 10% experienced headache. 
Chronic 13-lli-RA treatment caused elevation of serum triglycerides (very low 
density lipoprotein; VLDL) (Katz et al., 1980). Elevated serum triglycerides 
and enhanced sedimentation were found in 25 and 50% of the patients, 
respectivel y (Pawson et al., 1982). Ten percent of the patients treated with 
etretinate developed hypertriglyceridemia (Elias and Williams, I 981 ). 
Although no consistent changes in skin triglyceride concentrations were 
found in patients treated with oral 13-ffi- RA, surface cholesterol increased, 
and wax esters and squalene decreased, perhaps due to decreased sebum 
production (Strauss et al., 1980). In a study of 53 patients receiving 
mg/ kg/ d 13-ffi-RA for treatment of acne, mean triglyceride levels rose from 
80 mg/ dl to 103 mg/ dl in women, and from 82 mg/ dl to 129 mg/ dl in men after 
four weeks of treatment. Triglyceride levels remained elevated through the 
20th week of therapy. Plasma cholesterol levels also increased in women and 
men by four weeks and remained elevated through the 20th week of therapy. 
High density lipoprotein (HDL) cholesterol levels initially decreased in women 
and men by the fourth week and remained suppressed through the 20th week. 
Low density lipoprotein (LDL) cholesterol levels rose in women and men by the 
fourth week. In men, LDL decreased to baseline levels by the eighth week , 
but the women's LDL cholesterol levels remained elevated. All parameters 
returned to baseline levels within eight weeks post-treatment. The authors 
cautioned that treatment which resulted in prolonged changes in plasma 
lipoproteins could increase the risk of cardiac disease (Bershad et al., 1985). 
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Pittsley and Yoder (1983) described four cases of skeletal toxicity 
associated with long-term administration of 13-cis-RA to control ichthyosis. 
Two of the cases received 3 mg/ kg/ d, one case 4 mg/ kg/ d; the other dose was 
not reported. All four, who had been treated for at least two years, suffered 
from an ossification disorder similar to idiopathic skeletal hyperostosis. 
Arthraglias were relieved with discontinuation of the treatment, but 
ossification did not regress. 
Two men with metastatic melanoma were treated with 0.002 mg/ kg/ d for 
eight weeks of the aromatic retinoid (arotinoid) p-[(J::.)-2(5,6,7,8-
tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]-benzoic acid ethyl ester (Ro 
13-6298). The effects of Ro 13-6298 on normal skin after eight weeks of 
treatment consisted of minor epidermal alterations (Tsambaos and Orfanos, 
1982). Tsambaos and Orfanos (1983) described two cases (a woman and a man) 
of severe psoriasis and psoriatic arthritis. Each case failed to respond to 
conventional therapy, including etretinate, but responded favorably to 0.002 
mg/ kg/ d of Ro 13-6298. Side effects were limited to dry lips and nasal 
mucosa, palmarplantar desquamation in both cases, and skin thinning, transient 
hair loss, and itching in one case . In one case the erythrocyte sedimentation 
rate (ESR) was slightly elevated. Biochemical and hematological parameters 
were not altered by arotinoid treatment, serum cholesterol levels decreased, 
and serum triglycerides remained constant in one case. Subsequent to 
arotinoid treatment in the other case, pathologically high levels of alkaline 
phosphatase and Y -glutamyltransferase levels returned to normal. Serum 
triglycerides and cholesterol levels were unchanged and slightly increased, 
respectively (Tsamboas and Orfanos, 1983). 
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Dysmorphogenicity 
Most aspects of retinoid toxicity can be controlled by adjusting the dose 
and/ or regimen of ingestion. The teratogenicity of retinoids is the most 
serious aspect of their toxicity because of the permanency of damage to the 
human embryo. The susceptible period for teratologic damage occurs prior to 
the time a woman suspects the pregnancy. 
lsotretinoin (13-ffi-RA) administered orally during the first trimester of 
pregnancy has resulted in 34 cases of fetal teratology and 30 cases of 
spontaneous abortion in humans (Willhite et al., 1986). Lammer et al. (1985) 
studied 154 cases of embryonic and/ or fetal exposure to isotretinoin; exposure 
was associated with a relative risk of 25.6% (95% confidence interval 11.4 to 
57 .5). Outcomes of the 154 cases were: 95 elective abortions, 12 spontaneous 
abortions, 21 malformed infants, and 26 infants without major malformations. 
The dosage and critical period of exposure during embryogenesis resulting in 
human terata have not been precisely determined. Willhite et al. ( 1986) 
compared the susceptible period of human embryogenesis of a malformed infant 
whose mother received 1.37 mg/ kg isotretinoin per day through the fifth week 
of gestation (day 42) with the gestational age of isotretinoin-treated hamster 
embryos. A critical stage of development in the hamster is on day 8, when 
the hamster embryo has 10-14 somites. The equivalent period of human 
embryogenesis occurs within stages 8-12, days 18-26. The infant discussed 
above was treated within the critical period to stage 15 and exhibited a 
variety of dysmorphia. Figures 11.1, 11.2, and 11.3 are photographs of the 
infant described above (see figure legends for explanations). The dose, period 
of exposure, and dysmorphogenicity of observed human terata for infants 
exposed to isotretinoin are summarized in Table 11.1 . 
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Figure 11.1. Male infant whose mother was exposed to 80 mg isotretinoin/ d 
( 1.37 mg/ kg/ d) through day 42 of gestation. Note the depressed nasal bridge, 
micrognathia, and orbital hypertelorism. The infant also had a cleft of the 
soft and hard palates. (From Willhite et al., 1986, used with permission.) 
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Figure 11.2. Superior view of infant in figure 11.1. Note the triangular-shaped 
cranium and the narrow frontal bone. (From Willhite et al., 1986, used with 
permission.) 
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Figure 11.3. Side view of infant in figure 11.1. Note the micrognathia, absent 
external auditory meatus, and the low-set rudimentary pinna. (From Willhite et 
al., 1986, used with permission.) 
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TABLE 11.1 
DYSMORPHIA OF HUMAN INFANTS EXPOSED TO ISOTRETINOIN 
Exposure 
Isotretinoin 
40 mg/ d 
14-65 d 
Isotretinoin 
80 mg/ d 
0-42 d 
Dysmorphia 
~: depressed nasal bridge 
~: low set right pinnae, skin tags, 
atretic canal 
Skull: low hairline on forehead, 
bilateral asymmetrical parietal sutures 
CNS: leptomeningeal cyst, cerebellar 
vermis absent, cerebellum small, hetero-
topic neural tissue, hippocampal gyri 
small, depleted malformed spinal tract, 
inferior olive malformed, ventricles 
dilated 
Cardiovascular system: complete trans-
position of the great vessels, ventri-
cular septal defect, right subclavian 
artery distal to the left and right 
atrium and ventricle distended, super-
ior vena cava congested, 
Other: skin thick at neck . 
~: depressed nasal bridge, hyper-
telorism, micrognathia, left facial 
paralysis 
~: did not follow, visual evoked 
potential abnormal, flat orbital ridges 
Ears: bilateral ear tags at angle of 
mandibile, absent external canals, 
latency in auditory brain stem response 
Palate: cleft palate, only palatal 
ridge present 
Skull: triangular skull, narrow slop-
ing forehead , prominent occiput 
Muscletone: decreased tone and mass 
in lower extremities 
Genitourinary: large scrotal sac 
Cardiovascular system: ventricular 
septal defect, aortic stenosis, pul-
monary stenosis, dysplastic pulmonary 
and aortic valves 
Other: simean crease on left hand, res-
piratory distress, feeding problems 
Reference 
Braun et al. , 
1984 
Hill, 1984 
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Exposure 
Isotretinoin 
20 mg/d 
0-49 d 
lsotre tinoin 
50 mg/d 
0-49 d 
lsotretinoin 
80 mg/d 
0-49 d 
TABLE 11.1 (CONTINUED) 
Dysmorphia 
Face: depressed nasal bridge, micro-
gnathia, anteverted nares 
~: small palpebral fissures deep 
orbits, did not follow , microphthalmia 
£llli: low set, small undifferentiated 
ear, absent helix, small ear canal 
Skull: prominent forehead, large 
anterior occiput 
Muscletone: hypotonic 
l:NS: hydrocephalus, V -P shunt 
Cardiovascular system: teratology of 
Fallot, right vetricular prominence 
Other: feeding difficulties, meningitis 
~: anteverted nares, prominent 
nose, thin lips, micrognathia, de-
pressed nasal bridge 
~: small palpebral fissures, deep 
orbits, hypertelorism, microphthalmia 
Ears: low set, small undifferentiated, 
absent helix 
Palate: hard and soft cleft palate 
Skull: brachycephaly, low posterior 
hair line 
Muscle tone: floppy 
l:NS: Dandy-Walker of posterior fossa, 
V -P shunt, seizures 
Other: assisted ventilation, respira-
tory distress, apnea, repeated infections 
~: micrognathia 
~: antimongoloid slant to fissures, 
hypertelorism 
£llli: right ear atretic, small pennae, 
hypoplastic left external meatus 
Palate: U -shaped cleft palate 
Skull: distorted occiput, anterior 
lateral displacement of pareital whorl 
Muscle tone: flaccid 
Pulmonary: incomplete lobulation of 
left lower and right middle lobes 
Reference 
Benke, 1984 
Benke, 1984 
Fernhoff and 
Lammer, 1984 
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Exposure 
lsotretinoin 
80 mg/ d 
0-49 d 
lsotretinoin 
Dose unknown 
ca. 28-42 d 
lsotretinoin 
40 mg/d 
0-105 d 
TABLE 11.1 (CONTINUED) 
Dysmorphia 
~: ventricles mildly dilated, hypo-
plastic cerebellum with absent vermis, 
abnormal migration of neural cells in 
cerebellum 
Cardiovascular system: large ventri-
cular septal defect, double outlet right 
ventricle, interrupted aortic arch, 
truncus arteriosis, patent ductus arteri-
osis, left and right subclavian arose 
from descending aorta 
Other: deep plantar creases 1st, 2nd, 
and 2nd, 3rd toes . 
&_m: microphthalmia 
Ears: bilateral rudimentary pinnae, 
absent 8th nerve function 
Sbill: microcephaly 
Genitourinary: attenuated nephrogenic 
zone 
~: seizures, bilateral grade IV in-
traventricular hemorrhage (IYH) hydro-
cephalus secondary to IVH, lissencephaly 
Cardiovascular System: atrial septal 
defect, ventricular septal defect, aortic 
stenosis, patent ductus arteriosis , hypo-
plasia of ascending aorta, interrupted 
aortic arch 
Q!hll: hyperbilirubinemia, enlarged 
liver with cholestasis, webbed neck 
~: depressed nasal bridge, broad 
nasal tip, thick alae nasi, downward 
turned mouth 
~: hypertelorism, asymmetrical pal-
pebral fissures, left-sided epicanthus, 
no occular pursuit, visual evoked potential 
abnormal 
Ears: low dysplatic, atretic external 
canals, abnormal helices 
Sbill: prominent occiput, hair whorl 
on right vertex, high forehead, asymme-
trical 
Muscle tone: hypotonic 
Reference 
De La Cruz et 
al., 1984 
Lott et al. , 
1984 
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Exposure 
lsotretinoin 
40 mg/ d 
26-46 d 
lsotretinoin 
80 mg/ d 
0-84 d 
lsotretinoin 
1-20 capsules/d 
0-84 d 
TABLE 11.1 (CONTINUED) 
Dysmorphia 
~: aqueductal stenosis, hydrocepha-
lus V -P shunt, dilated cysterna vena 
magna and occipital horns, psycomotor 
retardation. 
Other: dorsiflexed toes, di mp led elbows 
~: rudimentary proximal phalanges 
left hand, no fingers right hand, tibia 
and fibula tapered at ends of right 
leg, absent 2nd and 3rd phalanges of 2nd 
toe of right foot 
Face: limited facial movement 
~: microphthalmia, Doll's eye, 
absent vertical movement 
&!!a: rudimentary pinna, atretic right 
external auditory canal 
~: large cleft palate 
Muscle tone: floppy 
Pulmonary: incomplete lobulation lower 
left and right middle lobes 
~: absent cerebellar vermis, moderate 
hydrocephalus 
Cardiovascular system: ventricular sep-
tal defect, interrupted aortic arch, 
patent ductus arteriosis, truncus arteri-
osis, double outlet ventricle 
~: webbed neck 
&!!a: small and low-set 
l:NS: hydrocephalus with posterior 
fossa cyst 
lsotretinoin &!!a: micropinnae, possible occluded 
80 mg/ d external auditory canals 
Exposure unknownl:NS: hydrocephalus 
lsotretinoin Ears: absent external ears, atretic 
Dose unknown external auditory canals 
Exposure unknown Slill!l: microcephalus 
Reference 
McBride, 1984 
Hansen and 
Pearl, 1984 
Rosa, 1984 
Rosa, 1984 
Rosa, 1984 
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The pattern of malformations observed in infants included dysmorphia of 
the face consisting of depressed nasal bridge, micrognathia, small palpebral 
fissures with deep orbits, and orbital hypertelorism. Anteverted nares, 
prominent nose, thin lips, broad nasal tip, thick alae nasi, and downward 
turned mouth have also been reported. Left facial paralysis and limited facial 
movement were observed in some infants. In several cases the eyes were 
microphthalmic. The ears were characteristically displaced ventrally and 
represented by small hypoplastic pinnae or skin tags with an absent helix. The 
external auditory canal was usually atretic or stenotic . Absent 8th nerve 
function was observed in one infant. The forehead was often sloping with a 
narrowing of the biparietal diameter and a prominent occiput resulting in a 
triangular head. Hair whorls were misplaced and skull sutures may have been 
asymmetrical. The hairline was low, and the neck contained lateral skin folds . 
A cleft of the hard and soft palate was usually observed. The auricular and 
facial dysmorphia share a number of anatomical features with the 
Treacher-Collins syndrome (mandibulofacial dysostosis) (Poswillo, 1975). 
Reported malformations of the central nervous system (CNS) are 
hydrancephaly, hydrocephaly, microcephaly, and lissencephaly. Various types of 
obstruction to spinal fluid flow have been reported to cause hydrocephaly (e.g., 
aquaductal stenosis, Arnold-Chiari malformation, 
Dandy-Walker syndrome). One infant suffered 
leptomeningeal cyst, 
from hydrocephaly 
and 
and 
intracranial hemorrhage (De La Cruz et al., 1984). The most consistent 
malformation of the CNS was the absence of the cerebellar vermis with 
abnormal migration of neural cells. Seizures were observed in two cases , but 
the authors considered seizures secondary to other complications (Benke, 1984; 
De La Cruz et al., 1984). 
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Cardiovascular system mal formations have generally consisted of 
overriding aorta, truncus arteriosis, double outlet ventricle, ventricular septal 
defect, patent ductus arteriosis, d ys plastic pulmonary aorta , and the tetralogy 
of Fallot. Infants with conotruncal heart or aortic arch defects suffered from 
ectopic , hypoplastic , or aplastic th ymic abnormalities (Willhite et al., 1986). 
The infants were usually flaccid or hypotonic and did not have normal reflexes. 
They were prone to infection with frequent infections of pneumonia, sepsis, 
and meningitis, and problems with feeding or nursing occurred often. 
Micrognathia and cleft palate were accompanied by respiratory obstruction 
necessitating ventilatory support. In two cases the lungs had incomplete 
lobulation of the lower left and right middle lobe (Table 11.1 ). 
Occasional anomalies of the appendicular skeleton have been observed. 
Anomalies included rudimentary proximal phalanges with oligodactyly, absent 
fingers and toes, tapering of the tibia and fibula, unusual plantar creases 
between the toes, and hypoplastic fingers and nails. Not all pregnant women 
exposed to isotretinoin have resulted in negative outcomes, however (Kassis et 
al., 1985). 
Etretinate (Tigasor®J, the trimethylmethoxyphenyl (TMMP) ethyl ester 
analog of all-!!:l!ill.-retinoic acid (tretinoin, all-trans-RA), is also a human 
teratogen. Happle et al. (1984) reported 19 cases of embryonic and/or fetal 
exposure to etretinate. Ten of the infants were normal; 3 abortuses were 
normal; 3 infants were abnormal; and I fetus from a miscarriage and two 
abortuses were malformed. Craniofacial defects included high arching palate , 
low-set ears, synostosis of cranial sutures, and other malformations of the 
calvaria. In one case abnormal cervical vertebrae were observed. Defects of 
the appendicular skeleton consisted of missing fingers, syndactyly, shortened 
thumbs, malformed hip and ankle joints, and defective forearm bones. 
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Meningoencephalocele, meningomyelocele, and anophthalmia were observed in 
the spon taneous and elective abortuses. The exact doses and duration of 
exposure associated with specific dysmorphia were not presented. The doses 
for the affected infants or fetuses ranged from 11 .0-55.0 mg/d for days 0-45. 
Based on a 55 kg female the teratogenic dose can be estimated to be 0.2 
mgjkg/d. In general, mothers who bore normal children received lower doses, 
and two of the exposures occurred after the period of organogenesis. The 
human teratogenic dose of 0.2 mg/ kg/ d for etretinate compared to a human 
teratogenic dose of 1.37 mg/ kg/ d for 13-lli-RA (Willhite et a!. , 1986) 
demonstrates that etretinate is approximately 7x as teratogenic as 13-lli-RA. 
It is interesting to note that etretinate is at least 4x as teratogenic as 
13-ffi -RA in the hamster (Willhite and Shealy, 1984; Williams eta!., 1984). 
Iso lated reports of vitamin A-induced human terata have not shown 
conclusively that vitamin A is a human teratogen. Berhardt and Dorsey ( 1974) 
reported an infant born to a mother who had taken 25,000 I. U. vi tamin A 
(from fish li ve r oils) from conception through the third month of gestation and 
continued with 50,000 I.U. daily until delivery. The child had a urinary 
obstruction due to aberrant insertion of the ureters and a ureterocele. A 
double collecting system of the left kidney, hydronephrosis, and hydroureters 
were also noted. Another infant whose mother ingested 40,000 I.U. of vi tamin 
A daily between 6 and I 0 weeks of gestation was reported by Pilotti and 
Scorta ( 1965). The infant suffered from hydronephrosis and absent ureteral 
orifices with apical vesicle diverticulum. Strange et a!. (1978) described a 
child with hypopolastic kidneys, small adrenals, and dilation of the cerebral 
ventricle due to stricture of the aqueduct of Sylvius . 
was found to have blood in its skull cavity. 
At autopsy the infant 
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ANIMAL TOXICITY 
Acute Subchronic and Chronic 
The toxicity of retinoids depends upon their route of administration , 
chemical structure, and dose . Single oral doses of retinoids in common 
laboratory animals are generally of low toxicity, with the exception of certain 
conformationally restricted retinoids (arotinoids). There are no marked species 
differences. The acute oral median lethal dose (LDsol in mice ranged from 
6,000 mg/ kg for retinyl palmitate , 4,000 mg/ kg for retinyl acetate , 3,400 mg/ kg 
for 13-lli-RA to 2,200 mg/ kg for all-l!:llM-RA. The oral LDso in mice for the 
aromatic retinoid, etretinate, was greater than 2,000 mg/ kg (Kamm, 1982). 
Hixson and Denine (1978) reported the LDso for all-l!:llM-RA at 31 mg/ kg i.p. 
and 1,100 mg/kg p.o. after 21 consecutive days of administration to mice . In 
contrast, the oral LDso for 13-ill-RA was 26,000 mg/kg and the i.p. LDso was 
140 mg/ kg. The oral LDso of all-l!:llM-RA was approximately 23 times that of 
13-ill-RA, and the lethal oral dose of either all-trans-RA or the 13-ill 
congener was much less after i.p. injection than after oral intubation (36x and 
190x, respectively). 
Common signs of chronic retinoid toxicity in rats and mice included 
cartilage and bone resorption, bone fracture, subcutaneous and internal 
hemorrhage, elevations in CSF pressure, fatty infiltration into hepatic 
parenchyma, and epithelial drying and scaling (Singh et al., 1968; Mallia et al., 
1975). The subchronic and chronic effects of retinoid administration have been 
studied in rats, mice, and dogs. Similar to the toxicity observed in humans, 
reductions in body weight, hair thinning, dermatitis, mucocutaneous lesions, 
elevated alkaline phosphatase, albumin, hemoglobin, erythrocyte count, 
triglyceride levels, and transaminase activity in animals were common. Hepatic 
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pathology and testicular atrophy with interruption of spermatogenesis also 
occurred. Bone fractures, corneal opacity, epiphora, cardiovascular lesions, and 
erythrophagocytosis in lymph nodes were observed after ingestion of relati vely 
high levels for prolonged periods (Kamm, 1982; Teelmann, 1983). For example, 
oral administration of 150-250 mgjkg of all-trans-RA induced alopecia, weight 
loss, and mucocutaneous disorders (Kretzschmar and Leuschner, 1975). Oral or 
i. p. treatment with all-trans- or 13-ill-RA for 21 days was associated with 
epidermal and dermal inflammation and hyperkeratosis in male and female mice 
(Hi xson and Denine, 1978). Testicular necrosis and suppression of 
spermatogenesis occurred in males. 
Retinoid-induced hematologic changes included a dose-dependent 
peripheral anemia, erythrocytopenia, and decreased hemoglobin and packed cell 
volumes. Orally administered retinoids decreased serum albumin and increased 
plasma alkaline phosphatase (Sani and Meeks , 1983). The synthetic retinoids 
(a ll - tra ns- N -eth y lretinamide , all- trans-2-hydroxyethylretinamide, a nd 
all-!.@m-4-hydroxyphenylretinamide) were, in general, less toxic than 
all-trans-RA, but the 13-ill analogs were less toxic than any of the all-!.@m 
forms. At high doses the retinamides also induced subacute, multifocal hepatic 
inflammation, mild hepatocellular vacuolization and hepatic necros is, 
hypertrophy, and cytomegaly. Testicular toxicity included coagulation necrosis 
and arrested development of spermatogonia, spermatocytes, and spermatids. 
Sertoli cells were the last testicular cell population to be affected; th ymic and 
cardiac lesions were reported also (Sani and Meeks, 1983). 
Liver and Lipid Disorders 
The naturall y occurring retinoids are transported from the gut in 
chylomicrons via the portal sys tem and concentrate in hepatocytes (Lo tan , 
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1980; Goodman, 1984; Pawson et al., 1982). Synthetic retinoids tend to 
concentrate in the liver, where a number of pathological and biochemical 
alterations can occur. Treatment of male rats with 100 mg/ kg 13-ill-RA in 
the diet for II weeks reduced hepatic microsomal phosphatidylcholine and 
increased phosphatidylethanolamine concentrations (Alam et al., 1984). The 
activities of the 9-desaturase and 6-desaturase enzymes in rat liver after 
retinol treatment were decreased and increased, respectively (Fell and Steele, 
1982). The enzymatic changes were consistent with decreased hepatic 
concentrations of S-adenosylmethionine, a cofactor responsible for 
phosphatidylcholine synthesis from phosphatidylethanolamine (Fell and Steele, 
1982). Radcliffe (I 983) reported that feeding all-trans- !::1. -4-
hydroxyphenylretinamide at 782 mg/ kg to female rats increased the total liver 
triglyceride and cholesterol concentrations. 
Circulating triglyceride and cholesterol concentrations were increased 
after chronic retinoid treatment as well. Administration of all-!.mM- or 
13-cis-RA to rats induced hypertriglyceridemia (Gerber and Erdman, 1981), in 
addition to changes in the composition of liver fatty acids (Gerber and 
Erdman, 1980). When 13-ill-RA was fed to rats at 300 mg/ kg of diet for 4 
weeks, hepatic phosphatidylcholine 
phosphatidylethenolamine concentrations 
lipid composition and reduction in 
concentrations decreased, 
increased. The changes in 
the double bond index for 
and 
hepatic 
total 
phospholipids suggests decreased conversion of linoleic acid to arachidonic acid, 
possibly mediated though inhibition of microsomal desaturases and 
chain-elongating enzymes (Alam and Alam, 1983). Gerber and Erdman (1982) 
suggested that at least two physiologic mechanisms can account for changes in 
hepatic lipid composition and accumulation. In hypervitaminosis A, adrenal 
cortex hypertrophy and enhanced glucocorticoid synthesis can induce hepatic 
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triglyceride synthesis and decreased fatty acid secretion. The combination of 
excessive synthesis and decreased secretion leads to fatty livers. Additionall y, 
decreased peripheral tissue activity of lipoprotein lipase may contribute to the 
elevations in circulating triglycerides and reductions in cholesterol. 
At physiologic concentrations, retinoids had direct effects on hepatocytes 
(Gerber and Erdman, 1982). Hepatic triglyceride synthesis increased , and 
cholesterol synthesis decreased. Alterations in skin lipids were not considered 
the result of changes in circulating lipids, but they may have been a direct 
consequence of retinoid action on sebaceous glands. The effects of retinoids 
on hepatocytes, however, cannot be attributed to changes in drug-
metabolizing enzymes. Intubation of 1-5 mgj kg/ d of 13-cis-RA or 0.1-0.5 
g/ kg/d of the arotinoid ethyl ester (Ro 13-6298) for up to 28 days failed to 
induce the cytochrome P- 450 system in rats (Goerz et al., 1984). 
Bone and Connective Tissue 
Acute, subchronic, and chronic toxicities of retinoids on bone and other 
connective tissues in laboratory 
administration. Intubation of 
an imals are related to dose and length of 
all-l.!:illli-RA and other naturally occurring 
retinoids induced disturbances in calcium metabolism as evidenced by bone 
thinning , osteoporosis, and calcification of soft tissues (Leelaprute et al., 1973). 
For instance, oral administration in rats of up to 10 mg/kg/d of all-l.!:illli-RA 
for 17 weeks induced osteocytic osteolysis, subperiosteal and osteoclastic 
resorption, and dissolution of bone matrix (Ohern and Goret-Nicaise, 1984). 
Doses of 0.4-10 mg/ kg p.o. in rats for 90 days (Cahn et al., 1975) or dietary 
ad ministration of 300-1,500 I. U. all-l.!:illli-RA for 84 days to rats (Zbinden, 
1975) increased the concentrations of serum alkaline phosphatase, a change 
indicative of increased osteoblast activity. Administration of all-trans- or 
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13-Q.s.-RA for 21 days induced dose-dependent fractures of the long bones, 
dermal and epidermal abnormalities, cartilage degeneration, and elevations in 
plasma alkaline phosphatase (Hixson and Denine, 1978). However, changes in 
alkaline phosphatase were not always associated with bone fractures . Changes 
in connective tissues are often observed in concert with hepatic toxicity, such 
as dose-related decreases in plasma albumin (Hixson et al. , 1979). 
A number of synthetic retinoids have lower acute and chronic toxicities 
than all-~-RA . Treatment with up to 330 mg/ kg retinylidene dimedone 
(all-trans-2-retinylidene-5 ,5-dimethyl-1 ,3-cyclohex anedione) failed to induce 
bone fractures, growth depression, anemia, elevated serum alkaline phosphatase, 
or testicular degeneration induced by daily oral doses of all-trans-RA (Kurtz et 
al., 1984). Kistler and coworkers {1984) found that oral administration of the 
arotinoid ethylsulfone (Rol5-J570; ethyl p-[(E)-2-(5,6, 7,8-tetrahydro-5,5,8,8-
tetramethyl- 2- naphthyl)- propenylphenyl sulfone]) to rats failed to cause 
fractures of the long bones that were induced by oral treatment with 
etretinate or all-.tr.il.M-RA (primarily the distal femur or proximal tibia). Skin 
toxicity (rough coat, erythema, alopecia, and epiphora) and weight Joss , induced 
by subchronic oral doses of the retinoids, were more severe in females than in 
males. The decreased bone toxicity of the arotinoid compared with etretinate 
or all-~-RA was reflected in decreased bone-ash weights for the latter 
compounds compared with those from animals treated with the 
sulfur-containing retinoid (Kistler et al. , 1984). 
The influence of naturally occurring retinoids on the skin has been 
reviewed {Christophers and Wolff, 1975b; Jarrett, 1975). Topical application of 
0.15 mg/d of al1-~-RA to nude mice for one month caused epidermal 
hyperplasia and acanthosis in 70% of the animals and hyperkeratosis in 25%. 
Skin toxicity was accompanied by increased alkaline phosphatase activity of 
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sebaceous glands as well as increased nucleic acid content and changes in the 
distribution of skin lipids (Cahn et at., 1975). Doses of 0.006 mgj kg/ d of the 
arotinoid Ro 13-6298 administered p.o. to guinea pigs for four and eight weeks 
resulted in slight epidermal changes similar to those observed in humans 
(Tsambaos and Orfanos, 1982). Three days after treatment of 0.1 mg/kg/d 
numerous small vacuoles were observed under an orthokeratotic horny layer. 
One week after 0.1 mg/ kg/ d the horny layer was lacking in nearly all animals, 
and massive and edematuous changes in the remaining epidermis were observed 
(Tsambaos and Orfanos, 1982). Application of all-!.ffi.!li-RA to rat or human 
skin increased oxygen consumption and inhibited the pentose phosphate shunt 
(Raab and Gmeiner, 1976). Addition of all-!.ffi.!li-RA to cultured epidermal cells 
enhanced their growth and stimulated DNA synthesis (Christophers and Wolff, 
1975a). Subcutaneous injection of isotretinoin into male hamsters inhibited 
sebaceous glands, but similar treatment with etretinate failed to cause 
involution of these glands (Gomez, 1982). The relative effectiveness of 
isotretinoin in acne treatment as compared with etretinate may be due to 
isotretinoin inhibition of sebum production and diminution of the sebaceous 
gland. 
Dysmorphogenicity 
Hypervitaminosis A induced teratogenicity has been studied in numerous 
laboratory animal models: rat (Cohlan, 1953), mouse (Giroud and Martinet, 
1959), guinea pig (Giroud and Martinet, 1959; Robens, 1970), hamster (Robens, 
1970; Marin-Padilla and Ferm, 1965), rabbit (Giroud and Martinet, 1959), 
chicken (Cadi et al., 1983; Cadi et al., 1984), pigtail monkey (Fantel et al., 
1976), and rhesus monkey (Wilson, 1971; Hendrickx et al. , 1980). The 
teratogenic syndrome induced by administration of retinoid analogs is 
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essentially that of naturally occurring forms of vitamin A administered during 
the same period of embryogenesis. Geelen ( 1979) assembled a detailed review 
of hypervitaminosis A and teratogenesis induced by naturally occurring 
retinoids. 
In the hamster, malformations induced by a single dose (p.o.) at 10:00 
A.M. on day 8 of gestation (the day following the evening of breeding being 
day I) are dose-related; as the dose of the active retinoid increased, the 
severity of malformations and percentage of malformed fetuses increased. 
Intubation of 50 mg/ kg all-trans-retinylidene meth yl nitrone (ED5o 39.1 
mgf kg) (Willhite and Balogh-Nair, 1984), 25 mg/ kg 13-cis-RA (ED5o 22.3 
mg/ kg) (Willhite and Shealy, 1984), 2.8 mg/ kg etretinate (ED5o = 5.7 mg/ kg) 
(Williams et a!., 1984), 75 mg/ kg all-trans-9-(exo-2-bicyclo[2.2 .1 ]heptyl)-
3, 7-dimethyl-2,4,6,8-nonatetraenoate, 50 mg/ kg ali-!J:l!m-retinoyl fluoride (ED 5o 
53.8 mgf kg), 81 mgf kg all-t.rnru.-5-[2,6-dimethyl-8-(2,6,6- trimethyl-
cyc lohexen-1-yl)-1 ,3 ,5, 7 -octatetraen-1-yl] te trazole, 84 mg / kg e th yl 
all-trans-4-[2- methyl-4-(2,6,6-trimethyl- 1-cyclo- hexen-1- yl)-1 ,3- butadien- I- yl] 
benzoate (Willhite et a!., 1984), 38 mg/ kg 7,8-dihydroretinoic acid, 37 mg/ kg 
7 ,8-dehydroretinoic acid, 25 mg/ kg 9-ill_-retinal (ED5o=23.5 mg/ kg) (Willhite, 
1986) increased the number of affected litters (one or more malformed fetuses) 
compared to vehicle only treatment. The malformations included: unilateral or 
bilateral palpebral aplasia with subsequent exophthalmia, microphthalmia , and 
anophthalmia. Micrognathia with primary microglossia, protruding tongue , 
unilateral or bilateral macrostomia , cleft palate , and agnathia were also 
observed. An apparent maxillary retrocession was often observed and thought 
to be secondary to lordosis and reduction of the basichondrocranium. At lower 
doses palpebral aplasia and macrostomia were the most common malformations . 
As doses were increased, more severe malformations such as micrognathia , cleft 
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mandible, and agnathia were observed (Willhite et at., 1984; Willhite , 1986). 
Mid-sagittal sections of grossly normal and abnormal day-14 fetuses are shown 
in figures 11.4 and II .5, respectively (see figure legend for explanation). The 
facial skeletal dysmorphia was believed to be the result of delayed and 
disorganized patterns of cranial neural crest cell migration with death and 
damage of the crest cells (Wiley et at., 1983). 
Malformations of the ears included ventrally displaced imperforate 
external auditory meatus and hypoplastic auris externa. Microcephalus 
characterized by anterioposterior reduction and elongation in the superinferior 
plane with reduction of frontal, parietal, temporal, and occipital bones 
occurred. Arnold-Chiari malformation types I and II, which are characterized 
by underdevelopment of the basioccipital, resulted in lordosis of the 
basichondrocranium, reduction of the pontine flexure, and increased angle of 
cervical flexure of the hind brain. The cerebellum was displaced caudally with 
compression of the medulla, and the odontoid process protruded into the 
cranial cavity (Marin-Padilla and Marin-Padilla, 1981). Cranioschisis occulta 
with meningoencephalocele or meningocele and cranioschisis aperta with 
encephaloschisis were also observed (Willhite, 1984). 
A caudal regression syndrome characterized by anal atresia, hypoplastic or 
aplastic tail, sacral rachischisis aperta with myeloschisis or sacral rachischisis 
occulta with myelo- or meningomyelocele occurred. Infrequently, umbilical 
hernia or gastroschisis with omphalocele were reported (Willhite et at., 1984; 
Willhite, 1986). Genitourinary malformations consisted of renal agenesis, 
bladder exstrophy, and horseshoe kidney. 
Intubation of 40-80 mg/ kg all-.trllru.-RA induced cardiac malformations, 
including ventricular septal defect, transposition of the great vessels, double 
outlet right ventricle, overriding aorta with pulmonary stenosis, hypoplastic 
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Figure Jl.4. Mid-sagittal section of grossly normal day-14 hamster fetus 
recovered from a dam administered Tween 20 on day 8 of gestation. Note the 
size of brain and calvaria. The basichondrocranium forms a 90° angle with the 
odontoid process of the second cervical vertibra. (From Willhite and Shealy, 
1984, used with permission.) 
Figure Il.5 . Mid-sagittal section of a grossly malformed day-14 hamster fetus 
recovered from a dam treated with 75 mg/ kg body weight retinoic acid on day 
8 of gestation. Note the agnathia, microcephaly, and microglossia. The 
basichondrocranium is shorter than that of the control fetus (Figure 11.4) and 
is lordo tic to the vertebral axis. It forms nearly a 180° angle with th e 
odonto id process. (From Willhite and Shealy, 1984, used with permiss ion.) 
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aorta, right-sided aortic arch, atrial septal defect, and other circulatory 
anomalies (Shenefelt, 1972; Taylor et al., 1980). 
Willhite and Balogh-Nair (1985) induced terata in Swiss-Webster mice with 
75 mg/ kg all-trans-retinylidene methyl nitrone or all-~-retinol given at 
10:00 A.M. on days 7 through II (vaginal plug = day I for the following mouse 
studies). Retinol increased the number of malformed litters on days 7, 8, 9, 
and II; the nitrone induced significant increases on days and 9. 
All-~-retinol was always associated with a higher percentage of malformed 
fetuses than was the synthetic retinoid. Kochhar et al. {1984b) investigated 
palate and limb malformations in ICR mice with all-~-RA and 13-ill-RA. 
Treatment with 100 mg/ kg 13-ill-RA failed to induce terata and 200 mg/ kg 
induced minor limb and some palatal malformations. Four hundred mg/kg 
13-ill-RA induced limb and palatal defects similar in severity to a dose of 100 
mg/ kg all-~-RA . 
Doses of 3 mg/ kg etretin (the free acid form of etretinate) administered 
p.o. to Fu-albino mice on days 7-16 resulted in an elevation in the percentage 
of malformed fetuses. One mg/ kg etretin failed to induce malformations 
(Kistler and Hummler, 1985). The arotinoid Ro 13-6298 induced malformations 
in NMRI mice at doses as low as 0.0 I 0 mg/ kg/d i.p. on days I 0-12 or 13-15. 
A single i.p. injection on days 9 through 15 of 0.20 mg/kg Ro 13-6298 also 
induced malformations similar to those induced by all-~-RA (Zimmermann et 
al., 1985). 
A single oral dose of 200 mg/ kg 13-ill-RA administered to C57Bl / 6J mice 
induced ear, thymic, great vessel, and facial abnormalities (Johnston et al., 
1985; Jarvis et al., 1985). Histological changes were specific for neural crest 
cells. Kochhar and coworkers {1985) induced teratogenesis in ICR mice with 
all-~-RA, 13-cis-RA, etretinate, and etretin and tested these retinoids for 
32 
their ability to suppress chondrogenesis in limb bud mesenchymal cell cultures. 
Etretinate was the most potent teratogen, but failed to suppress 
chondrogenesis in vitro. All-lll!M-RA was a more potent teratogen in vivo 
than 13-ill-RA, but both had equivalent in vitro activity. 
In vitro studies with mouse limb buds have been employed. Forelimb buds 
of 10 to 12 day ICR/JLC mice embryos were exposed to 10 I.U./ml retinol for 
24 h. Abnormal limb development was observed (Nakamura, 1977). Kwasigroch 
et al. (1984) treated pregnant ICR mice on day II with all-trans-RA and 
subsequently cultured the embryonic limb buds for 3 days. When compared to 
limbs of 17 day in utero fetuses , the limb culture effects were qualitatively 
similar with micromelia and digital defects. Mouse limb bud mesenchymal cells 
cultured with I pg/ ml all-lll!M-RA had a 10% inhibition of growth and a 24% 
decrease in [3H]glucosamine-labeled glycosaminoglycan synthesis . Retinoic acid 
treated-cells released twice as much hyaluronic acid into the medium as did 
control cells (Kochhar et a!., 1984a). Zimmerman and Tsambaos (I 985) cultured 
NMRI mouse limb buds and embryonic-mouse mesenchymal cells in high-density 
cultures with all-lrl!!li-RA, 13-ill-RA, etretin, or motretinid (the ethyl amide 
analog of etretinate) at 0.1, 1.0, and 10.0 ug/ ml. All of the retinoids initiated 
dose-dependent inhibition of differentiation of limb buds from the blastoma 
stage and of chondrogenic differentiation in organ culture and high-density 
culture . The efficacy of the retinoids varied: all-lll!M-RA > 13-ill-RA > 
etretinate > motretinid. 
Steele et a!. (I 982) employed whole embryo culture techniques to 
investigate the teratogenic effects of vitamin A (purchased in soluble 
unspecified form) . Rat embryos were cultured with serum drawn from rats or 
humans previous to or after ingestion of 100,000 I.U. vitamin A. Somite 
number and protein content in the post-vitamin A serum cultured embryos were 
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reduced after 48 h. Pratt et al. ( 1985) cultured day 8 CD-I mouse embryos for 
48 h with 13-cis-RA. Defects of the first and second visceral arches and their 
derivatives were observed at 0.6 pg/ ml. Using day 10 mouse embryos, 6 pg/ ml 
13-cis-RA induced limb and palate defects. 
Intubation of 25 mg/ kg all-trans-RA to day-nine Sprague-Dawley rats was 
embryolethal by full term. Lethality was attributed to agenesis or hypogenesis 
of the chorioallantoic placenta (Vickers , 1985). Etretinate, etretin, and 
13-cis-RA are also teratogenic in the rat. Two, 4, or 8 mg/ kg etretinate or 15 
or 30 mg/ kg etretin administered orally on days 7-16 induced a variety of 
dysmorphia similar to those described for the hamster. Additionally, etretinate, 
etretin, all-trans-RA, and 13-cis-RA are teratogenic in the rabbit (Kamm, 1982; 
Kistler and Hummler, 1985; Hummler and Schupback, 1981). 
Hendrickx et al. (1980) administered all-trans-RA orally to rhesus 
monkeys, 20 or 40 mg/ kg, between days 19-45 or 17-45, respectively. Of 15 
animals dosed, 10 fetuses were malformed; 4 were normal; and I was resorbed. 
Malformations were similar to those previously described for humans. Fan tel 
et al. (1976) obtained similar ·results with oral all-trans-RA in the pigtail 
monkey . 
In bone cultures with fetal rat humeri, all-trans-RA induced cartilage 
resorption . Inhibitors of DNA synthesis did not affect the resorption process, 
indicating that cell division is not a necessary component of the resorption 
process. Resorption was dependent on RNA, protein , and glycoprotein 
synthesis. These data were interpreted as an indication that retinoic acid 
altered gene expression (Kistler, 1982). Arotinoid Ro 13-7410 (the free acid 
form of arotinoid Ro 13-6298), Ro 13-6307 (the tetramethylatedtetralin 
derivative of retinoic acid), all-trans-RA, 13-cis-RA, etretin, or etretinate (if 
activated, e.g . de-esterified) induced cartilage resportion when added to day 13 
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rat limb bud cultures . Arotinoid Ro 13-7410, the most effective retinoid, was 
ca. 1,000 times more potent than all - trans- RA. Ro 13-6307 was followed by 
that of etretin, etretinate and all- trans-RA in their efficacy to induce 
resorption. The retinoid Ro 15- 0778, the same molecule as Rol3-7410 without 
a carboxyl terminal moiety , lacked acti vity (Kistler, 1985). 
The embryonic chick has also been employed to assess retinoid ability to 
adversely affect development. A single injection of 125 g all-trans-RA or 
other active synthetic retinoids into the amniotic cavity of day 10 chick 
embryos induced ptilopody (feathers on normally scaly feet ), crossed beak, 
acropodial truncature, and club-shaped feather filaments (Cadi et al. , 1984; 
Dhouailly and Hardy, 1978). The retinoids which exhibited the most toxic 
effects (e.g., 100% mortality or more severe malformations) were those with 
one or two supplementary side-chain rings: Ro 13-6307, its ethyl ester (Ro 
13-2389) and the arotinoid acid (Ro 13-7410) and its ethyl ester (Ro 13-6298). 
Recently Kistler (1986b) demonstrated that retinoic acid-induced 
teratogenicity could be suppressed in a dose-dependent fashion by 
simultaneously dosing rats p.o. with the cyclohexanetrione Ro31-0521 
( 3 ,3, 5 ,5- tetraall yl- 2- hydroxy-!i- (5- methyl- 3- isoxazolyl)- 4,6 - dioxo- I- cyclo 
hexene-1-carboxamide sodium salt), which stimulates prostaglandin synthesis, 
and retinoic acid. In vitro, Ro 31-0521 suppressed retinoic acid-induced 
cartilage resorption (Dhouailly and Hardy, 1978). 
The dose-response curves for induction of terata by retinoids in the 
hamster are significantly parallel suggesting a common embryotoxic mechanism. 
The structural requirements for induction of terata by retinoids in hamsters 
are primarily dependent upon the presence of, or biotransformation to, a free 
carboxyl or other moiety with an equivalent pKa at C 15, not upon the 
stereochemistry about C 13 nor the size of the molecular substituent at C 15. In 
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addition they are dependent upon a carbon side-chain of more than 5 carbon 
atoms and upon conservation of the curved hydrophobic plane of the polyene 
chain. All of the retinamides and retinylidene 1,3- diketones tested in 
hamsters were devoid of teratogenic activity, except when administered at dose 
levels associated with maternal toxicity (Willhite and Shealy, 1984; Willhite et 
al., 1984; Willhite, 1986). A free carboxyl group at Cl5 is required for binding 
of retinoids to cellular retinoic acid-binding protein (cRABP) (Chytil and Ong, 
1983). Cellular retinoic acid-binding protein (cRABP) has been identified in all 
fetal rat tissues, in the intestine, brain, and kidney of the fetal rabbit, and in 
limb buds of the mouse (Chytil and Ong, 1983; Rainier et al., 1983; K warta et 
al., 1985). In mouse limb buds, all-!mru.-RA has a 315-fold greater affinity for 
cRABP than 13-lli-RA (Kwarta et al. , 1985). This parallels in vivo data: 
13-lli-RA is one-half as teratogenic as all-!mru.-RA in the hamster (ED5o = 
22.3 mg/ kg for 13-lli-RA; ED5o = 10.5 mg/ kg for a!Hra.n.s.-RA, 66) and four to 
eight times less embryopathic than all-!mru.-RA in the mouse (Kochhar et al., 
1984b). However, it is still unknown if binding of retinoids to cRABP is 
imperative for teratogenic activity. Additional studies of the 
S-cyclogeranylidene ring and side chain modifications will provide more 
information on the exacting requirements of the retinoid structure for 
teratogenic activity . 
Hamsters are apparently more sensitive to the teratogenic effects of 
retinoids than mice. When treated with retinylidene methyl nitrone, hamsters 
were afflicted with a more severe syndrome of malformation than mice 
(Willhite and Balogh-Nair, 1984; Willhite and Balogh-Nair, 1985). A dose of 100 
mg/ kg 13-lli-RA failed to induce limb malformations in ICR mice on day II 
(Kochhar et al., 1984b), but 25 mg/ kg 13-lli-RA significantly increased the 
number of affected litters in hamsters on day 8 (Willhite and Balogh-Nair, 
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1984). The species differences may be related to differential absorption from 
the gut, species-specific biotransformation patterns , pharmacokinetic or 
disposition differences, or to differential levels of or binding affinity for 
embryonic cRABP. 
Mutagenicity and Carcinogenicity 
The mutagenic and carcinogenic potentials of the retinoids have been 
summarized by Hummler and Schupback (1981) and Kamm (1982). Retinal, 
etretinate, 13-cis-RA, and all-m-RA were not mutagenic for Salmonella 
typhimurium (Kamm, 1982). Etretinate was not mutagenic for Escherichia coli 
WP2, nor was it mutagenic in the mouse host-mediated S. typhimurium assay at 
up to an oral dose of I mgj kg. Etretinate showed no clastogenic activity in 
mice (Hummler and Schupback, 1981 ). 
Carcinogenesis bioassay of rats orally exposed to 13-ill-RA at up to 32 
mg j kg/ d found an increased incidence of pheochromocytoma, possibly related to 
retinoid-induced adrenal hypertrophy (Kamm, 1982). The incidence of hepatic 
adenomas and angiomas and leukemia decreased relative to controls. Oral 
isotretinoin doses of 3, 20, 60, or 120 mgj kg/ d in dogs for up to one year 
caused a dose-related toxicity of the cardiovascular system (fibrosis, focal 
calcification, and elastic fiber degeneration), testicular degeneration, fatty 
liver, and lymph node edema, but no evidence for a significant carcinogenic 
response was reported. Chronic toxicity of etretinate in dogs was confined to 
the usual hypervitaminosis A syndrome (Teelmann, 1981), but no evidence for a 
carcinogenic response was reported. No increase in tumor incidence was 
observed in rats fed up to 3 mgj kg/ d etretinate for two years. Dietary 
administration of I or 3 mg/ kg/ d was associated with a decreased number of 
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rats bearing spontaneous multiple tumors, and at 3 mg/ kg/ d the number of 
mammary tumors in female rats decreased (Kamm, 1982). 
In sharp contrast to these studies , Ohshima et al. (I 985) found an 
increase in pancreatic islet cell adenomas in aged male ACI/ segHapBR rats 
when all-trans-tf-(4-pivaloyloxyphenyl) retinamide or all-.trl!.M-4-tf-(2-
hydroxyethyl) retinamide were administered at 951 mg/ kg and 687 mg/ kg diet, 
respectively, for up to 54 weeks. Female Fisher 344 rats dosed with 600 mg 
tf-butyl-tf-(4-hydroxybutyl) nitrosamine over a 6 week period and fed 515 
mg/ kg diet all-trans-2-h ydroxyethyl retinamide had an increase in the 
incidence of bladder tumors after one year compared with animals given the 
nitrosamine alone . Two years subsequent to nitrosamine and retinoid 
administration , the retinoid treatment group's tumors had progressed farther 
than the group administered nitrosamine alone (Quander et al., 1985). 
STRUCTURE-TOXICITY RELATIONSHIPS AND 
POSTULATED MECHANISMS OF ACTION 
Conformationally restricted retinoids, sometimes referred to as arotinoids, 
are held in a fixed cisoid arrangement (Loeliger et al., 1980; Dawson et al., 
1984). These multi-ring retinoids contain two aromatic rings, such that the 
retinoid resembles structurally the I 0, 11-illllli! and/ or the 12, 13-cisoid 
rotameric forms of retinoic acid. The para-substitutions on the phenyl ring 
act as spacers between Cll and the carboxyl terminus to maintain conjugation; 
the rings are held away from one another forming a 71° angle. The multi-ring 
retinoids are 3-1,600 times more toxic to mice than all-.trl!.M-RA. These 
retinoids are also more active than all-.trl!.M- or 13-ill-RA in hamster tracheal 
explant cultures (Newton et al. , 1980), have activities similar to that of 
all-.trl!.M-RA for inhibition of tumor promoter-induced mouse epidermal 
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ornithine decarboxylase (Dawson et al., 1984), and are more potent teratogens 
in hamsters than all-trans-RA, etretinate, or other synthetic retinoids 
{Flanagan et al., 1987). The tetramethylated indanes and tetralins of the 
£-configuration were the most active in the mouse papilloma assay. To date, 
the most toxic retinoid reported has been the aldehyde-containing arotinoid, 
inducing hypervitaminosis A in mice at 0.0125 mg/kg (Loeliger et al., 1980). 
Substitution of a sulfur-containing group at the polar terminus failed to block 
retinoid toxicity, but the b.-isomers of carbon (Loeliger et al., 1980) or 
sulfur-containing (Klaus et al., 1983) restricted retinoids were devoid of 
pharmacologic activity or toxicity in mice at up to 400 mg/kg. The &-
configuration appears to be an obligatory condition for biologic activity. The 
sulfide derivative of the arotinoid structure was the least toxic compared with 
the sulfoxide and sulfone; all three retinoids may serve as parent compounds 
for sulfinic and sulfonic acid metabolites (Klaus et al., 1983). Binding of 
conformationally restricted retinoids to cRABP correlates with their biological 
activity (Sani et al. , 1984). However, some retinoids, such as the ethyl sulfone 
arotinoid, do not bind to the protein and are still highly active {Klaus et al., 
1983 ). Such retinoids may serve as "pro-drugs", whose acidic metabolites may 
be responsible for in vivo pharmacological activity. 
The mechanism of retinoid action has been attributed to their amphipathic 
characteristics causing membrane alterations via detergent disruption (Fell and 
Dingle, 1963), glycosylation of cell surface glycoproteins via formation of 
retinyl mannose phosphate intermediates (De Luca et al., 1979), and activation 
and suppression of the genome (Sporn and Roberts, 1983). Retinoid-induced 
teratogenicity cannot be due to non-specific membrane disruption, because 
certain retinoids containing the hydrophilic carboxyl terminus, a 9-carbon 
flexible side-chain, and the S -cyclogeranylidene ring were ineffective at 
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inducing terata (Willhite, 1986). Nor can the toxicity be attributed to 
involvement of retinoids in sugar transfer reactions, as the retinoidal benzoic 
acid derivative Ro 13-6298 does not participate in retinyl phosphate mannose 
pathways (Sporn and Roberts, 1983). 
Several groups have provided biochemical data on retinoid control of 
cellular proliferation. When retinoic acid was used to induce differentiation in 
HL-60 cells, it suppressed expression of the mY£ oncogene, a nucleotide 
sequence considered to be involved in excessive proliferation of HL-60 cells 
(Sporn and Roberts, 1983 ). Omori and Chytil (1982) demonstrated that feeding 
retinyl acetate, retinoic acid, or 3,7, 11,15-tetramethyl-2,4,6, 10,14-
hexadecapentaenoic acid (a synthetic retinoid) to retinol-deficient rats 
suppressed production of a 22 kDa protein; whereas retinoic acid and the 
synthetic retinoid also induced a 55 kDa protein . Sporn and Roberts (1983) 
and Omori and Chytil (1982) suggested that retinoids are modifiers of gene 
express ion . Chytil and Ong ( 1979) suggested that retinoids are bound in the 
cytosol by either cellular retinol-binding protein (cRBP) (if an alcohol) or 
cellular retinoic acid-binding protein (cRABP) (if an acid) and transported into 
the nucleus where they can modify gene expression. An alternative to the 
steroid-like mechanism for retinoids has been proposed by Sporn and Roberts 
(1983). They suggested that retinoids "control gene expression via interaction 
with protein kinases both cyclic adenosine 3',5'-monophosphate [cAMP] 
dependent and [cAMP] independent" (Sporn and Roberts, 1983, p.3037). 
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CHAPTER III 
STRUCTURE-TOXICITY RELATIONSHIPS OF THE TETRA METHYL A TED 
TETRALIN AND INDANE ANALOGS OF RETINOIC ACID 
INTRODUCTION 
The retinoids, some of which exert prophylactic effects against cancer in 
laboratory animals (Moon and McCormick, 1982; Hartmann and Bollag, 1985), 
are employed clinically to treat certain dermatologic disorders (Ward et al., 
1983; Orfanos, 1985; Cunliffe et al., 1985). Certain retinoids are potent 
teratogens in humans (Fehr and Koch-Weser, 1983; Ruther and Kietzmann, 1984; 
Grote et al., 1985; Willhite et al., 1986; Happle et al., 1984; Lammer et al., 
1985; Rosa et al., 1986) and hamsters (Willhite and Shealy, 1984; Williams et 
al., 1984). The toxicology of retinoids in humans and animals has been 
summarized (Howard and Willhite, 1986; Geelen, 1979). 
Retinoids that contain one or two aromatic rings in their side chain are 
more potent inhibitors of fetal rat bone chondrogenesis (Kistler, 1981) and of 
chick skin differentiation (Kistler, 1984) in vitro than such tetraene retinoids 
as all-!rl!.!!i-retinoic acid (all-!rl!.!!i-RA). These multi-ring retinoids are 10-
I ,000 times more effective in the mouse antipapilloma assay (Loeliger et al., 
1980) and are more effective towards induction of differentiation of human 
promyelocytic HL-60 cells (Bollag, 1985) than tetraene retinoids. In this 
chapter the effects of modifications of the ring and side-chain on the 
teratogenic potency of retinoids in hamsters are reported. The results are 
compared with established structural relationships for retinoid teratogenic 
activity in hamsters. 
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MATERIALS AND METHODS 
Chemicals 
The retinoids all-!Ii!.!)j_-3, 7 -dimethyl-9-( I, I ,3,3-tetramethylindanyl)-2,4 ,6,8-
nonatetraenoic acid (Ro 13-4306), (.&_)-7-(5,6, 7,8-tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-3-methyl-2,4,6-octratrienoic acid (Ro 13-6307), and ethyl (&)-
7 - (5 ,6, 7 ,8- tet rah ydro- 5,5, 8,8 -tetramethyl-2- naphthalenyl)- 3- methyl- 2 ,4,6-
octratrienoate (Ro 13-2389) (Figure m.I) were gifts from Hoffmann-La Roche, 
Inc. (Nutley, NJ). The retinoids were stored under desiccant at -80°C. All 
retinoids had a purity of greater than 98 percent when assayed at 340 and 254 
nm with acetonitrile-! percent aqueous ammonium acetate 85:15 and 93:7 as the 
mobile phase using a Spherisorb ODS 5-)lm column (Universal Scientific, 
Atlanta, GA) and a flow rate of 1.0 ml/ min. Retinoids were dissolved in a 
small volume of reagent grade acetone and solubilized in Tween 20 
(polyoxyethylenesorbitan monolaurate, Sigma, St. Louis, MO). 
Animals 
Virgin female Syrian Golden hamsters [LAK:L VG (SYR)] were purchased 
from the Charles River Breeding Laboratories, Inc., Wilmington, MA . Hamsters 
were mated by the method described by Ferm (1967). The day following the 
evening of breeding was considered day one of gestation. Male and female 
animals were allowed free access to tap water and laboratory stock diet 
(Wayne F6 Lab B!o:® #8664-00) and were housed separately in polycarbonate 
cages with pine shavings as bedding. The light cycle was maintained at 14 h 
light/ 10 h dark. Animals were housed in an AAALAC- accredited facility . 
A single oral dose was administered by gavage at I 0:00 A.M. on day 8 of 
gestation at a rate of 5 ml/ kg of body weight. Retinoid doses were selected 
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Ethyi!El · 7 · I 5 . 6. 7 .8-tauahydro-5. 5,8,8-tatra-
mattr,i-2-naphthalenyll-3-methyl-2.4,6· 
... .,...., • • J .J -Om.thyt-9-11 .1.3.3-tatr•· 
mt~m.,tindanvll- 2.4.6, 8-nonaotab'HI"'Iic .ckl 
~COOH 
lxU 
~COOC2H5 
~COOH 
Figure III. I. Molecular structures of selected retinoids. 
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by inspection as calculated from their molar concentrations relative to that of 
all-trans-RA. When a limited amount of retinoid was available, a dose 
equimolar with that of 75 mg/ kg of all-trans-RA was administered to the 
pregnant dam. Animals were killed in a saturated C02 environment on day 14 
and the pregnant uteri collected by laparotomy. Fetuses were blotted dry on 
absorbent paper and weighed. The numbers of resorptions, number of dead, 
and number of living fetuses were recorded. All live fetuses were examined 
with a binocular dissecting microscope for the presence of gross congenital 
malformations. One-third of each litter was fixed in Bouin's solution, 
sec tioned in the midsagittal plane, and examined for internal abnormalities 
(Willhite and Shealy, 1984). The remaining two-thirds were fixed in 95% 
ethanol , cleared in 2% KOH, stained with ali zarin red S, and examined for 
confirmation of skeletal anomalies. 
Statistics 
The litter was considered the experimental unit for statistical procedures. 
The maternal weight change was calculated by subtracting the total litter 
weight (including dead, autolyzed fetuses) from the dam's weight change 
between days 8 and 14. Univariate analysis of variance was used to analyze 
maternal weight change and fetal weights (Sokal and Rohlf, 1981 ). The 
Newman-Keuls test was used to test differences between the vehicle-treated 
control and treatment group means, subsequent to a significant F-test (Sokal 
and Rohlf, 1981). The number of resorptions for each retinoid dose was 
compared to the vehicle-treated control value using the nonparametric Mann-
Whitney test (Sokal and Rohlf, 1981 ). A litter was considered affected, if it 
contained one or more malformed or dead fetuses or three or more resorptions. 
Fisher's exact test for a 2 x 2 contingency table (Sokal and Rohlf, 1981) was 
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used to test the statistical significance of the affected litters at each retinoid 
dose . All statistical procedures were considered significant at the p=0.05 level. 
The dose-response curves, the median effective dose for induction of 
terata (ED5ol. and the embryonic LD5o were generated using the log-probit 
model for those retinoids associated with a significant teratogenic response 
(Schoofs and Willhite, 1984). The numbers of malformed fetuses at each dose 
were used to calculate the parameters of the dose-response curve. To 
determine parallelism and potency ratio, the slopes of the dose-response curves 
with their confidence limits for each retinoid associated with a significant 
teratogenic response were compared to the slope of the dose-response curve of 
an identical population of hamsters treated with the reference retinoid, all-
~-RA (Willhite and Shealy, 1984). 
RESULTS 
Three of the 28 dams treated with the Tween 20: acetone vehicle 
produced affected litters (Table Ill.l ). The single malformation was limited to 
a rib fusion . One litter contained a dead fetus, and the third litter contained 
three resorptions. At no point in the study were signs of maternal retinoid 
toxicity observed (e.g., maternal weight loss, alopecia, exfoliation, dermatitis, 
conjunctivitis). Oral intubation of 6.7 or 13.5 mg/ kg Ro 13-4603 increased 
significantly the numbers of affected litters compared to control litters. Doses 
of 6.7 or 13.5 mg/ kg Ro 13-4603 (equimolar doses corresponding to 6.25 and 
12.5 mg/kg all-~-RA) induced malformations in 73.4 and 100 percent of the 
recovered fetuses, respectively (Table III.!). The median effective teratogenic 
dose (ED5o) for Ro 13-4306 was 4.7 mg/ kg (4.2-5.2, 95 percent confidence 
interval). 
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TABLE 111.1 
TERATOGENIC ACTIVITY OF Ro 13-4306 ON HAMSTER 
EMBRYONIC DEVELOPMENT 
Dose (ma/kal 
0.67 2.14 6.7 13.S 
No. animals treated 30 7 10 II 
No. litters 28 3 10 9 
No. affected litters 3 0 3 9' 7' 
No. implantations 288 37 119 98 78 
No. resorbed (%) 8(2.7) 0 4(3.4) 3(3.1) 2(2.6) 
No. dead(%) 1(0.3S) 0 0 1(1.0) 0 
Fetuses ell:amined 279 37 liS 94 76 
No. abnormal 
fetuses (IM,) 1(0.36) 8(7.0) 69(73.4) 76(100) 
Mean litter frequency 
of malformed fetuses 0.036 0.80 7.7 10.9 
Mean fetal body 
wr. cuso) 1.24t0.14 1 . .37±0.04 1.29tO.OS 1.16tO.IS 1.18±0.09 
Mean maternal wt. 
chanae fuSD) 13.9t6.0 17.8t4.8 IS .9t3.2 17.4±4.0 16.3t3.0 
Malformations 
Microcephaly 48 
Arnold-Chiari 
malformation 3 
Encephalocele I 3 
Exencephaly 3 4 
Cystic rachischisis 0 I 
Microstomia I 48 
Macrostomia S4 17 
Maxillary 
retrocession 13 31 
Rib fu:sion 8 39 
Palpebral apluia 
with exophthalmia 32 61 
Anophthalmia I 0 
Protrud ins; tongue 0 47 
Hypoplastic tail 0 3 
lordotic skull base 2 3 
Atretic or stenotic 
external auditory 
meatus 61 
Lowset, hypoplastic, 
malformed, or absent 
pinnae 33 76 
• p<0.05 compared to vehicle control. 
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Doses of 0.71 mg/kg or higher Ro 13-6307 increased significantly the 
number of affected litters compared to control values (Table III.2). Doses of 
0.35, 0. 71, or 2.2 mg/ kg of Ro 13-6307 (doses equimolar to 0.31, 0.63 , and 2.0 
mg/ kg all-trans-RA, respectivel y) induced malformations in 12.1, 53.3, and 98.2 
percent of the recovered fetuses, respectively (Table 111.2). Doses of Ro 13-
6307 at 7 .I, 14.2, or 28.4 mg/ kg induced malformations in all recovered fetuses. 
The mean fetal body weights of fetuses recovered from dams treated with 14.2 
or 28.4 mg/ kg Ro 13-6307 were depressed significantly compared with those 
from vehicle-treated dams (Tables III.! and 111.2). As the dose increased, both 
the numbers of malformed fetuses and numbers of malformations per fetus 
increased (Table 111.2). The ED5o for Ro 13-6307 was 0.66 mg/ kg (0.60-0.72). 
Doses of 0.75 mg/ kg or higher Ro 13-2389 increased significantly the 
number of affected litters above control values (Table 111.3). Fetuses 
recovered from dams treated with 0.38, 0.75 , or 2.4 mg/kg Ro 13- 2389 had 
corresponding malformation rates of 2.4, 64.0, and 98.5 percent. The total 
numbers of resorptions and malformed fetuses were dose-dependent; all 
implantation sites were resorbed in the highest (30.0 mg/ kg) dose group (Table 
111.3). The mean fetal body weight was depressed significantly in the 7.5 and 
15.0 mg/ kg dose groups. The teratogenic ED5o for Ro 13-2389 was 0.71 mg/ kg 
(0.66-0.78), and the embryonic LD50 was 8.65 mg/ kg (7.50-10.15). 
The syndrome of malformations induced by these three retinoids was 
identical to that observed after treatment with a teratogenic dose of all-trans-
RA during an identical gestational stage (Willhite and Shealy, 1984). Prominent 
dysmorphia common at the higher doses included craniofacial and axial skeletal 
defects, as well as a caudal regression syndrome consisting of a hypoplastic or 
aplastic tail, anal atresia, and sacral cystic rachischisis. Macrostomia and 
microstomia dominated the lower dose ranges (approximately I mg/ kg Ro 13-
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TABLE 01.2 
TERATOGENIC ACTIVITY OF Ro 13-6307 ON HAMSTER 
EMBRYONIC DEVELOPMENT 
Dmt (mllkJl 
O.lS 0.71 2.2 7.1 14.2 21.4 
l<o. aniDWs U..ted II 12 12 9 II II 
No. litters I 9 10 I 7 7 
No. atrected litter 
' 
I. 10" I. J- J-
No. implaataticnu 101 92 117 19 u 71 
No. morbed ('II) 2(2.0) 2(2.1) J(U) 2(2.2) 21(32.9)" 7(7.9) 
No. dad('ll) 0 0 0 0 3(3-') 4(S.6) 
F.._ uamiDed 99 92 114 17 ,. 60 
No. abDormal 
fetuses('ll) 12(12.1) 49(S3.3) 112(91.2) 17(100) 54(100) 60(100) 
Mean litter frequency 
ot malformed fetuses 1.$ S.4 ll.l 10.1 7.7 u 
Meu few body 
wt.(GtSD) 1.2St,2.9 l.l!lxQ.09 1.17;t.O.II 1.13;t.0.07 O.liS;t.O.u• I.O;t.0.11• 
Me:aa maternal wt. 
chaaao (USD) 16.St,2.9 13.9t,2.1 13.4:,.1 11.21;$.9 14.31;4.3 l.l1;IO.l 
Malformations 
Microacathla/aaoathia' 0 0 0 17 41 4S 
Microcephaly 0 0 40 
" 
31 30 
Anlold-Ch;.n 
malt ormation 0 0 4 4 12 7 
Eocepbalaulo 0 0 14 4 I I 
E.teacopbaly 0 I 6 6 23 29 
Cystic nchisdtisis 0 0 0 I 33 l6 
Mkrostoali.a 0 0 67 S2 - 10 u 
Microstomia 9 47 26 17 0 0 
Muillary 
retrccessioa II ., 0 0 
Jtib fusioa I II 14 32 
hlpebralaplasia 
•itb e:.:opbthaJmia 0 21 16 71 42 60 
ADOpbthalmia 0 0 0 I 0 0 
Protrudina toaaue 0 0 
" 
67 17 12 
MicroJ)ossia 0 0 II 0 4 10 
Hypoplastic tall 0 0 0 9 24 S2 
!.Drdotic skull base 0 0 4 4 12 7 
Absent or b)l)Oplastic 
kidDe)' 0 0 0 7 a 
Ac:ystia 0 0 0 0 2 
ADIIItr~ia 0 0 0 14 ~9 
Atretic: or stenotic 
external auditory 
meatus 23 73 n l9 
Lo'NSet, hypoplutic, 
malformed, or absent 
pioo.ae 12 II l4 l9 
• p.cO.Oji compared to vehicle control. 
1 tadudes cleft mandible. 
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TABLE III.3 
TERATOGENIC ACTIVITY OF Ro 13-2389 ON HAMSTER 
EMBRYONIC DEVELOPMENT 
OOS& (mgtkg} 
0.38 0.15 2.4 1.5 15.0 30.0 
No. animals treated 10 II 13 12 10 
No. Iitten 10 9 II II 10 
No. affected litters 2 9' II' II' 10' 7' 
No. im plantations 128 107 149 129 114 78 
No. resorbed (%) 4(3.1) 1(.9) 10(6.7) 33(25.5)' 103(90)' 78(100) ' 
No. dead ('lb) 0 0 0 2(1.6) 0 0 
Fetuses examined 124 106 139 94 II 0 
No. abnormal 
fetuses(%) 3(2.4) 68(64) 137(98.5) 94(100) 11 (100) 
Mean litter frequency 
of maJfonned fetuses 0.3 7.6 11.6 8.5 3.7 
Mean fetal body 
wt. (uSD) 1.27±0.07 1.31t0.09 1.23±0.08 I.O±O.QS• 0.90±0.3• 
Mean maternal wt. 
change (&±SO) 18.6±4.3 13 .1±0.1 12.9±3.8 19.5±6.8 17.3±8.9 11.9±4 .0 
Malformations 
Micrognathiajagnathiaa 0 79 II 
Microcephaly 32 79 II 
Arnold-Chiari 
malformation 0 0 6 
Encephalacele 0 2 6 
Exencephaly 0 2 17 
Cystic rachischisis 0 0 20 
Microstomia 0 67 12 
Macrostomia 65 54 3 
Maxillary 
retrocession 31 
Cleft palateb 3 
Rib fusion 35 
Palpebral apla.5ia 
with exophthalmia 0 2 124 89 II 0 
Anophthalmia 0 0 0 4 0 0 
Protrudjng tongue 0 0 61 IS 0 0 
Microglossia 0 0 0 14 3 0 
Hypoplastic tail I 0 s 24 II 0 
Lordotic skull base 0 0 0 6 0 0 
Anal atresia 0 0 0 24 II 0 
Renal agenesis 0 0 0 2 I 0 
Acystia 0 0 0 I 0 0 
Atretic or stenotic 
externa l aud itory 
meatus 90 II 
l owset, hypoplastic, 
malformed, o r absent 
pinnae 82 93 I I 
• p<O .OS compared to vehicle control. 
3 Includes cleft mandible. 
b Includes cleft lip. 
6307 or 13- 2389) with the more severe malformations of the face and jaw 
(micrognathia and agnathia) prevailing at higher doses (Tables III.!, III.2, and 
111.3 ). Frequently a fused amorphous boney mass and mandibular ankylosis 
were observed after alizarin straining of fetuses that, upon initial gross 
examination, were classified as agnathic or micrognathic. Ossification of the 
lower spine was decreased markedly in fetuses afflicted with cystic rachischisis 
(data not shown). 
The dose-response curves for Ro 13-4306, Ro 13-6307, and Ro 13-2389 
were significantly parallel with that of aii-.!Il!.rn.-RA (p=0.00007, p=O.OOOOOI and 
p=0.004, respectively). The slopes of the retinoid Ro 13-4306, Ro 13-6307, and 
Ro 13-2389 dose-response curves were 5.8 (4.8-6 .7), 5.6 (4 .6-6.6) , and 6.7 (5 .6-
7.9, respectively. On a mg/ kg basis, Ro 13-4306, Ro 13-6307, and Ro 13-2389 
were 2.3 (2.0-2.5,) 16.1 (14.4-18.0), and 15.1 (13.6-16.6) times more potent 
teratogens than all - trans- RA, respectively. On a molar basis, Ro 13-4306 was 
2.4 times as potent as all-trans-RA . The retinoids Ro 13-6307 and Ro 13-2389 
were 18.0 times more potent teratogens in hamsters than aii-.!Il!.rn.-RA . 
DISCUSSION 
The retinoids studied here contain either a 5,5,8,8-tetramethylated tetralin 
(Ro 13-2389 and Ro 13-6307) or 1,1,3,3-tetramethylated indane (Ro 13-4306) 
ring system. This double-ring system contrasts with the simple s-
cyclogeranylidene ring of such tetraene retinoids as retinol and retinoic acid. 
The present results show not only that these synthetic multi-ring retinoids are 
more potent teratogens than all-trans-RA, but that retinoids containing the 
tetramethylated tetralin system were times more potent teratogens than 
retinoids with the tetramethylated indane system. 
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This same relationship was true for other in vivo and in vitro assays; the 
tetramethylated teralin retinoids were more active than tetramethylated 
indanes. Cadi et al. (1984) reported that Ro 13-2389 and Ro 13-6307 were 
substantially more effective at modification of chick embryo tarsometatarsal 
morphogenesis than all-.trl!Jli-RA, but Ro 13-6307 and Ro 13-2389 were only 0.1 
times as potent as the cisoid free acid retinoidal benzoic acid (arotinoid) 
congener, Ro 13-7410. In the mouse antipapilloma assay, Ro 13-2389 was more 
effective at decreasing papilloma diameter than either Ro 13-4306 or all-.trl!Jli-
RA (Loeliger et al., 1980). Ro 13-2389 was approximately I 00 times as potent 
as all-!.m!!1-RA and was 17 times more potent than Ro 13-4306 at induction of 
hypervitaminosis A in mice . However, the therapeutic ratio of Ro 13-2389 was 
2.5 times more favorable than all-trans-RA (Loeliger et al. , 1980). Table III.4 
contains data summarized from the literature on the relative biologic potency 
of the retinoids studied here . The tetralin and the indane congeners were 
consistently more biologically active than all-!.m!!1-RA - between 10- to I ,000-
fold more active across a multitude of in vitro and in vivo structure-activity 
studies (Table III.4). 
In previous studies (Willhite et al., 1984) tetraene retinoid teratogenic 
activity in hamsters was dependent upon the presence of or biotransformation 
to a free carboxylic acid or other moiety with an equivalent pKa at Cl5. The 
teratogenic activity was dependent upon a side-chain of more than 5-carbon 
length, conservation of the curved, hydrophobic plane and preservation of 
electron delocalization across the polyene chain (Willhite , 1986). Reduction of 
in situ production of the acidic congener with an amide (Howard et al., 1986) 
or dimedone (Willhite et al., 1984) substitution rendered the retinoid 
teratogenically inactive in hamsters. It is reasonable to assume that the 
similar teratogenic profile of the ethyl ester Ro 13-2389 can be attributed to 
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TABLE III.4 
RETINOID ACTIVITY IN VITRO AND IN VIVO 
MOUSE CHICK 
FETAL RAT MAMMARY LIMB BUD FOOT 
GLAND CHONDROGENESIS SKIN 
RETINOID Ti~l~~~~~~y CU~~~~Eb 
PROMYELOCYTIC 
HL-60 CELL 
CULTURE[ 
(nM) 
CUL TUREc CULTUREd CULTURE• 
II>Mol/kg) (nM) (nM) (nM) (nM) 
35.03 1,200 
!3-6307 1.95 35 
13-2389 1.95 400 
JJ-.no6 14.5 200 
1,000 
1.0 
- g 
100 
100 
0.60 
3 EDso data from Willhite and Shealy {1984) 
b ED40 da!a summarized from Kistler (1981) 
c Lowest inhibiting concentration data summarized from KUder (19868) 
d ICso data summarized from Kistler (1985) 
e Complete inhib ition data summarized from Kistler (1984) 
f EDso data summarized from Bollag {1985) 
8 No data available 
10,000 
10 
100 
100 
8.0 
80 
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in situ generation of the free acid, just as with etretinate (Ro I 0-9359) 
(Williams et al., 1984) or arotinoid ethyl ester (Ro 13-6298) (Flannagan et 
a!. , 1987), where the ester underwent hydrolysis to the free acid congeners 
etretin (Ro 10-1670) and Ro 13-7410, respectively. It is the free acid form of 
the retinoid that binds to cellular retinoic acid-binding protein (cRABP) in 
hamster tissue (Brandes et al., 1983). This binding protein has also been 
detected in a number of human tumors including breast, lung, prostate, cervix, 
and colon, in addition to several animal tumor models. In animals, however, 
cRABP occurs at higher concentrations and in more fetal tissues than in adult 
tissues. There appears to be a mechanistic link between the toxicity of 
retinoids in embryonic development and intrinsic pharmacologic activity in 
carcinogenesis. 
The retinoidal benzoic acid derivatives such as (.I;.)-4-(2-(5,6, 7 ,8-tetra-
hydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl) benzoic acid (Ro 13-
7410) are the most potent retinoid teratogens yet reported (Flanagan et al. , 
I 987). These retinoids are at least 750 times more teratogenic than all-trans-
RA in hamsters. The tetramethylated tetralin analogs are the next most potent 
retinoidal teratogens studied to date, followed by the tetramethylated indane 
(Ro 13-4306), etretinate (EDso= 5.7 mg/ kg) (Williams et al., !984), all-trans-RA 
(EDso= !0.5 mg/kg) and 13-lli-retinoic acid (EDso= 22.3 mg/kg) (Willhite and 
Shealy, 1984 ). The teratogenic activity of the retinoid increased with the 
degree of conformational restriction, provided an acidic moiety was present in 
either the parent retinoid or in a metabolite of the parent compound. Willhite 
( 1986) found that the no modification of the side-chain per se enhanced 
embryotoxicity. Introduction of the planar aromatic ring in lieu of the chair 
or boat natural s -cyclogeranylidene ring increased embryotoxic activity 
(Williams et al., 1984). Introduction of an aromatic ring in the side-chain as 
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in Ro 13-4306 or Ro 13-6307, corresponding to the 7-8 region of all-trans- RA, 
along with gem dimethyl modification of the natural cyclohexene ring, not onl y 
res tricted side-chain flexibilit y and preserved the hydrophobic plane of the 
chain , but facilitated n -electron delocalization across the retinoid . 
Facilitation of charge-transfer across the retinoid molecule (Leavitt and Mass, 
1985) appears to be an important aspect of retinoid structure-teratogenicity 
relationships. 
The increased teratogenic activity of the arotinoids and of the multi-ring 
retinoids studied here, as contrasted with such tetraene retinoids as all-trans-
and 13-ili-retinoic acid, cannot be ascribed completely to maternal 
pharmacokinetic or placental permeability factors (Creech-Kraft et al. , 1987). 
There are several orders of magnitude difference in teratogenic potency among 
the retinoids. It is unlikely that a I ,000-fold lower maternal oral dose of a 
highly toxic retinoid (e.g., arotinoid) would result in greater retinoid 
concentrations in the embryo. Binding affinities for cRABP correlate with the 
biological activity of retinoids in hamster tissues (Sani et al. , 1984). Binding 
affinities for cRABP also correlate with the ability of retinoids to induce limb 
bud malformations in chicks (e.g., Ro 13-7410 was the most potent inducer of 
limb malformations and also the most effective competitor for cRABP) (Maden 
and Summerbell, 1986). The relative biological potencies of these retinoids are 
consistent across a multitude of in vivo and in vitro assays suggesting the 
existence of specific cellular receptor(s) responsible for pharmacologic and 
toxicologic activities. Increased binding affinities for embryonic cRABP of the 
retinoids studied here , as contrasted to the simple tetraene retinoids, may 
account for the marked differences in teratogenic activity . 
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CHAPTER IV 
STRUCTURE-ACTIVITY RELATIONSHIPS OF RETINOIDS IN DEVELOPMENTAL 
TOXICOLOGY: CONTRIBUTION OF THE VITAMIN A 
B -CYCLOGERANYLIDENE RING 
INTRODUCTION 
Retinoids are employed clinically to treat actinic keratosis, bronchial 
metaplasia, laryngeal papillomatosis, cervical dysplasia, and myelodysplastic 
syndromes, and for treatment of such dermatologic conditions as psoriasis, 
Darier's disease, and cystic acne. The use of retinoids as preventive and 
therapeutic anticancer agents has been reviewed (Lippman et al., 1987a, 1987b). 
The toxicity of retinoids in humans and animals has been reviewed (Howard 
and Willhite, 1986). 
Oral retinoid treatment in pregnant hamsters produced a syndrome of 
malformations strikingly similar to those observed in human infants exposed 
prenatally to retinoids (Willhite et al. , 1986). Previous structure-activity 
investigations have considered the contribution of the polar terminus (Willhite 
et al., 1984; Willhite and Balogh-Nair, 1984; Willhite and Shealy, 1984) and the 
polyene side-chain (Willhite, 1986) in retinoid teratogenicity. The present work 
focuses on the influence of the B -cyclogeranylidene ring of the vitamin A 
molecule on teratogenicity in hamsters. 
MATERIALS AND METHODS 
Chemicals 
Hoffmann-La Roche, Inc., Nutley, NJ, supplied the retinoids Ro 12-4824 
(all-trans-4-oxoretinoic acid), Ro 12-4825, Ro 8-9750, Ro 10-1770, Ro 8-7699 
(ace tyldimethylcyclopentenyl retinoic acid), Ro 8-8717, Ro 11-1430 (motretinid; 
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TasmaderofE1. Ro 11-4768, the 2-chloro analog of etretinate Ro 12-0995, and 
Ro 21-6667 (Table IV.!). The congener juvenile hormone III (Table IV.!) was 
purchased from Calbiochem, La Jolla, CA. SRI 2712-24 (Table IV.!) was 
synthesized as described by Dawson and associates (1981). All retinoids were 
stored under inert gas at -80°C. 
Retinoids were analyzed by isocratic high performance liquid 
chromatography (HPLC) using a Varian 5000 chromatograph with a Spherisorb 
ODS 5-pm column (Universal Scientific, Atlanta, GA) and a Spherex SC18 5-cm 
x 4.6-cm pre-column (Phenomonex, Rancho Palos Verdes, CA). The retinoids 
were assayed at 340 and 254 nm with acetonitrile-!% aqueous ammonium 
acetate (85: 15 or 93:7) as the eluent. Retinoids were monitored with a Varian 
Vari-Chrom UV / Visible spectrophotometer, and the peak area was integrated 
with a Hewlett-Packard model 3390 A integrator. HPLC grade acetonitrile and 
water (J.T. Baker, Jackson, TN) were filtered and vacuum-degassed prior to 
use. Injection samples (2 )11) were prepared by dissolving each retinoid ( 1.0 
mg/ ml) in either acetonitrile or methanol. Retinoid purity was estimated as 
shown in Table IV.2. Juvenile hormone Ill (Calbiochem, La Jolla, CA) was 
purchased as not less than 96 percent pure. Ro 21-6667 was administered as 
supplied by Hoffmann-La Roche. 
All retinoids, except juvenile hormone III, were dissolved in a small 
quantity of reagent grade acetone and solubilized in Tween 20 
(polyoxyethylenesorbitan monolaurate, Sigma Chemical Co., St. Louis, MO), such 
that the final concentration of acetone did not exceed 5%. Juvenile hormone 
III was purchased dissolved in hexane, and the hexane was evaporated under 
nitrogen to near dryness in a volume of not more than !50 )11. The hormone 
was then dissolved in Tween 20 so that the hexane concentration was less than 
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TABLE IV.! 
MOLECULAR STRUCTURE OF RETINOIDS 
C0111POUNO NAME 
aii-ILW: 3. 7 -d ime!hyl-9-(2,6,6-t rime thy 1-1-
cyc!ohex en -1-yl)-2,4.6 ,3-nona tetraenoic acid 
(all-trans-ret inoic acid) 
all-tr_ans-3 ,7-dimethyl-9-(2.6,6-trimethyl-3-
oxo-1-cycl ohexen-1-yl)-2,4,6,8-nona tel raen· 
oic acid {al!-trans-4-oxore!inoic acid) 
all·!.!!.!:!,!·9·{2·hydroxymethyl-6,6-dimethyl-
1·cycloh exen -1-yl)-3,7 -dimethyl-2,4,6,8· 
nonatetraenoie acid 
all·(8.!!.;-9-{2-luryl)·3,7-dimethyl-2,4,6,8-
nonatetraenoic acid 
all-trans-9-[2·{1-methoxyethyl)-5,5-di-
methyl·1-cyclopenten-1-yl]-3,7-dimethyl-
2,4 ,6,8-nonatetraenoic acid 
all-trans-9-(2-acetyl-5,5-dimethyt-1-cyclo-
penten-1-yt)-3,7-dimethyl-2,4,6,8-nonatetra· 
enoic acid 
all-~·3 ,7-dimethyl-9-phenyl-2,4,6,8-
nonatetraenoic acid 
tl-ethyl all-trans-9-(4-methoxy-2,3,6-tri-
methylphenyl)-3,7-dimethyl-2,4,6,8-nona-
tetraenoamide (Motretinid) 
ethyl all-l!..ml-9-(4-hydroxy-2,3,6-tri-
methylphenyl)-3,7-dimethyl-2,4,6,8-nona· 
tetraenoate 
methyl all-trans-10, 11-epoxy-3,7, 11-tri-
methyl-2,6-dodecadienoate (juvenile hormone 
Ill) 
CODE NUMBER 
Ro 12-4824 
Ro 12-4825 
Ro 8-9750 
Ro 10-1770 
Ro 8·7699 
Ro 8-8717 
Ro 11·1430 
Ro 11-4768 
all-trans-9-(2-ethyl-6,6-dimethyl-1-cyclo- SRI 2712-24 
hexen-1·yl)·3,7-dimethyl-2,4,6,8-nonatetra· 
enoic ac id 
all-lrans-8-{4-methoxy·2,3 ,6·1rimethyl- Ro 21-6667 
phenyllh i0)-3, 7 ·dimethyl-2,4,6-oc tatrienoic 
ac id 
ethyl all-trans-9-(2-chloro-3,6-dimethyl- Ro 12-0995 
4-methoxyphenyl )-3,7-dimethyl-2,4 ,6,8-nona-
terraenoate 
STRUCTURE 
~OzH 
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TABLE IV.2 
PURITY OF RETINOIDS 
254 run 340 run 
Solvent PUrityh tz.C PUrity tr 
Reti.ooid ~ (%) (min) (%) (min) 
Ro 12-4824 A 100 6.8 99.8 6.8 
B 100 13.8 99.1 13.8 
Ro 12-4825 A 100 6.9 100 6.9 
B 100 14.6 100 14.6 
Ro 8-9750 A 100 2 . 9 99 . 4 2.9 
B 100 5.3 99.6 5 . 3 
Ro 1Q-1770 c 100 4.9 100 4.9 
Ro 8-7699 c 86.1 4.9 95 4.9 
Ro 8-8717 A 100 2.9 99.4 2 . 9 
B 100 5.3 99.6 5.3 
Ro 11-1430 B 100 5.8 99.9 5.8 
Ro 11-4768 A 98.8 6.0 98.1 6.0 
B 99.7 6. 8 99.7 6.8 
Ro 12-o995 A 98.7 16.2 
SRI 2712-24 A 98.4 9.0 95.5 9.0 
<!solvent system: A (acetonitrilej1% anmcnium acetate (85:15); B 
[acetonitrilej1% anmcnium acetate (93:7)); c (acetonitrile/ 1% 
amronium acetatejtetrahydrofuran (76:16:8) ]. 
brurity determined by peak area cx:rrpared to total area un:ier peaks. 
Ctz.: retention time. 
0.05 percent. All retinoids and solutions were handled and administered under 
yellow light with as little exposure to air as possible. 
Animals 
Animals were housed, bred, and treated as described in chapter III. 
Statistics 
Statistics were performed as described in chapter III. 
RESULTS 
Neither signs of the hypervitaminosis A syndrome nor other evidence of 
maternal intoxication were observed in any of the dams during the 
experimental period (including maternal weight loss, chelitis, stomatitis, 
conjunctivitis, erythema, desquamation, alopecia, xerosis, pruritus, or 
exfoliation). Three of the thirty-nine litters recovered from Tween 20: acetone 
(95:5, v/v)-treated control dams were considered affected. One litter contained 
a dead fetus; the second contained one malformed fetus (a fused rib); and the 
third had three resorptions (Table IY.3). 
Treatment with 4.9 mg/kg or more of all-J.mM-4-oxoretinoic acid (Ro 12-
4824) increased significantly the number of affected litters compared to the 
vehicle-treated control (Table IV.3). Doses of 19.6 and 39.2 mg/kg increased 
significantly the number of resorptions compared to the control. The 
teratogenic EDso for Ro 12-4824 was 9.3 mg/kg (8.6- 10.0, 95% confidence 
interval). The dose-response curve was significantly parallel (p=0.0029) with 
that of all-trans-RA with a slope of 6.4 (5.3-7.4), and 4-oxoretinoic acid was 
1.1 (1.0-1.3) times more potent a teratogen than all-J.mM-RA on a mg/kg basis. 
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TABLE IV.3 
TERATOGENIC ACTIVITY OF Ro 12-4824 
Dose (mgjkg) 
Tween 20 4.9 9.8 20 
No. animals treated 42 9 10 8 No. litters 39 8 7 8 No. affected litters 3 5* 7* 8* No. implants 437 107 92 115 No. resorbed (%) 8 (1.8) 1 (0.93) 3 (3. 3) 9* (7.8) No. dead fetuses (%) 1(0.2) 0 (0) 1 (1.1) 1 (0.9) No. fetuses examined 428 106 88 105 No. abnormal fetuses (\) 1(0.2) 12 (11. 3) 35 (39 .8) 105 (100) Mean litter frequency of 
malformed fetuses 0.026 
Mean fetal body weight 
1.5 5.0 13.1 
(g±SD) 
Mean maternal weight 
1. 26±0.14 1. 22±0.13 1. 26±0.06 1.11±0.11 
change (g±SD) 14.4±5.4 16.7±6.5 15.2±3.3 20.2±4.4 Mill formations 
Macrostomia 0 10 31 16 Microcephaly 0 0 0 63 Encephalocele 0 0 0 11 Exencephaly 0 0 0 16 Rib fusion 1 2 4 75 Arnold-Chiari malformation 
types I or II 0 0 0 11 Cystic rachischisis 0 0 0 83 Rachischisis aperta 0 0 0 3 
39 78 
6 6 
6 4 
6* 4* 
95 46 
16* (16.8) 4 (8. 7) 
3 (3. 2) 1 (2 . 2) 
76 41 
76 (100) 41 (100) 
12.7 10.3 
0.94±0.18*0 . 97±0.14* 
22.8±4.5* 27.3±2.9* 
4 0 
58 32 
9 3 
17 9 
69 39 
17 11 
60 29 
16 11 
"' 0 
TABLE IV.3 (CON'T) 
TERATOGENIC ACTIVITY OF Ro 12-4824 
Dose (mgjkg) 
Tween 20 4 . 9 9.8 20 39 78 
Microstomia 0 0 0 73 39 1 Maxillary retrocession 0 0 0 12 0 0 Palpebral aplasia with 
exophthalmia 0 0 0 86 73 40 Protruding tongue 0 0 0 60 31 0 Aplastic or hypoplastic 
tail 0 0 0 87 76 41 Anal atresia 0 0 0 93 76 41 Lordotic skull base 0 0 0 11 17 11 Low-set, hypoplastic, or 
absent pinnae 0 0 0 105 75 41 Renal agenesis 0 0 0 9 19 1 3 Microglossia 0 0 0 0 16 9 Micrognathia or agnathiaa 0 0 0 0 36 40 General edema 0 0 0 0 4 2 Gastroschisis 0 0 0 0 3 1 
a Includes cleft mandible 
* Significantly different (p<0.05) compared to vehicle control. 
a-
Oral intubation of 9.8 or 20 mg/ kg of the Cl8 hydroxylated congener of 
all-trans-RA (Ro 12-4825) increased significantly the number of affected litters 
and decreased significantly the mean fetal body weight (Table IV.4). The mean 
litter frequency of malformed fetuses increased as the dose increased (Table 
IV.4). The ED5o for Ro 12-4825 was 9.1 mgfkg (8.5-9.7). The dose-response 
curve slope was 7.2 (5.9-8.5), and the probability that the curve was parallel 
with that for all-trans-RA was p=0.054. The potency ratio for the teratogenic 
dose-response curve of Ro 12-4825 to that of all-.tmM-RA was 1.2 (1.1-1.3). 
Intubation of the retinoid SRI 2712-24 was associated with a significant 
teratogenic response in dams treated with 5.25 mg/ kg or greater (Table IV.5). 
The highest dose of SRI 2712-24 (21 mg/ kg) also induced a significant increase 
in the number of resorbed conception sites (Table IV.5). The mean litter 
frequency of malformed fetuses increased with increasing doses of SRI 2712-24 
(Table IV.5). The teratogenic ED50 for SRI 2712-24 was 6.1 mg/kg (5.7-6.5). 
The slope of significantly parallel dose-response curve (p=O.OOO II) was 6.1 (5. 7 
- 6.5). The potency ratio for induction of terata by SRI 2712-24 versus that 
by all-.tmM-RA was 1.7 (1.6-1.9). 
Intubation of 0.53 mg/kg or higher of Ro 10-1770 increased significantly 
the number of affected litters compared to vehicle-treated animals (Table IV.6). 
The mean fetal body weight of fetuses recovered from 1.1 and 2. 7 mg/ kg-
treated dams was decreased significantly (Table 1¥.6). The mean litter 
frequency of malformed fetuses increased in a dose-dependent fashion (Table 
IV.6). The teratogenic ED5o for Ro 10-1770 was 0.55 mg/kg (0.51-0.58); Ro 
10-1770 was 19.3 times (17.6-21.1) as potent a teratogen as all-trans-RA . The 
slope of the significantly parallel dose-response curve (p=0.0036) was 6.5 (5.5-
7.4). Again, as with other retinoids in this series, although there were severe 
congenital malformations at doses of 1.1 or 2.7 mg/kg, the exposure to the 
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TABLEIV.4 
TERATOGENIC ACTIVITY OF Ro 12-4825 
[k:lse (nqlkg) 
4.9 9.8 20 
No. animals treated 7 10 6 
No. litters 7 8 6 
No. affected litters 3 7* 6* 
No. i..Jrp1ants 107 127 87 
No. resorbed (%) 1 (0.9) 4 (3.1) 4 (4.6) 
No. dead fetuses (%) 0 (0) 0 (0) 1 (1.1) 
No. fetuses examined 106 123 82 
No. abnonnal fetuses (%) 6 (5.7) 67 (54.5) 82 (100) 
Mean litter frequency of 
malfonned fetuses 0.86 8.9 13.7 
Mean fetal body 
weight (qtSD) 1.14±0.09 1.09±0.05* 1. 05±0. 07* 
Mean maternal weight c::hanJe 
(qj:SD) 14.7±3.3 17.9±3.3 16.2±5.3 
Malfonnations 
~y 0 0 6 
Mi~y 0 1 34 
~ocele 0 1 6 
Arnold-<lliari malfonnation 
types I or II 0 0 6 
Microstania 0 8 30 
Macrostania 3 34 29 
Palpebral aplasia with 
exq:tlthalmia 0 18 54 
Rib fusion 3 16 27 
Protnld.irq torvjue 0 5 33 
Maxillary retrocession 0 9 24 
cystic rachlschisis 0 0 15 
I.cM-set, hYJ;lqllastic, malfonned, 
or absent pinnae 0 30 81 
Hypcplastic tail 0 0 1 
Anal atresia 0 0 5 
lDrdotic slalll base 0 0 6 
Hypcplastic kidney 0 0 2 
*Significantly different (p<0.05) CCilpared to vehicle control. 
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TABLE IV.5 
TERATOGENIC ACTIVITY OF SRI 2712-24 
D:::se ( uq/l<g) 
2.6 5.3 10.5 21 
No. aninels treated 10 10 11 11 
No. litters 10 10 11 10 
No. affecta:l litters 4 10* 11* 10* 
No. inplants 119 107 147 129 
No. resorbed (\) 2 (1. 7) 0 (0) 6 (4.1) 10• (7 .8) 
No. dead fetuses (\) 1 (0.8) 1 (0 . 9) 0 (0) 0 (0) 
No. fetuses examined 116 106 141 ll9 
No. atnoDIBl fetuses (\) 3 (2.6) 43 (40.6) 128 (90.8) 116 (97 . 5) 
Mean litter freq.lency of 
!!Blfanned fetuses 0.30 4 . 3 11.6 11.6 
Mean fetal body weight (qtSD) 1.22±0.11 1.25±<J. 11 1.29±<J.08 1.l5±<J. OS 
Mean mternal weight 
dlan;le (qtSD) 13 . 2±4 . 2 15.8±5.2 15.8±8 . 2 20.2±7. 7 
Malfonratials 
Arnold-Oti.ari !!Blfomatim 
types I ar II 0 0 0 4 
Mic:rooep,aly 0 0 0 21 
~y 0 0 1 12 
~ooele 0 0 1 9 
1 38 128 43 
Maxillary retrocessim 1 3 10 33 
Rib fllsim 1 3 11 49 
Microstania 0 0 0 47 
Protnxtirq taque 0 0 0 36 
cystic rachischJ.sis 0 0 0 2 
IDrdotic skull base 0 0 0 4 
llypc¢astic kidney 0 0 0 2 
ID.>-set, hypoplastic, ar 
absent pinnae 0 5 65 106 
Palpebral aplasia with 
exqiltbalmia 0 0 0 7l 
Arlqttthalmi.a 0 0 0 2 
llypq:>lastic tail 0 0 0 3 
Gastrosdli.sis 0 0 0 4 
*Significantly different (p<0.05) CXIIplred to vehicle caltrol. 
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TABLE IV.6 
TERATOGENIC ACTIVITY OF Ro 10- 1770 
Dose (nq/J<g) 
0 . 3 0.5 1.1 2. 7 
No. animals treated 10 10 12 10 
No. litters 9 .10 12 10 
No. affected litters 3 9* 12* 10* 
No. i.Jq;>lants 115 120 161 128 
No. resox:becl (\) 3 (2.6) 5 (4 . 2) 5 (3 . 1) 4 (3 . 1) 
No. dead fetuses (\) 0 (0) 2 (1. 7) 2 (1.2) 0 (0) 
No. fetuses examined 113 113 154 124 
No. aln:mDal fetuses ( \) 12 (10.6) 33 (29 . 2) 153 (99 . 3) 124(100) 
Mean litter frequency of 
mlfanned fetuses 1.33 3.2 12.7 12.4 
Mean fetal body weight (g±SD) 1.32±(l.05 1 . 26±<J.ll l.lJ±(l. 09• 1.09±(l.09• 
Mean maternal weight 
~(<jj:SD) 12.4±3 . 4 l3.0;t6 . 3 13.6±5.5 19.6±3.4 
l!iilltarmati>!§ 
llic:rcgnathia or agnathiaa 0 0 0 38 
l!l.c:rooepJaly 0 0 8 71 
~y 0 0 5 14 
ErDeP>aJ.ocele 0 0 18 9 
Arnold-<hi.ari malfonnatic:n 
types I or II 0 0 0 5 
cystic rachi.schlsis 0 0 21 86 
-=rostania 8 17 115 32 
Moxil.lary ret:rcx::essim 0 3 63 32 
Rac:hisc:hlsis aperta 0 0 2 1 
Rib fusim 4 12 56 66 
Micrcstani.a 0 0 11 54 
Protzulin:] talgue 0 0 14 70 
Iarclotic skull base 0 0 0 5 
I<lo.>-set, hypcplastic, ar 
al:lsent pinnae 0 130 121 
Plllpebral aplasia with 
exq1lthaJ.ml.a 0 0 77 115 
Arqiithalm.ia 0 0 1 1 
Anal atresia 0 0 0 109 
Gast:roadlisis ar c:apw.ocele 0 0 0 6 
General- 0 0 0 l 
~c ar hypcplastic tail 0 0 8 102 
ltjpq>lastic or aplastic kidney 0 0 l 13 
*Significantly different (p<O. 05) 
a Incl. \Des cleft mandible. 
cxmporecl to vehicle cmtrol . 
highly teratogenic retinoid failed to cause a marked increase in embryonic or 
fe tal deaths as compared to the control. 
Intubation of Ro 8-7699 induced a significant increase in the number of 
affected litters at doses of II mg/ kg or higher (Table IV.7). The mean fetal 
body weight in the 5.5 mg/ kg dose group was elevated significantly compared 
with vehicle-treated controls, whereas treatment with 52 mg/ kg resulted in a 
significant decrease. As the dose of Ro 8-7699 was increased from 5.5 to 39 
mgj kg, there was an increase in the percentage of total fetuses considered 
malformed. The percentage of malformed fetuses remained at 99-100 at the 
higher dose levels. Mean maternal body weight change was increased 
significantly in the 26 and 52 mgj kg-treatment group (Table IV.7). The ED50 
for Ro g- 7699 was 11.0 mg j kg ( 10.2- 12.0) . The slope of the dose-response 
curve was 6.9 (5 .7-8.2) and was significantly parallel (p=0.0085) with that for 
all - trans- RA . Ro 8-7699 was 1.2 (1.1-1 .3) times less potent a teratogen than 
all-!mm.-RA. At the doses studied, there was an inconsistent rate of 
embryonic death. As the dose was increased from 5.5 to 52 mg/ kg, the 
resorption percentage increased , but at 79 mgj kg the percentage of resorbed 
embryos decreased to values nearly equivalent to that of the vehicle control. 
Juvenile hormone III was teratogenically inactive at doses of 33 and 67 
mg/kg (Table IV.8), doses equimolar to 39 and 75 mg/ kg of all-trans-RA, 
respectively . None of the recovered litters exposed to juvenile hormone Ill 
was affected, with only one resorption in one litter occurring in the 33 
mg j kg-dose group (Table IV.8). 
Intubation of 1.6 mgj kg or more of the chlorodimethylmethoxyphenyl 
analog (Ro 12-0995) increased significantly the number of affected litters 
(Table IV.9). Litters recovered from dams treated with 1.6, 3.1 and 6.2 mg j kg 
of Ro 12-0995 had corresponding malformation rates of 40.2, 88.5, and 98.6 
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No. animals treated 
No. litters 
No. affected litters 
No. implants 
No. resorbed (\) 
No. dead fetuses (\) 
No. fetuses examined 
No. abnormal fetuses (\) 
Mean litter frequency of 
malformed fetuses 
Mean fetal body weight (g±SD) 
Mean maternal weight 
change (g±SD) 
Malformations 
Micrognathia or agnathiaa 
Microcephaly 
Arnold-Chiari malformation 
types I or II 
Encephalocele 
Exencephaly 
Cystic rachischisis 
Rachischisis aperta 
Microstomia 
Macrostomia 
Maxillary retrocession 
Gastroschisis or omphalocele 
Cleft palate 
Rib fusion 
Palpebral aplasia with 
exophthalmia 
TABLE IV.7 
TERATOGENIC ACTIVITY OF Ro 8-7699 
Dose (mg/kg) 
5.5 11 26 39 
9 8 9 11 
7 7 7 9 
1 7* 7* 9* 
83 94 80 98 
1 (1.2) 6 (6.5) 6 (7. 5) 8* (8.16) 
1 (1.2) 1 (1.1) 2 (2 .5) 5 (5.1) 
81 87 72 85 
1 (2. 3) 49 (56.3) 69 (96.0) 85 (100) 
0.14 7.0 9.9 9.4 
1.42±0.11* 1.21±0.07 1.19±0.13 1.14±0 . 12 
14.3±4.0 19.6±4.0 22.4±2.8* 18.6±4.4 
0 0 15 22 
0 0 16 57 
0 0 3 18 
0 0 2 9 
0 2 2 3 
0 2 33 78 
0 0 1 5 
0 0 2 24 
0 32 18 22 
0 18 38 14 
0 0 0 5 
0 0 0 0 
1 10 26 42 
0 8 49 76 
52 79 
9 9 
8 9 
8* 9* 
96 109 
32* (33.0) 3 (2.8) 
5 (5. 2) 1 (0 . 9) 
59 105 
59 (100) 104 (99) 
7.4 11.8 
0.99±0.22* 1. 20±0 . 18 
~3.7±5.1* 15 . 6±5 . 4 
40 0 
48 68 
9 24 
1 2 
10 6 
47 63 
0 0 
13 50 
6 13 
4 47 
4 3 
0 2 
33 48 
56 83 
"" 
.._. 
TABLE IV.7 (CON'T) 
TERATOGENIC ACTIVITY OF Ro 8-7699 
Dose (mgjkg) 
5.5 11 26 
Anophthalmia or microphthalmia 0 0 0 
Microglossia 0 0 0 
Protruding tongue 0 1 8 
Aplastic or hypoplastic tail 0 0 18 
Anal atresia 0 0 21 
Lordotic skull base 0 0 3 
Horseshoe kidney 0 0 0 
Hypoplastic kidney 0 0 0 
Renal agenesis 0 0 4 
Low-set, hypoplastic, or 
absent pinnae 0 6 43 
•significantly different (p<0.05) compared to vehicle control. 
arncludes cleft mandible. 
39 52 
0 1 
0 9 
20 10 
75 52 
79 50 
18 9 
0 0 
7 0 
9 11 
82 57 
79 
0 
0 
68 
82 
90 
24 
3 
9 
6 
58 
"' 00 
TABLE IV.8 
TERATOGENIC ACTIVITY OF JUVENILE HORMONE III 
No. animals treated 
No. litters 
No. affected litters 
No. iDplants 
No. resorbed (%) 
No. dead fetuses (%) 
No. fetuses examined 
No. abnoDDal fetuses (%) 
Mean litter frequen:::y of 
malfonned fetuses 
Mean fetal body weight (gtSD) 
Mean maternal weight dlarqe (gtSD) 
Dose (ngjkg) 
33 
4 
4 
0 
54 
1 (1.8) 
0 (0) 
53 
0 (0) 
0 
1.36±0.04 
11.5±3.3 
67 
6 
6 
0 
77 
0 (0) 
0 (0) 
77 
0 (0) 
0 
1.31±0.06 
12.9±1.4 
69 
70 
TABLE IV.9 
TERATOGENIC ACTIVITY OF Ro 12-0995 
D:lse (nqlkg) 
o.8 1.6 3.1 6 . 2 
No. animals txeata:i l2 l2 10 10 
No. litters 8 8 9 6 
No. affected litters 3 7* 9* 6* 
No.illplants 100 101 132 75 
No. resarllErl (t) 2 (2.0) 4 (4.0) 1 (0.8) 1 (1.3) 
No. dead fetuses (%) 1 (l.O) 0 (0) 0 (0) 0 (0) 
No. fetuses examined 97 97 131 74 
No. alnD::mal. fetuses (t) 4 (4.1) 39 (40. 2) 116 (88 . 5) 73 (98 . 6) 
Mean litter trequenc:y of 
ma.l.fomed fetuses 0.50 4 . 8 12.9 12.2 
Mean fetal body weight {CJ±SD) l. 32±:0.10 1.29±:0.08 1.21±:0. 10 1.22±:0. 10 
Mean maternal weight 
chan:}e (q±SD) l8.l;t7 .9 16.1±3.9 18.1±2.6 15.9±5.4 
Malformticns 
MicrcceP>oUy 0 0 0 21 
Mic:rcstaDia 0 6 0 5 
Mac:ra;tania 0 26 108 67 
Maxillary retttx:essicn 3 5 9 62 
Palpe!Jral aplasia with 
~ 0 0 41 67 
Rib !Usicn 1 l 7 2 
I.a..l-set, hypoplast..ic, or 
absent pinnae 0 0 1 33 
*Significantly different (p<0.05) CCIIpOrEd to vehicle cr::ntrol. 
percent (Table IV.9). The ED50 for Ro 12-0995 was 1.8 mg/ kg (1.7-1.9), and 
the slope of the dose response curve was 5.7 (4.9-6 .6). The dose-response curve 
for Ro 12-0995 was significantly parallel with the of all-trans-RA (p=O.OOOl). 
Ro 12-0995 was 5.9 (5.3-6.5) times more potent a teratogen than all-trans-RA 
on a mgj kg basis. Intubation of Ro 12-0995 was, however, not embryolethal; 
even at the highest dose studied wherein nearly 99 percent of the fetuses were 
afflicted with obvious, severe malformations, only a 1.3 percent resorption rate 
was observed. This was nearly identical to the embryonic death rate of 1.8 
percent in the vehicle control group (Table IV.3). 
Doses of 85 mg j kg or more of the 4-hydroxy congener of etretinate (Ro 
11-4 768) increased significantly the number of affected litters (Table IV.! 0) . 
The numbers of resorptions were elevated significantly at the 113 and 170 
mg/ kg-dose levels . Fetuses recovered from dams treated with 113 or 170 
mg j kg of Ro 11 - 4768 had corresponding malformation rates of 85.7 and 95.0 
percent (Table IV. lO). Because the mean litter frequency of malformed fetuses 
was very similar at the 57 and 85 mgj kg-doses (Table IV.lO), the 85 mg/ kg 
data were omitted, and the ED50 of Ro 11-4768 was calculated as 87.3 mg j kg 
(80.8-93.9). Because of the similar teratogenic response rate at the 57 and 85 
mgj kg-dose levels, the dose-response curve of Ro 11-4768 was not considered 
as significantly parallel (p=0.068) with the dose-response curve for all-trans-
RA. The slope of the dose-response curve for Ro 11-4769 was 7.3 (6.1-8.5). 
On a mg,l kg basis Ro 11-4768 was 8.2 times (7.5-9.1) less potent than all-trans-
RA. 
Oral intubation of 32 mg/kg or more of the phenyl analog Ro 8-8717 
elevated significantly the number of affected litters and the number of 
resorptions . Doses of 32, 64, and 128 mg/kg were associated with resorption 
rates of 38, 79, and 100 percent, respectively (Table IV.ll). However, at doses 
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TABLE IV.10 
TERATOGENIC ACTIVITY OF Ro 11-4768 
Dose (mgjkg) 
28 57 85 113 170 
No. animals treated 8 8 11 9 9 
No. litters 8 8 7 8 9 
No. affected litters 1 3 5* 8* 9* 
No. implants 73 87 79 74 98 
No. resorbed (%) 0 (0) 4 (4. 6) 3 (3. 9) 11* (14.9) 8* (8.2) 
No. dead fetuses (%) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2. 0) 
No. fetuses examined 73 83 76 63 88 
No. abnormal fetuses (%) 1 (1.3) 5 (6.0) 4 (5.2) 54 (85.7) 84 (95.0) 
Mean litter frequency of 
malformed fetuses 0.13 0.63 0.57 6.4 9.3 
Mean fetal body weight (g±SD) 1.24±0.09 1.26±0.13 1.14±0. 01 1. 20±0 .11 1.20±0.21 
Mean maternal weight change 
(g±SD) 15.1±2.5 14.5±5.3 16.3±2.7 16.2±2.2 18.7±5.4 
Malformations 
Micrognathia or agnathia 0 0 0 3 27 
Microcephaly 0 0 0 9 34 
Arnold-Chiari malformation 
types I or II 0 0 0 3 3 
Encephalocele 0 0 0 2 1 
Exencephaly 0 0 0 0 7 
cystic rachischisis 0 0 0 0 44 
_, 
N 
TABLE IV.IO (CON'T) 
TERATOGENIC ACTIVITY OF Ro 11-4768 
---
Dose (mgjkg) 
28 57 85 
Rachischisis aperta 0 0 0 
Microstomia 0 0 0 
Macrostomia 0 3 1 
Maxillary retrocession 1 1 1 
Gastroschisis or omphalocele 0 0 0 
Rib fusion 0 2 3 
Palpebral aplasia with 
exophthalmia 0 1 0 
Anophthalmia/microphthalmia 0 0 0 
Protruding tongue 0 0 0 
Microglossia 0 0 0 
Aplastic or hypoplastic tail 0 0 0 
Anal atresia 0 0 0 
Lordotic skull base 0 0 0 
Renal agenesis 0 0 0 
Hypoplastic kidney 0 0 0 
Low-set, hypoplastic or 
absent pinnae 0 0 0 
*Signif i cantly different (p<0 . 05) compared to vehicle control. 
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10 
3 
31 
30 
0 
11 
49 
1 
7 
0 
0 
0 
3 
0 
0 
5 
170 
3 
12 
34 
34 
2 
27 
58 
1 
9 
3 
39 
40 
3 
12 
1 
41 
..... 
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TABLE IV. ll 
TERATOGENIC ACTIVITY OF Ro 8-8717 
D:Jse (rrgjkg) 
32 64 128 
No. animals treated 14 7 6 
No. litters 12 6 5 
No. affected litters 8* 6* 5* 
No. inp1ants 171 67 59 
No. resorbed ( %) 65* (38.0) 53* (79.1) 59* (100) 
No. dead fetuses (%) 2 (1.2) 0 (0) 0 (0) 
No. fetuses examined 104 14 0 
No. al:n:mna.l fetuses (%) 5 (4.8) 1 (7.1) 0 (0) 
Mean litter frequency of 
malfoi:IIlerl fetuses 0.42 0.17 0 
Mean fetal bcrly weight (qtSD) 1.15±0.11 1.03±0.12* 
Mean maternal weight change 
(qtSD) 21.1±6.0* 18. 7±1.9 25.2±4.1* 
Malfonnations 
QJPlalocele 0 1 
Rib fusion 4 0 
Al"lqiltha.lnri.a 1 0 
*Significantly different (p<0.05) c:atpa.re:l to vehicle control. 
of 32 and 64 mg/ kg only 4.8 and 7.1 percent, respectively, of the recovered 
fetuses were malformed. The mean fetal body weight of fetuses recovered 
from dams treated with 64 mg/ kg of Ro 8-8717 was decreased significantly. 
The mean maternal weight change of dams treated with 32 or 128 mg/ kg of Ro 
8-8717 was increased significantly (Table IV.ll ). The embryonic LD50 for Ro 
8-8717 was 36.7 mg/kg (35.6-41.0; 95% confidence interval). The slope of the 
dose-response curve was 2.6 (2.1 - 3.0). Ro 8-8717 was 1.5 ( 1.3 - 1.8) times 
as embryolethal as all-trans-RA. The dose-response curve for embryolethality 
of Ro 8-8717 was significantly parallel with the embryonic LD50 curve of all-
lll!ill.-RA (p=O.OOI). 
A dose of 61 mg/ kg of the fury! analog Ro 8-9750 (equimolar to 75 mg/ kg 
all-lll!ill.-RA) neither induced the characteristic syndrome of malformations 
observed with retinoid treatment nor induced a significant increase in the 
number of litters containing abnormal fetuses (Table IV.I2). All of the 
recovered fetuses were considered normal. Low rates of embryonic death were 
associated with intubation of the fury! retinoid analog. 
Intubation of 83 or 166 mg/ kg of Ro 21-6667, doses respectively 
equimolar to 75 and 150 mg/ kg of all-lll!ill.-RA, failed to induce a teratogenic 
response (Table IV.l3). All of the recovered fetuses from both dose groups 
were normal. The number of resorptions observed was near that observed in 
the control group with one and two resorptions being recorded in the 83 and 
166 mg/kg-dose groups, respectively (Table IV. l3). 
Intubation of up to 177 mg/ kg of motretinid (Ro 11-1430), the ethyl 
amide congener of etretinate (Ro I 0-9359), failed to induce a significant 
teratogenic response, however at a dose of 350 mg/ kg such a response did 
occur with five of the seven litters being affected (Table IV.l4). The 
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TABLE IV.I2 
TERATOGENIC ACTIVITY OF Ro 8-9750 
lklse (mgjkg) 
No. animals treated 
No. litters 
No. affected litters 
No. i.rrplants 
No. resorbe:i (%) 
No. fetuses examined 
No. abnormal fetuses (%) 
Mean litter frequency of 
malfonned fetuses 
Mean fetal body weight (qtSD) 
Mean maternal weight~ (qtSD) 
TABLE IV. l3 
61 
7 
4 
0 
42 
2 (4.8) 
40 
0 (0) 
0 
1.25±0.08 
14.9j:5.1 
TERATOGENIC ACTIVITY OF Ro 21-6667 
No. animals treated 
No. litters 
No. affected litters 
No. ilrplants 
No. resortlErl (%) 
No. dead fetuses (%) 
No. fetuses examined 
No. abnormal fetuses (%) 
Mean litter frequency of 
malfonned fetuses 
Mean fetal body weight (qtSD) 
Mean maternal weight ~e (qtSD) 
lklse (mgjkg) 
83 
8 
7 
0 
73 
1 (1.4) 
0 (0) 
72 
0 (0) 
0 
1.27.±0.10 
17.6±3.8 
166 
3 
3 
0 
46 
2 (4.3) 
0 (0) 
44 
0 
0 
1.19±0.16 
14.5:±3.1 
76 
77 
TABLE IV.I4 
TERATOGENIC ACTIVITY OF Ro 11-1430 
Dose (uq/kg) 
88 177 350 
No. animals treated 7 5 7 
No . litters 6 3 7 
No. affected litters 0 1 5* 
No. :i.q>lants 55 27 76 
No . resorbed (%) 0 (0) 0 (0) 2 (2.6) 
No 0 dead fetuses (%) 0 (0) 0 (0) 0 (0) 
No. fetuses el<3lllined 55 22 74 
No 0 ab1onnal fetuses (%) 0 (0) 1 (4.5) 14 (18.4) 
Mean litter frEqJency of 
malforn;d fetuses 0 0.25 2.0 
Mean fetal lx:dy weight (qtSD) 1.17:±().07 1.09±Q.l5 1.ll,_-Kl.ll 
Mean maternal weight 
change ('l!;SD) 14.2:±9.6 U.8±1.8 10.5±6.2 
MalfQI!MtiaJS 
~ocele 0 1 0 
Macrostania 0 0 9 
Maxillary retrccessicn 0 0 6 
Rib fusicn 0 0 5 
*Significantly different (p<0.05) ~to vehicle control. 
malformations included macrostomia, maxillary retrocession, and fused ribs 
(Table IV.l4). 
Each retinoid associated with a significant teratogenic response induced 
an identical syndrome of malformations that were characteristic of and 
indistinguishable from that induced by oral intubation of all-trans-RA. At 
lower doses (i.e., doses that induce ca. 50 percent malformed fetuses) these 
malformations consisted of macro- or microstomia, palpebral aplasia with 
exophthalmia and fused ribs. In general, as the retinoid dose was increased, 
the number of malformed fetuses, number of malformations per fetus, and the 
severity of malformations increased (e.g., Table IV.7). At higher doses (i.e., 
doses that induce 100 percent malformed fetuses) the more severe craniofacial 
malformations and malformations of the central nervous system predominated, 
such as microcephaly, exencephaly, and the Arnold-Chiari malformation. At 
these high doses the ears were frequently low-set, malformed, or absent with 
an atretic or stenotic external auditory meatus. The characteristic caudal 
regression syndrome composed of cystic rachischisis, rachischisis aperta, 
hypoplastic or aplastic tail, and anal atresia was routinely observed in fetuses 
recovered from dams treated with retinoid doses that induced a high 
percentage of malformed fetuses. 
DISCUSSION 
The present results demonstrate that major modifications of the natural 
8-cyclogeranylidene (2,6,6-trimethyl-1-cyclohexenyl) ring of the retinoid 
skeleton can be made without eliminating teratogenic potency, as was 
previously found on studies with the norbornyl and cyclohexyl ring analogs 
(Willhite et al., 1984). In the present study, two different classes of ring 
modifications, polar substituent changes on the ring of all-!rl!.ill.-RA (Ro 12-
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4824, Ro 12-4825, Ro 10-1770, Ro 8-7699, Ro 8-9750, SRI 2712-24, and juvenile 
hormone III) and modifications of the trimethylmethoxyphenyl ring of 
etretinate (Ro 8-8717, Ro 11-1430, Ro 11-4768, Ro 21-6667, Ro 12-0995), were 
investigated. Major perturbations in ring structure do not have the 
corresponding effect on teratogenic potency that similar modifications in the 
retinoid polar terminus (Willhite et al., 1984) or polyene chain (Willhite, 1986) 
have. 
all-.trl!m.-4-0xoretinoic acid (Ro 12-4824), a metabolite of orally 
administered all-trans-RA in hamsters (Frolik et al., 1979; 1980; Frolik, 1981 ), 
exhibited teratogenic potency on a molar basis (ED50= 30 pmole/ kg) that was 
essentially equivalent to that of all-trans-RA (ED50= 35 }!mole/ kg) (Willhite and 
Shealy, 1984). This ring modification, which is the same as that found in that 
natural carotenoid cathaxanthin, is indicative of metabolic deactivation (Frolik 
et al., 1979;1980; Frolik, 1981), according to the present results the metabolite 
is equitoxic to the parent acid. At present it is unknown to what extent the 
oxidized, teratogenic metabolites contribute to the embryotoxicity of all-J..[llm-
RA and 13-lli-retinoic acid (13-lli-RA, isotretinoin). These observations are 
consistent with those of Goulding and Pratt (1986), Webster et al. (1986), and 
Kochhar and Penner (1987), who found the 4-oxo metabolite of 13-ill-RA 
equipotent to 13-ill-RA in intact pregnant ICR or C57 Bl/6J mice, cultured 
CO-l mouse embryos, cultured CFHB rat embryos, and cultured ICR mouse 
forelimb buds. 4-0xoretinoic acid was nearly as active as all-trans-RA in the 
hamster tracheal organ culture assay (4-oxoretinoic acid ED50 = 700 pM; all-
J..[llm-RA ED50 = 30 pM) (Newton et al., 1980). Introduction of either a 
hydroxyl group (Ro 12-4825) or a methyl group (SRI 2712-24) on the methyl 
group at the 2-position of the trimethylcyclohexenyl ring failed to markedly 
alter teratogenic potency as compared to all-trans-RA. Replacement of 
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trimethylcyclohexenyl ring with a 5,5-dimethyl-1-cyclopentenyl ring having a I-
methoxyethyl group (Ro 10- I 770) or an acetyl group (Ro 8-7699) at the 2-
position was associated with significant teratogenic activity. In fact, Ro I 0-
I 770 was 19 times more potent a teratogen than all-trans-RA, and Ro 8-7699 
had activity comparable to all-trans-RA. Ro 10- I 770 was almost as active as 
all-trans-RA in the hamster tracheal organ culture assay (Sporn et al., I 975; 
Newton et al., I 980) and was at least as effective in binding to chick embryo 
skin cellular retinoic acid-binding protein (cRABP) (Sani et al., 1978). Ro 8-
7699 induced embryonic chick tarsometatarsal ptilopody at the same 
concentrations as all-trans-RA (Cadi et al., 1984), was more potent than all-
trans-RA in the fetal rat bone culture (Kistler, I 98 I), and possessed greater 
affinity for chick skin cRABP (Sani and Hill, 1974;1976). Its ester derivative 
induced regression of mouse skin papillomas and had a more favorable 
therapeutic ratio than that of all-.trl!ill,-RA (Mayer et al., 1978). Therefore, 
polar groups can be introduced at positions corresponding to the 2- and 3-
positions of the cyclohexenyl ring without loss of teratogenic potency. 
The last compound in this series that was examined was juvenile hormone 
IJJ, which only retains three carbons of the cyclohexene ring and the methyl 
at the 2-position. In addition, the ring double bond has been replaced by a 
oxyrane ring and the bonds corresponding to the 7,8- and 9,10-double bonds of 
the retinoid side chain have been saturated. This compound was not 
teratogenic in hamsters, just as it was inactive in the hamster tracheal organ 
culture assay (Newton et al., 1978). 
As early as 1960, Morton suggested that retinoid analogs having 
hydroxylated polyene chain or ring would be useful compounds. Replacement 
of the trimethylcyclohexenyl ring of ethyl all-.trl!ill,-retinoate with a 2,3,6-
trimethyl-4-methoxyphenyl ring affords the dermatological agent etretinate (Ro 
80 
I 0-9359) , a human (Happle et al., 1984; Grote et al., 1985) and hamster 
(Williams et al. , 1984) teratogen that is twice as potent as all-trans-RA . 
Replacement of the 2-methyl group with a smaller, electron-withdrawing chloro 
group afforded Ro 12-0995, which was six times more potent as a teratogen in 
hamsters than all-trans-RA and at least three times more potent than 
etretinate. In contrast, Ro 12-0995 had low activity in inducing differentiation 
of HL-60 leukemia and RDFD myeloblast cells, was only a poor inducer of 
cAMP-dependent protein kinase activity (Fontana et al., 1986), and was 
relatively inactive in the hamster tracheal organ culture assay (Newton et al., 
1978). It was only somewhat active in causing the regression of mouse 
epidermal papillomas and had a therapeutic ratio in mice that was ten-fold 
lower than that of all-.tmm.-RA (Mayer et al. , 1978). Replacement of the 
methoxy group on the ring with the more polar hydroxyl (Ro 11-4768) 
decreased teratogenic potency 15-fold compared with etretinate (Williams et al., 
1984). This phenol was inactive in the hamster tracheal organ culture assay 
(Newton et al. , 1980). 
Removal of the substituents from the phenyl ring afforded Ro 8-8717, 
which was embryolethal, being approximately 1.5 times as toxic as all-trans-
RA, but did not induce the characteristic teratogenic syndrome in fetal 
hamsters observed for teratogenic retinoids (Table IV.II). Ro 8-8717 was a 
poor ligand for chick embryo skin cRABP (Sani and Hill, 1976), was not a 
ligand for embryonal carcinoma cells (Jetten et a!., 1982), failed to induce 
differentiation of embryonal carcinoma cells, and had only marginal activity in 
the hamster tracheal organ culture allay (Newton et a!., 1980). The related 
furan (Ro 8-9750) was not teratogenic (Table IV.I2). It was also inactive in 
the hamster tracheal organ culture (Newton et a!., 1980), showed I 0 percent of 
the activity of all-trans-RA in embryonal chick skin (Wilkoff et al., 1976), 
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but could compete effectively for the retinoic acid-binding site of chick 
embryo skin cRABP (Sani and Hill , 1976). The results on Ro 8-8717 and Ro 8-
9750 indicate that the substituents on the aromatic ring are required for 
activity. 
Two other retinoids in this series were also examined. The analog of 
etretin having a thiomethylene group on the side chain in place of the trans 
8,9-double bond (Ro 21-6667) did not show teratogenic effects up to a dose of 
166 mg/ kg. In contrast, 7 ,8-dihydroretinoic acid exhibited significant 
teratogenic activity (Willhite, 1986). Therefore, the double bond adjacent to 
the aromatic ring does not appear necessary for activity because saturation, 
which increases rotation about the bond and disrupts rr -electron delocalization 
ac ross the retinoid, did not abolish activity. It is more likely that rapid 
metabolism of the thio group afford more polar, inactive species. This 
compound was also inactive in the hamster tracheal organ culture assay 
(Newton et al., 1978) and was a poor ligand for chick embryo cRABP (Sani et 
al., 1978). 
The N-ethyl amide (Ro 11-1430, motretinid) of etretin, which is the major 
teratogenic metabolite of etretinate (Kistler and Hummler, 1985), was inactive 
as a teratogen at a dose of 177 mg/ kg, however an extremely large dose (350 
mg/ kg) was teratogenic. This same paradigm was observed for other 
retinamides including the N-ethyl and N-(2-hydroxyethyl) amides of all-J.!:ill-
RA and 13-ru-RA (Willhite and Shealy, 1984). The significant teratogenic 
response of motretinid (Table IV.I4) at the large dose is consistent with the 
suggestion (Kochhar et al., 1987) that after a very large dose the limited in 
lllli biotransformation of the amide to the acid assumes toxicological 
significance. These results contrast with those of Kochhar et al. (1987), who 
reported that a single oral I 00 mg/ kg dose of motretinid to pregnant ICR and 
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NMRI mice induced a 35% and 70% frequency , respectivel y, of cleft palate . 
The present results in hamsters agree with other findings of low activity or 
inactivity for the amide such as those of Kistler (1981) of inactivity in fetal 
rat bone culture and of Zimmerman and Tsambaos ( 1985) in embryonic mouse 
limb bud mesenchymal cell cultures. The amide and its ethyl ester congener 
did not suppress chondrogenesis in cultured ICR mouse limb buds, whereas the 
free acid, as well as aii-~-RA and 13-Qi-RA, at a dose of 50 ng/ ml did 
(Kochhar et al., 1987). The amide was ineffective against experimental 
mammary or urinary cancer in rats (Moon et a!., 1983 ). In other assay 
systems, motretinid displayed biological activity and low toxicity. It inhibited 
radiation-induced oncogenic transformation (Harisiadis et a!., 1978), enhanced 
ce ll-mediated immunity (Athanassiades, 1981), and induced the reg ress ion of 
carcinomas and established papillomas in mice (Bollag, 1975; Bollag and Matter, 
1981). It was reported to have a more favorable therapeutic ratio than all-
trans- RA (Mayer et a!. , 1978), was as active as etretinate in reversing 
epithelial cell keratinization in hamster tracheal organ culture (Newton et al., 
1978), and was active in the embryonal chick skin bioassay (Wilkoff et al., 
1976). 
Motretinid is clinically available in Europe (Cunningham and Ehmann, 
1983) for the control of cystic acne as an alternative to systemic 
administration of the human teratogen 13-Qi-RA (Lammer et al., 1985). It is 
effective when applied topically against ichthyosis vulgaris (Berger and 
Tsambaos, 1981) and against papular and pustular acne vulgaris as a 0.1% 
solution having less skin irritation than topical all-trans-RA (Scherrer and Ott, 
1976). This ethyl amide congener may present a larger, and hence more 
favorable, therapeutic ratio for dermatologic purposes than other currently 
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available retinoids when the high risk of toxicity in women of childbearing age 
is considered (Lammer et a!., 1985). 
When the present results in hamsters are compared with those in intact 
chick embryos, cultured embryonal cells, the hamster tracheal organ culture 
assay, and cell-free systems with their known or anticipated metabolic 
products, consistent patterns emerged. The hydrophobic head of the retinoid 
skeleton can assume either a twist chair or aromatic planar conformation and 
retain teratogenic activity providing sufficient hydrophobic substituents are 
present on the ring. These substituents may reside either out of the plane of 
the ring as in the case of the cyclohexenyl ring-bearing retinoid or in the 
plane of the aromatic ring as in the case of the etretin congeners . Polar 
groups such as methoxy, hydroxy, and keto may be substituents on either the 
ring or on carbons adjacent to the ring without loss of teratogenic activity. 
Thus, retinoid teratogenicity is dependent upon not only a polar terminal group 
having an acidic pKa and uninterrupted TI -electron delocalization across a 
molecule of sufficient length but also on the hydrophobicity of the head. The 
three-dimensional structure and · charge-transfer properties of retinoids have 
roles in their teratogenic activities (Flanagan et a!., 1987). Studies on the 
contributions of retinoid conformation and the roll of the cellular binding 
proteins in retinoid teratogenesis are necessary to formulate more accurate 
structure-activity predictions. 
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CHAPTER V 
COMPARATIVE DISTRIBUTION, PHARMACOKINETICS, AND PLACENTAL 
PERMEABILITIES OF ALL-TRANS-RETINOIC ACID, 13-CIS-
RETINOIC ACID, ALL-TRANS-4-0XO-RETINOIC ACID, 
9-QS-RETINAL, AND RETINYL ACETATE 
INTRODUCTION 
Certain retinoids are potent human (Lammer et a!., 1985; Willhite et a!., 
1986; Happle et a!., 1984) and animal (Howard and Willhite, 1986) teratogens. 
Various investigators have examined the effect of polar terminus (Willhite et 
a!., 1984; Willhite and Shealy, 1984), side-chain (Willhite, 1986), and 
cyclohexenyl ring (chapter IV) modifications on teratogenic potency. The 
differences in teratogenic potency may be related to differences in absorption, 
elimination, distribution, placental permeability, or to differential binding 
affinity(ies) with (a) putative intracellular receptor(s). 
The pharmacokinetics and distribution of five retinoid analogs in pregnant 
hamsters were studied here. The retinoids included the reference compound 
all-trans-retinoic acid (all-tmM-RA), the side-chain modified 13-cis-retinoic 
acid (13-cis-RA), the polar end group modified retinyl acetate, the ring 
modified all-trans-4-oxoretinoic acid (all-trans-4-oxo-RA), and the side-chain 
and polar terminus modified 9-ffi-retinaldehyde (9-cis-retinal). 
MATERIALS AND METHODS 
Chemicals 
The tritiated retinoids all-tmM-[10,11-3H2]-retinoic acid (95%, 3.39 
Cijmmole in toluene), 13-cis-[ll-3H]-retinoic acid (95.9%; 3.21 Ci/mmole in 
toluene), all-trans-4-oxo-[ll-3H]-retinoic acid (95.2%; 3.1 Ci/mmole in toluene), 
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9-ru-[ll-3H]-retinaldehyde (95.0%; 1.97 Ci/ mmol in toluene), and all-l!:ll.!!.!.-
[ 10, ll-3H2]-retinal acetate (95 .2%; 3.39 Ci/mmol in toluene) were obtained 
under the courtesy of the Biological and Chemical Prevention Program, 
Chemical and Physical Carcinogenesis Branch, Division of Cancer Cause and 
Prevention, National Cancer Institute , NIH, Bethesda, MD. Nonlabeled all-
trans - retinoic acid (all-trans-RA), 13-ru-retinoic acid (13-ill-RA), and retinyl 
acetate were purchased from Kodak , Rochester, NY. all-trans-4-0xoretinoic 
acid (Rol2-4824; all-l!:ll.!!.!.-4-oxo-RA) , 9-ru-retinaldehyde (9-cis-retinal) and the 
metabolite of 13-ru-RA, 13-ill-4-oxoretinoic acid (13-ill-4-oxo-RA) were gifts 
of Hoffmann-La Roche, Inc ., Nutley, NJ . Nonradioactive compounds were 
chromatographed by a previously described system (Willhite and Shealy, 1984); 
all were greater than 95% pure. 
Aliquots of radioactive retinoids (in toluene) were pipetted into a 
volumetric flask, and the cold retinoid was added and dissolved. The solution 
was then diluted in Tween 20 (polyoxyethylenesorbitan monolaurate, Sigma 
Chemical Co., St. Louis, MO), such that the final toluene concentration was 
20%. Nonlabeled retinoids were dissolved in a small volume of reagent grade 
acetone (Fisher Scientific, Pittsburgh, PA) and subsequently dissolved in Tween 
20. The final acetone concentration did not exceed five percent. 
Animals 
Animals were purchased, bred , and housed, as described in chapter III. 
Treatment 
Two studies were performed. The first study investigated the comparative 
distribution and placental permeabilities, and the second evaluated comparative 
pharmacokinetic parameters of the parent retinoids . In the first study (Phase 
I), six pregnant hamsters were dosed with a single oral intubation of [3H]-all-
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.trl!ill_-RA, and six additional pregnant hamsters were dosed with [3H]-13-cis-
RA. Five pregnant hamsters were given [3H]-all-trans-4-oxo-RA, and five 
received [3H]-retinyl acetate . Four pregnant hamsters received [3H]-9-cis-
retinal. Administered doses were equivalent to 10.5 mg/kg all-.trl!ill_-RA (35 
,umol/ kg; 35 ,uCi/animal) in Tween 20 on day eight of pregnancy. The plasma 
was collected at prespecified intervals (see below) and the radioactivity 
counted. The dams were killed 96 h after dosing. Tissues were collected, 
digested, and radioactivity was counted. In the second study (Phase II) 
nonradiolabeled compound was administered to three animals for each chemical , 
and plasma was collected up to 24 h after dosing. Plasma was assayed by high 
performance liquid chromatography to quantify retinoid levels. 
Blood and Tissue Collection Schedule 
Blood was collected from the post-orbital plexus in heparinized glass 
hematocrit tubes at 0.5, I, 2, 4, 6, 8, 12, 24, 36, 48, 72, and 96 h after 
administration of the radiolabeled retinoids. The heparinized blood was 
centrifuged immediately after collection in a microhematocrit centrifuge for 10 
min to obtain plasma. The plasma was weighed, placed into scintillation vials, 
and mixed with 200 Jll of 70% aqueous perchloric acid (Fisher Scientific, 
Pittsburgh, PA). The plasma solution was incubated at 60°C for 4 h. The 
incubated solution was cooled to room temperature and mixed with 500 ,ul of 
30% hydrogen peroxide (Fisher Scientific). The samples were subsequently 
incubated at 60°C for 4 h to decolorize. Samples were cooled to room 
temperature, and 15 ml of scintillation fluid were added (7:3 toluene-
scintillation surfactant with 0.28 percent Preblend 2a70, Fisher Scientific, 
Pittsburgh, PA and Research Products International Corp., Mount Prospect, lL, 
respectively). Tissues were homogenized with two volumes of distilled water, 
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and a 150 pi aliquot was taken to be processed as described above . The 
residual radioactivity was counted in a Beckman LS 380 I scintillation counter. 
Tritium activity was quantified by using an external standard quench correction 
mode. 
High Performance Liquid Chromatography 
In the second phase of the study, whole blood was collected, centrifuged, 
and weighed as described above. Three hundred ul of HPLC grade methanol 
(Fisher Scientific) were added to each plasma sample (90-150 pg) , the samples 
purged with argon and stored at -80°C, until chromatographic separations could 
be performed. Samples were thawed in a dark room at room temperature and 
then centrifuged at I 0,000 x g for 30 min. The supernatant was decanted and 
filtered through 0.2 )Jm microfilter (Bioanalytical Systems, West Lafayette , IN) 
at I ,000 x g for 5 min. The methanol extracted samples were analyzed by 
HPLC using a Varian Model 5000 chromatograph equipped with a Spherisorb 
ODS 5-)Jm column (Universal Scientific, Atlanta, GA) and a Spherex CIS 5-cm 
X 4.6-cm pre-column (Phenomonex, Rancho Palos Verdes, CA). The HPLC 
grade acetonitrile and water (J. T. Baker, Jackson, TN) were filtered (0.2 )Jm) 
and vacuum-degassed prior to use. Two hundred )Jl of extracted plasma were 
injected onto the column. The retinoids all-!rll.!Jj_-RA, 13-cis-RA, and all-
trans-4-oxo-RA were monitored at 365 nm with a flow rate of 1.5 mljmin. 
The 9-ill-retinal was chromatographed using a flow rate of 1.0 ml/ min and 
monitored at 365 nm. Retinyl acetate was chromatographed using a flow rate 
of 1.5 ml/ min and monitored at 340 nm. Under these respective conditions all-
trans-RA, 13-cis-RA, all-!rll.!Jj_-4-oxo-RA, and 13-ill-4-oxo-RA had respective 
retention times of 8.86, 5.91, 3.87, and 3.70 min. Handling of retinoid solutions 
was done under yellow light. Retinoid levels were quantified using a Hewlett-
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Packard model 3390A (Hewlett Packard, Rockville, MD) integrator in peak 
height mode with an external standard. 
Plasma concentration values were fitted to a curve with a nonlinear 
regression program (Metzler et al., 1974; Sedman and Wagner, 1977) Area 
under the curve (A UC) was calculated using the trapezoidal method of Giabaldi 
and Perrier (1982 ). 
RESULTS 
Distribution 
Ninety-six h after administration of 10.5 mgj kg [3H]-all-trans-RA, 
radioactivity was distributed equally to all sampled tissues, except perirenal fat 
(Figure V.I). The perirenal fat contained 0.9 nmol eq./g tissue; whereas, other 
sampled tissues contained approximately 2.5-3.0 nmol eq./ g tissue. The liver 
had the most radioactivity (3.5 nmol eq. j g tissue , Fig. V. l). 
The pattern of radioactive distribution 96 h following an oral dose of 10.5 
mg/ kg [3H]-13-ill,-RA closely resembled that of [3H]-all-l.!:l!.!ll-RA (Fig . V. l). 
As was the case for [3H]-all-l.!:l!.!ll-RA, the perirenal fat contained 
approximately three times less radioactivity than other tissues; the liver 
contained the most (7 .1 nmol eq.jg tissue) (Fig . V. l) . The amount of 
radioactivity in tissues, except fat, was greater for 3H-13-ill,-RA than for 
[3H]-all-l.!:l!.!ll-RA (Fig. V.l). 
Radioactive tissue distribution after an equivalent dose (II mg j kg) of 
[3H]-all-trans-4-oxo-RA was very similar to the radioactive distribution of the 
free acids 3H-all-l.!:l!.!ll-RA and [3H]-13-cis-RA (Fig. V.I). Again, as with the 
first two free acids, perirenal fat contained the least amount of radioactivity 
96 h after dosing. The amount of radioactivity found in tissues after oral 
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Figure V.I. Distribution of radioactivi~ in pregnant hams~ers following oral 
administration of [3H)-all-triii1-RA, [ H]-13-ili-RA, or [ H)-aii-1IIII1-4-oxo-
RA. Tissues were sampled 96 h after doses of 10.5 mgjkg 13-ill-RA (I), 11.0 
mg/kg all-llliM-4-oxo-RA Q:::z), or 10.5 mg/kg all-.tam-RA (p). Disintegrations 
per minute (DPM) were converted to nmol equivalents/ gram tissue. Bars 
represent S.E.M. 
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administration of [3H]-all-trans-RA was consistently lower after administration 
of an equimolar amount of [3H]-all-!rl!!!i-4-oxo-RA (Fig. V. l). 
In sharp contrast to the distribution of the free acids, [3H]-9-lili.-retinal 
and [3H]-retinyl acetate were distributed in a dissimilar manner. Radioactivity 
accumulated in the lungs and liver of animals treated with 10.5 mgjkg [3H]-9-
m-retinal; the organs contained 118 and 96.8 nmol eq./g tissue, respectively 
(Fig . V.2). Remaining tissues also contained radioactivity, but at levels less 
than nmol eq.(g tissue (Fig. V.2). Treatment with 12.1 mgj kg [3H]-retinyl 
acetate also resulted in the bulk of radioactivity accumulating in the lungs and 
liver with lesser amounts being distributed to other tissues (Fig. V.3). The 
lungs and liver of animals treated with [3H]-retinyl acetate had corresponding 
concentrations of 17.2 and 16.5 nmol eq./ g tissue. 
Pharmacokinetics 
The level of all-!rl!!!i-RA peaked at I h after oral administration with a 
rapid decline between 2 and 4 h sampling. (Fig. V.4). The apparent elimination 
half-life for all-trans-RA was estimated to be 0.5 h. The metabolites 13-lli-
RA and all-trans-4-oxo-RA were present at 0.5 h after dosing with 10.5 mg/ kg 
all-!rl!!!i-RA . These metabolites persisted for 12 and 24 h, respectively. Peak 
plasma concentrations of both metabolites occurred 2 h after dosing. 
Detectable amounts of all-!rl!!!i-RA were absent from the plasma after 4 h 
(limit of detection= 0.16 nmol/g plasma). 
The pharmacokinetic parameters of 13-lli-RA are presented in table V.I. 
The parameters were obtained from nonlinear regression fittings of animal 
plasma concentration-time values. The t1 ; 2 for 13-ill-RA was 4.41 h, and the 
AUC was 22.38 nmol.h/ g. Isotretinoin (13-lli-RA) reached peak plasma 
concentrations I h after dosing (Fig. V.5), followed by exponential elimination. 
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Figure V.3. Distribution of radioactivity 96 h after a single oral dose of 12.1 
mg/ kg [3H]- retinyl acetate to day-eight pregnant hamsters. Disintegrations per 
minute (DPM) were converted to nmol equivalents/ gram tissue . Bars represent 
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Figure V.4. Plasma concentrations of retinoids following administration of all-
trllM-RA to day-eight pregnant hamsters. Hamsters were dosed with 10.5 
mg/kg all-lillM-RA, and plasma was assayed by HPLC for concentrations of 
all-l!llru.-RA ~. 13-ru-RA ~). and all-trllM-4- oxo-RA !llj. Concentrations at 
time points greater than 4 and 12 h for all-lillM-RA and 13-ru-RA, 
respectively, were less than the analytical limit of detection (< 0.15 and 0.16 
nmol/g, respectively). Each point is the mean value of separate determinations 
of plasma obtained from three hamsters. Disintegrations per minute were 
converted to nmol eq~ivalents/ gram plasma for total radioactivity !Ell following 
oral administration of ( H]-all-lillM-RA. 
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TABLE V.l 
PHARMACOKINETIC PARAMETERS OF 13-QS-RA 
Animal Number 
Parameter 2 Mean± SO 
tl / 2 3.48 4.35 5.41 4.4! ± 0.97 
AUC (nmol.h/ g) 20.37 21.86 24.91 22.38 ± 2.31 
t1 ; 2 =Half-life for rapid elimination phase 
AUC = Total area under plasma concentration vs. time curve 
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Figure V.5. Plasma concentrations of retinoids following administration of 13-
!<il-RA to day-eight pregnant hamsters. Hamsters were dosed with 10.5 mg/kg 
13-!<il-RA, and plasma was assayed by HPLC for concentrations of 13-lli-RA 
~. all-tnM-RA (+), and 13-lili_-4-oxo-RA ~- Concentrations at time points 
greater than I and 12 h for all-.tr.aru-RA and 13-lili_-RA, respectively, were less 
than the analytical limit of detection (< 0.15 and 0.16 nmol/ g, respectively). 
Each point is the mean value of separate determinations of plasma obtained 
from three hamsters. Disintegrations per minute (DPM) were converted to 
nmol equivalentsl gram plasma for total radioactivity (-&) following oral 
administration of (JH]-13-s;U-RA. 
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The parent 13-lli-RA persisted for 12 h, after which it was undetectable (limit 
of detection = 0.15 nmol/ g plasma. Two metabolites, all-!rruJ.i-RA and 13-cis-
4-oxo-RA, were present after a 10.5 mg/ kg dose of 13-cis-RA (Fig. V.5). 13-
cis-4-0xo- RA was present in higher concentrations and persisted longer in the 
plasma than its parent, 13 - ill-RA. Low concentrations of all-!rruJ.i-RA were 
detected at 0.5 and I h (Fig . V.5). 
The pharmacokinetic parameters of all-!rruJ.i-4-oxo-RA are indicated in 
table V.2 . all-!rruJ.i-4-0xo-RA reached peak plasma concentrations 0.5 h after 
dosing followed by exponential elimination with a t1;2 of 5.67 h (Fig. V.6 and 
Table V.2). The AUC was 28.66 nmol.h/ g. 
The time-course of radioactivity for [3H]-9-ill-retinal and [3H]-retinyl 
acetate is shown in figures V.7 and V.8 , respectively. Pharmacokinetic 
parameters for 9-ill-retinal and retinyl acetate were not calculated due to 
undetectable plasma concentrations. (The limit of detection was 0.56 and 0.18 
nmol/g plasma, respectively, for 9-ill-retinal and retinyl acetate.) An 
unidentified, more polar metabolite of 9-ill-retinal appeared at 0.5 h, peaked 
at I h , and persisted for 4 h. The retention time of the peak did not 
correlate with that of all-!rruJ.i-retinaldehyde, all-!rrul.i-RA, or 13-ill-RA. 
DISCUSSION 
Distribution 
The radioactivity associated with retinoids studied here crossed the 
placental barrier and entered the conceptus. The placental transfer and 
concentration of vitamin A in placental and fetal tissues have been studied in 
a variety of species. Kochhar ( 1976) demonstrated transplacental passage of 
the label associated with [3H]-all-!rruJ.i-RA in mice. Creech-Kraft et al. (I 987) 
determined the transplacental passage of all-!rruJ.i-RA and 13-ffi-RA and their 
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TABLE V.2 
PHARMACOKINETIC PARAMETERS OF ALL-TRANS-4-0XO-RA 
Parameter 
tl / 2 
AUC 
4.32 
32.12 
Animal Number 
2 
3.54 
22.67 
t1 ; 2 • Half-life for rapid elimination phase 
3 
9.15 
31.20 
A UC • Total area under plasma concentration vs. time curve 
Mean± SD 
5.67 ± 3.04 
28.66 ± 5.21 
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Figure V.6. Plasma concentration of retinoid following administration of all-
~-4-oxo-RA to day-eight pregnant hamsters. Hamsters were dosed with 
I 1.0 mg/kg all-~-4-oxo-RA, and plasma was assayed by HPLC for 
concentration of all-~-4-oxo-RA t+). Each point is the mean value of 
separate determinations of plasma obtained from three hamsters. Disintegrations 
per minute (DPM) were converted to nmol equivalents/ gram plasma for total 
radioactivity fit following oral administration of (3H)-all-1mnl-4-oxo-RA. 
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Figure V.7. Plasma concentration of radioactivity following oral administration 
of 10.5 mg/kg [3H]-9-l:i1-retinal to day-eight pregnant hamsters. 
Disintegrations per minute (DPM) were converted to nmol equivalents/ gram 
pluma for total radioactivity, 
0 
0 
1 0 ~--------------------------------------------------. 
Ui 
t: 
Q) 
-ca 
.~ cu 
::I E 
0" VI cu 
-t· .·. ·~ Q) 
0 
E 
c: 
Q. 
Cl 
. 1~rr~~rr~~rr~~~~,-~~(~~.-~~--~-r.-~~ 
0 2 4 6 8 1 0 12 14 1 6 1 8 20 22 24 30 40 50 60 70 80 90 1 00 
Time (h) 
Figure V.8. Plasma concentration of radioactivity following oral administration 
of 11.2 mgfkg (3H)-retinyl acetate to day-eight pregnant hamsters. 
Disintegrations per minute (DPM) were converted to nmol equivalents/ gram 
pluma for total radioactivitY. 
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corresponding metabolites, all-.t.rllru.-4-oxo-RA and 13-ill-4-oxo-RA, in NMRI 
mice. Each compound was transferred to the embryo, but transfer of the .t.rllru. 
isomers was accomplished to a much greater extent than the I 3-ill isomers; 
the .t.rllru. isomers' concentration was 20-fold more than the 13-ill isomers' 
(Creech-Kraft et al., 1987). Based on radioactivity, the results here indicate 
neither isomer had appreciable accumulation in the fetus 96 h following dosi ng . 
However, this does not rule out the possibility of this occurring at earlier 
stages of embryogenesis. It must be recognized that much of the radioacti vity 
in circulation was in forms other than the parent compound and recognizab le 
metabolites at the time of tissue sampling. It may be assumed that only a 
small fraction of radioactivity in tissues represents active chemicals. 
In a human abortus obtained 72 h after the last oral dose of 13-ill- RA 
(isotretinoin; Accutan~, circulating maternal concentrations were 15 and 10 
ng/ ml, respectively, for 13-ill-RA and all-.t.rllru.-RA. The embryo (cephalic 
region) contained 1,200 and 2,800 ng/ g of 13-ill-RA and all-trans-RA, 
respectively, and the placental concentrations of 13-ill-RA were 2,800 - 3,000 
ng/ g. Circulating concentrations of the primary metabolite of 13-ill-RA, 13-
ill-4-oxo-RA, were also detected in the maternal blood and embryo (cephalic 
region) amounting to 32 and 74 ng/ g, respectively (E. Lammer, personal 
communication). Retinol concentrations were 600, 400, and 300-400 ng/ g 
corresponding to maternal blood, embryo, and placenta. It is unknown to what 
extent the 4-oxo metabolites of the .t.rllru. and 13-ill isomers contribute to the 
teratogenicity of the parent compound. In hamsters a single oral dose of all-
.t.rllru.-4-oxo-RA administered on day eight of gestation resulted in 
teratogenicity equal to that of all-.t.rllru.-RA (EDso = 10.5 mg/ kg for all-trans-
RA; EDso = 9.6 mg/ kg for all-.t.rllru.-4-oxo-RA) (chapter IV). 
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Pharmacokinetics 
Several investigators (Wang et al., 1980; Kalin et al., 1981) have reported 
nonexponential elimination of all-.tmru.-RA from mouse serum. Other 
investigators have indicated that all-.tmru.-RA was eliminated from rat serum 
following first-order kinetics as the dose was decreased (Swanson et al., 1980; 
Swanson et al., 1981). The saturable elimination of all-trans-RA differs from 
the exponential elimination of 13-ffi-RA observed in mice (Kalin et al., 1982) 
and hamsters (Table V.l). 
Isotretinoin (13-m-RA) is rapidly absorbed from the G.I. tract and 
undergoes enterohepatic circulation in humans (Colburn et al., 1983a; Khoo et 
al., 1982; Goodman et al., 1982). Peak plasma concentrations occurred between 
I and 4 h after administration (Khoo et al., I 982; Goodman et al., 1982; Lucek 
and Colburn, 1985; Colburn and Gibson, 1985). Human pharmacokinetic data 
could be described by bi- or triexponential equations (Khoo et al., 1982), but a 
recycling model fit the plasma data best. The presence of food in the gut and 
the type of pharmaceutical preparation (Colburn et al., 1983b; Shelley et al., 
1982) can affect the absorption of the drug. Peak circulating plasma 
concentrations and bioavailablility were greater when the drug was 
administered following a meal than when the gut was empty (Colburn et al., 
1983b). The elimination half-lives in man ranges from 4 (Kerr et al., 1982) to 
13 to 14 (Colburn et al., 1983a) to 25 h (Goodman et al., 1982; 1983) Neither 
the parent nor its metabolite, all-.tmru.-RA, is eliminated in the urine; they are 
primarily eliminated in the feces (Khoo et al., 1982). 
The primary metabolites of all-.tmru.-RA and 13-cis-RA in hamsters are 
the corresponding 4-oxo compounds (Frolik et al., 1979; I 980; Frolik, 1981; 
Vane et al., 1982; Colburn and Gibson, 1985; Brazzell et al., 1983). In humans 
receiving multiple doses of 13-m-RA, the circulating concentration of 13-lli-
103 
4-oxo-RA exceeded that of the parent compound (Brazzell et al., 1983). This 
was also observed with single oral doses administered to hamsters in this 
study. The production of the 4-oxo metabolites is catalyzed by hamster liver 
and tracheal tissues (Frolik et al., 1979; Roberts, 1981 ). In vivo 13-ill- RA is 
metabolized to all-trans-4-oxo-RA (Lucek and Colburn, 1985; McCormick et al., 
1983). In hamsters , all-trans-RA and 13-ffi-RA can be metabolized to 13-ill-4-
oxo-RA in vitro (RobertS and Frolik, 1979; Frolik, 1981). The degradation of 
all -!.!:l!Jl§.-RA can proceed by three differing pathways: epoxidation to all-trans-
5,6-epoxyretinoic acid, reduction in the length of the polyene side-chain, and 
loss of the terminal carboxyl carbon. In hamsters all-!.!:l!Jl§.-RA is metabolized 
to both 13-ffi-RA and all-!.!:l!.!l§.-4-oxo-RA (Fig. V.4) and that 13-ffi-4-oxo-RA 
and all-!.!:l!Jl§.-RA are metabolic products of 13-ill-RA (Fig. V.5). This was also 
the case for patients with advanced cancer who metabolized 13-ill-RA to the 
trans isomer (Goodman et al., 1982). Again, the extent to which the !rl!ill. 
isomers contribute to the teratogenicity of the 13-cis isomeric forms is 
unknown. The amount of all-!.!:l!Jl§.-RA found the human conceptus described 
above points toward the conclusion that all-!.!:l!Jl§.-RA may play a major role in 
the teratogenicity of 13-ffi- RA in humans. 
Considerably less is known regarding the metabolism of 9-ffi-retinal and 
retinyl acetate. Retinol and its esters are hydrolyzed in the gut and are 
subsequently re-esterified and transported to the liver via chylomicrons 
(Goodman, 1984). Retinaldehyde can also be reduced to retinol (the free acid 
forms cannot be reduced), esterified, and transported in the same way that 
retinol can (Goodman, 1984). In light of the fact that neither 9-ill-retinal nor 
retinyl acetate was present in maternal plasma in appreciable amounts, it is 
reasonable to assume that these two retinoids are metabolized to retinol and 
subsequently to retinyl esters, thus accounting for their high concentration in 
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the liver. Retinoic acid is a metabolic product of retinyl acetate in mice (Ito 
et a!., 1974). This is in contrast to the present results, where no retinoic acid 
was detected. It is unknown why the [3H]-Iabel associated with treatment of 
[3H]-9-cis-retinal and [3H]-retinyl acetate accumulated to a large extent in the 
lungs (Figs. V.2 and V.3). 
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CHAPTER VI 
PHARMACOKINETICS, TISSUE DISTRIBUTION, AND PLACENTAL 
PERMEABILITY OF ALL-TRANS- AND 13-CIS-~-ETHYL 
RETINIAMIDES IN PREGNANT HAMSTERS 
INTRODUCTION 
The retinamides (amide retinoid derivatives) are, in general, less toxic on 
an acute and chronic basis than free acid or esterified retinoids (Howard and 
Willhite, 1986). ~-Ethyl-13-cis- and ~-ethyl-all-~-retinamide and 
motretinid (the ethyl amide derivative of the human and animal teratogen, 
etretinate) were not teratogenic in Syrian hamsters after administration of oral 
doses up to 15 times an equimolar teratogenic dose of all-~-retinoic acid 
(all-~-RA) (Willhite and Shealy, 1984; Howard et al., 1986). Presented here 
are the results of studies on the distribution (Phase I) and pharmacokinetic 
parameters (Phase II) of ~-ethyl-13-cis-retinamide (CNERA) and its 
stereoisomer, ~-ethyl-all-~-retinamide (NERA) in pregnant hamsters. The 
present results are compared and contrasted to the results of previous 
investigators who studied the metabolic fate and tissue profiles of retinamides 
in rodents. 
MATERIALS AND METHODS 
Chemicals 
Radioactive ~-ethyl-13-ill-[ll-3H]-retinamide ([3H]-CNERA; 3.21 Ci/mmole 
in toluene) and ~-ethyl-all-~-[ll-3H]-retinamide ([3H]-NERA; 3.21 Ci/mmole 
in toluene) were obtained from SRI International , Menlo Park, CA, under the 
courtesy of the Biological and Chemical Prevention Program, Chemical and 
Physical Carcinogenesis Branch, Division of Cancer Cause and Prevention, 
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National Cancer Institute, NIH, Bethesda, MD. The radiolabeled retinoids were 
chromatographed by isocratic high performance liquid chromatography (HPLC) 
on a Radial Pak 8 C18 column with a mobile phase (2 ml/ min) of 
acetonitrile:water (8:2, vfv) and monitored at 325 nm. After integration of the 
area under the curve, the 13-ill and all-.trl!.m. isomeric preparations were 68.3 
and 82.5 percent pure, respectively. Subsequent attempts to purify the 
retinamides to greater chemical purity were unsuccessful due to the inherent 
radiolability of these retinoids, yet a final radiochemical purity of 95% was 
achieved. 
An aliquot of the radioactive retinamide in toluene was pipetted into a 
volumetric flask, and the cold retinamide 
solution was then diluted in Tween 20 
was added and dissolved. The 
(polyoxyethylesorbitan monolaurate, 
Sigma Chemical Co., St. Louis, MO), such that the final toluene concentration 
was 20%. 
Nonlabeled retinamides (CNERA, SoRI Lot No. C273-79-IJLF and NERA, 
SoRI Lot No. 9785-141-IJLF) were synthesized, characterized, and obtained as 
previously described (Willhite and Shealy, 1984). These retinoids were assayed 
by HPLC and found to be 99.8 percent pure. All retinoids were stored under 
argon at -80°C in amber glassware. 
Animals 
Animals were purchased, bred, and housed as described in chapter III. 
Treatment 
Two separate studies were performed: I) Comparative distribution and 
placental permeabilities were considered, and 2) the comparative 
pharmacokinetic parameters of the parent retinamides were evaluated. In the 
first study (Phase 1), six pregnant hamsters were given a single oral intubation 
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of either CNERA or NERA at 11.4 mg/ kg (35 ,.umol/kg; 20 )JCi/ animal) in Tween 
20 at 10:00 A.M. on day eight of pregnancy. The quantity of retinamide 
administered was a dose equivalent to 10.5 mg/ kg all-~-RA , a dose 
equimolar to the teratogenic ED5o of all-~-RA in hamsters (Willhite and 
Shealy, 1984). Blood was collected from the orbital sinus and counted for 
total radioactivity as described below. At 96 h after dosing, the dams were 
killed, and selected tissues , including the conceptus and the placenta, were 
collected, digested, and the radioactivity counted as described below. Six 
additional animals were dosed with an identical amount of tritiated compound; 
Three were killed at 4 h and three at 24 h after dosing. Tissues from these 
animals were likewise collected and the residual radioactivity determined. 
Blood and Tissue Collection Schedule 
Blood was collected from the post-orbital plexus in heparinized glass 
hematocrit tubes at 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 , and 96 h after 
intubation of the radiolabeled retinoid. Animals were killed in a saturated C02 
atmosphere at 4, 24, or 96 h after intubation. The heparinized blood was 
centrifuged immediately after collection in a microhematocrit centrifuge for 10 
min to obtain plasma. The plasma was weighed, placed into scintillation vials, 
and mixed with 200 ,ul of 70% aqueous perchloric acid (Fisher Scientific, 
Pittsburgh, PA). The plasma solution was incubated at 60°C for 4 h. The 
incubated solution was cooled to room temperature and mixed with 500 Jll of 
30% hydrogen peroxide (Fisher Scientific). The samples were subsequently 
incubated at 60°C for 4 h to decolorize. Samples were cooled to room 
temperature, and 15 ml of scintillation fluid were added (see chapter V). 
Tissues were homogenized with two volumes of distilled water, and a 150 }'l 
aliquot was taken to be processed as described above . The residual 
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radioactivity was counted in a Beckman LS 3801 scintillation counter. Tritium 
activity was quantified by the use of an external standard quench correction 
mode. 
High Performance Liquid Chromatography 
In the second phase of the study, whole blood was collected, centrifuged, 
and weighed as described above. Three hundred ul of HPLC grade methanol 
(Fisher Scientific) were added to each plasma sample (90-150 )lg) , the samples 
purged with argon and stored at -80°C, until chromatographic separations could 
be performed. Samples were thawed in a dark room at room temperature and 
then centrifuged at 10,000 x g for 30 min. The supernatant was decanted and 
filtered through 0.2 )lm microfilter (Bioanalytical Systems, West Lafayette, IN) 
at 1,000 x g for 5 min. The methanol extracted samples were analyzed by 
HPLC using a Varian Model 5000 chromatograph equipped with a Spherisorb 
ODS 5-mn column (Universal Scientific, Atlanta, GA) and a Spherex Cl8 5-cm 
X 4.6 em pre-column (Phenomonex, Rancho Palos Verdes, CA). The HPLC 
grade acetonitrile and water (J. T. Baker, Jackson, TN) were filtered (0.2 urn) 
and vacuum-degassed prior to use. Two hundred ,11! of extracted plasma were 
injected onto the column. Both retinoids were assayed at 340 nm (Varian 
Varichorm UV / VIS spectrophotometer) with acetonitrile-!% aqueous ammonium 
acetate (85:15, vf v) as the eluent with a flow rate of 1.2 ml/min. Under these 
conditions , retinamide retention times were 8.05 and 9.66 min for CNERA and 
NERA, respectively. All procedures were performed under yellow light with as 
little exposure of the samples to air as possible. The retinoids were quantified 
by peak height (Hewlett-Packard model 3390 A integrator) with an external 
standard and identified by their retention times. Plasma concentration values 
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were fitted to a curve, and the area under the curve (A UC) was calculated, as 
described in chapter V. 
RESULTS 
Distribution 
Radioactivity was distributed to all tissues sampled 4 h after a single 
dose of 11.4 mg/ kg of [3H]-CNERA (Fig. VI.l). The urinary bladder contained 
the highest concentrations of residual radioactivity/ g tissue at 4 h followed by 
the concentrations in the liver>conceptus>adrenal>perirenal fat. Radioactivity 
was rather evenly distributed among the remaining tissues at 4 h. The 
concentrations of residual radioactivity in peripheral tissues declined in a time-
dependent fashion (Fig. VI.l); at 96 h following administration of [3H]-CNERA 
hepatic tissues contained the highest concentrations of radioactivity. The ratio 
of radioactivity in the conceptus versus that in the maternal plasma was 1.5: 1 
after 4 h and was less than one after 24 or 96 h. In the placenta, 
substantially lower concentrations of radioactivity were detected; the ratio of 
activity in the conceptus versus . that in the placenta was 10.5:1 at 4 h, and 
this ratio declined to 1:1 at 24 and 96 h. 
Distribution of total radioactivity after administration of [3H]-NERA 
essentially mirrored that observed after [3H]-CNERA administration (Fig. VI.2). 
Radioactivity was concentrated primarily to the urinary bladder and the 
maternal liver at 4 h after a single oral dose of NERA and was distributed 
essentially equally to all other tissues sampled. Again, as was the case with 
CNERA, the radioactivity decreased in a time-dependent fashion. After 96 h, 
the detectable radioactivity was always greater in tissues from animals treated 
with [3H]-CNERA as compared to the activity recovered after an identical dose 
of its trans isomer. The ratio of total radioactivity in the conceptus compared 
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and 96 h (b) after dosing. Disintegrations per minute (DPM) were converted 
to nmol equivalents/ gram tissue. Ban represent S.E.M. 
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to the maternal plasma was 1:1 at 4 h after administration; the ratio of 
radioactivity in the conceptus compared to that in the placenta was 6.5: I . 
Within 96 h of an oral dose of [3H]-NERA, the ratio of total radioactivi ty in 
the conceptus to that in the placenta had declined to 1:1. It is important to 
emphasize here that these values represent those for total radioactivity . 
Pharmacokinetics 
The pharmacokinetic parameters for CNERA and NERA (Tables VI.! and 
VI.2) were obtained from nonlinear regression fittings of animal plasma 
concentration-time values (Figs. VI.3 and VI.4). The AUC for CNERA was 22.5 
percent greater than for NERA (Tables VI.I and V1.2). NERA was absorbed 
essentially instantaneously; whereas, CNERA reached a peak circulating 
concentration 1.84 h after dosing. Two elimination half -time values were 
observed for CNERA, yet only one was noted for NERA (Tables VI.l and VI.2) . 
The elimination half-time values for CNERA were 1.01 and 1.99 h for the rapid 
and slow elimination phases, respectively. The elimination t1 ; 2 for NERA was 
3.14 h. 
The plasma concentration-time curves for CNERA and NERA are shown in 
figures VI.3 and Vl.4, respectively. Both retinamides achieved mean peak 
circulating concentrations of approximately nmol/ g plasma, followed by 
exponential elimination. Detectable concentrations of either parent retinamide 
were absent from the plasma after 12 h (limit of detection = 0.6 nmol/ g plasma 
for both retinoids), yet from the measurements of total radioactivity (Figs. 
VI.3 and VI.4), unidentified metabolites of these retinoids persisted in the 
circulation for extended periods of time. The CNERA was metabolized in situ 
to NERA (Fig. VI.3), and the parent NERA was metabolized in the hamster to 
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TABLE VI.! 
PHARMACOKINETIC PARAMETERS OF CNERA 
Animal Num!:l~r 
Parameter 2 
t} /21f 0.30 0.63 
tl/2a 1.42 0.61 
tl /28 1.42 3.05 
Time to peak 
concentration (h) 2.00 1.77 
AUC (nmol.h/g) 3.57 3.96 
t1;2rr m Half-life for absorption 
t1; 2 a= Half-life for rapid elimination phase 
t 1/2 8 = Half -life for slow elimination phase 
3 
0.35 
0.99 
1.50 
1.74 
4.04 
AUC • Total area under plasma concentration vs. time curve 
Mean± SD 
0.43 ± 0.18 
1.01 ± 0.41 
1.99 ± 0.92 
1.84 ± 0.14 
3.86 ± 0.25 
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TABLE VI.2 
PHARMACOKINETIC PARAMETERS OF NERA 
Animal Number 
Parameter 2 3 Mean± SD 
tl / 2 2.40 3.98 3.04 3.14 ± 0.79 
AUC (nmol.h/ g) 2.42 2.98 3.58 2.99 ± 0.58 
t1 ; 2 - Half-life for rapid elimination phase 
AUC = Total area under plasma concentration vs. time curve 
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Figure VI.3. Plasma concentrations of retinamides following oral treatment 
with 11.4 mg/kg CNERA to day-eight pregnant hamsters. Concentrations at 
time points greater than 12 and 6 h for CNERA (+) and NERA <•>. 
respectively, were less than the analytical limit of detection (< 0.6 mnol/g) . 
Disintegrations per minute (DPM) were converted to nmol equivalents/ gram 
tissue for total radioactivity ~ following oral administration of (3H]-CNERA. 
Each point is the mean value of separate determinations of plasma obtained 
from three hamsters. 
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Figure Vl.4. · Plasma concentrations of retinamides following oral treatment 
with 11.4 mg/kg NERA to day-eight pregnant hamsters. Concentrations at time 
points greater than 12 and 8 h for NERA (+) and CNERA ~. respectively, 
were less than the analytical limit of detection (< 0.6 mnol/g). Disintegrations 
per minute (DPM) were converted to nmol equ~valents/ gram tissue for total 
radioactivity (tit) following oral administration of ( H)-NERA. Each point is the 
mean vnlue of separate determinations of plasma obtained from three hamsters. 
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its cis isomer (Fig. VI.4). Detectable amounts of all-t.rl!.!li- or 13-cis-retinoic 
acid were not generated in vivo. 
DISCUSSION 
Distribution 
The data presented in this chapter were consistent with those of Hultin 
et al. (1985) who demonstrated that N-(4-hydroxyphenyl) retinamide (4-HPR) 
concentrated in rat liver 8 h after cessation of oral dosing at 5 mg/ kg/ d for 5 
days. In mice dosed orally with 10 mg/kg N-(2-hydroxyethyl) retinamide (N-
HOERA), the parent retinoid was found in the liver, lung, fat, kidney , brain, 
heart, spleen, muscle, testes, and bladder (Kalin et al., 1982). In the case of 
the N-HOERA, the bladder had the longest elimination t1;2 of all tissues 
sampled; this was consistent with the observation made here that the 
radioactivity associated with an oral dose of CNERA or NERA was accounted 
for in large measure in the bladder. From this observation one may conclude 
that bladder tissue may reflect urinary elimination of the parent retinamide 
and/or its metabolic products. The amount of radioactivity remaining in the 
adipose tissue 96 h after dosing with [3H]-CNERA and [3H]-NERA was 5-fold 
greater for these lipophilic retinamides, as contrasted to the concentrations of 
residual radioactivity associated with administration of the more polar all-
trans-RA, 13-ill-retinoic acid, or their metabolite, all-t.rl!.!li-4-oxoretinoic acid 
(see Chapter V). Again, as stated in chapter V, it must be recognized that 
much of the radioactivity in circulation was in forms other than the parent 
compound and recognizable metabolites at the time of tissue sampling. It may 
be assumed that only a small fraction of radioactivity in tissues represents 
active chemicals. 
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Pharmacokinetics 
Kalin et al. (1982) investigated the disposition of N-HOERA in orally 
dosed mice. This retinoid exhibited a single plasma t 1/ 2 of 2.9 h. This value 
is similar to the elimination t1 ; 2 for NERA of 3.14 h (Table V.2). When N-
HOERA was administered intravenously its elimination was described best by a 
2-compartment system (Wang et al.,l980). The two elimination half-lives were 
0.3 and 1.5 h, corresponding to the rapid and slower elimination phases (Wang 
et al., 1980). Pretreatment of mice with phenobarbital, 3-methylcholanthrene, 
or N-HOERA decreased the AUC values of N-HOERA by 39, 30, and 13%, 
respectively, indicating that retinoid metabolism may be inducible (Kalin et al. , 
1984). 
Detectable amounts of all-trans-RA in plasma were not observed after 
oral treatment with either CNERA or NERA . This agrees with the data of 
Swanson et al. (1981; 1980), who observed no production of all-trans-RA in 
rats that received 4-hydroxyphenyl retinamide. The three retinamides , CNERA, 
NERA, and motretinid, are teratogenically inactive in hamsters (Willhite and 
Shealy, 1984; Howard et al. , 1986). Kochhar et al. (1987) suggested that after 
very large doses of motretinid to mice, limited biotransformation of the amide 
to the acid confers teratogenic activity. It is the free acid form of retinoids 
which binds to cellular retinoic acid-binding protein (cRABP) in hamster tissues 
(Brandes et al., 1983; personal observation, see chapter VIII). Thus, it can be 
assumed that the retinamides are teratogenically inactive, because they are not 
biotransformed to a free acid in appreciable amounts at position CIS, thereb y 
not binding with the putative receptor cRABP. 
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CHAPTER VII 
PHARMACOKINETICS, TISSUE DISTRIBUTION, AND 
PLACENTAL PERMEABILITY OF A RETINOIDAL 
BENZOIC ACID DERIVATIVE (AROTINOID 
Ro 13-7410) IN HAMSTERS 
INTRODUCTION 
The arotinoids, the third generation of retinoids, contain one or two 
aromatic rings in their cyclic end group, side-chain, or polar terminus. The 
arotinoid Ro 13-6298 (arotinoid ethyl ester) has been effective in patients who 
showed resistance to etretinate for treatment of severe generalized psoriasis 
and psoriatic arthritis (Tsambaos and Orfanos , 1983). 
arotinoids has been reviewed (Bollag, 1985). 
The pharmacology of 
The arotinoids are also the most potent hamster (Flanagan et a!., 1987) 
and mouse (Zimmermann et a!., 1985) retinoid teratogens reported to date. In 
hamsters the free acid arotinoid Ro 13-7410 (TTNPB) is at least 750 times as 
teratogenic as all-1r1!!Jj_-retinoic . acid (all-.trl!lli.-RA). The pharmacokinetics, 
tissue distribution, and placental permeability of Ro 13-7410 were determined in 
hamsters to assess the possibility whether the in vivo disposition properties of 
this chemical may account for its high toxicity. 
MATERIALS AND METHODS 
Chemicals 
The free acid arotinoid p-[(ID-2-(5,6, 7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthyi-6,7-3H2)-propenyl]-benzoic acid ([3H]-Ro 13-7410, 22.8 Ci/mmole in 
ethanol) was obtained from SRI International, Menlo Park, CA, under the 
courtesy of the Biological and Chemical Prevention Program, Chemical and 
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Physical Carcinogenesis Branch, Division of Cancer Cause and Prevention, 
National Cancer Institute , NIH, Bethesda, MD. When the radiolabeled retinoid 
was chromatographed by isocratic high performance liquid chromatography 
(HPLC) on a Radial Pak 8 C18 column, using ethanol:!% acetic acid (8:2 , v/ v) 
as the mobile phase, and monitored at 304 nm, it was found to be 88.9 percent 
pure. Nonlabeled Ro 13-7410 was received from Hoffmann- La Roche, Inc., 
Nutley, NJ. Cold Ro 13-7410 was 99% pure when assayed by HPLC at 304 nm 
using a previously described HPLC system (Willhite and Shealy, 1984). 
Animals 
Animals were purchased, bred , and treated as described in chapter III. 
Treatments 
The nonlabeled retinoid was dissolved in a small volume of reagent grade 
acetone, and the radiolabeled retinoid was pipetted into the acetone-retinoid 
solution. The acetone-ethanol-retinoid solution was then solubilized in Tween 
20 (polyoxyethylenesorbitan monolaurate , Sigma, St. Louis, MO), such that the 
final acetone or ethanol concentration did not exceed 5 percent. The retinoid 
solution was administered at a rate of 0.5 ml/ I 00 g body weight. 
Two separate studies were performed: I) The comparative distribution and 
placental permeabilities were considered, and 2) the comparative 
pharmacokinetic parameters of the parent arotinoid were evaluated. In the 
first study (Phase I), six pregnant hamsters were given a single oral intubatio n 
of 100 pg/ kg [3H]-Ro 13-7410 (35 pCi/ animal) in Tween 20 at 10:00 A.M. on 
day eight of pregnancy. Blood was collected from the orbital sinus and 
counted for total radioactivity as in chapter V. At 96 h after dosing, the 
dams were killed, and selected tissues, including the conceptus and the 
placenta , were collected, digested, and the radioactivity counted as described 
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below. Six additional animals were dosed with an identical amount of tritiated 
compound; three were killed at 4 h, and three were killed at 24 h after dosing. 
Tissues from these animals were likewise collected and the residual 
radioactivity determined. In the second study (Phase II), three animals were 
dosed with 1000 )!&/kg [3H]-Ro I 3-74 10; plasma was collected, chromatographed, 
and fractions collected for the amount of radioactivity present. 
Blood and Tissue Collecting Schedule 
Blood and tissues were collected and processed as described in chapter V. 
High Performance Liquid Chromatography 
Plasma was extracted and chromatographed as described in chapter V. 
The retinoids were eluted with acetonitrile- I% aqueous ammonium acetate 
(85: I 5) at 1.0 ml/min. One-half ml fractions were collected, processed, and 
counted in a Beckman LS 3801 liquid scintillation counter. Nonradioactive Ro 
13-7410 was used to determine the retention position of the parent molecule . 
Tritium activity was quantified in DPMs via the use of an external standard 
quench correction mode. 
RESULTS 
Distribution 
Radioactivity was evenly distributed to all sampled tissues, except the 
liver, by 4 h after a 100 JJ&/ kg dose of [3H]-Rol3-7410. The liver contained 
the highest amount of radioactivity (2800 pmol eq./ g tissue) followed by the 
conceptus (580 pmol eq./ g tissue) (Fig. VII.J ). The ratio of radioactivity in 
the conceptus versus the maternal plasma was 5.4:1 at 4 h. At 24 and 96 h 
the ratio of radioactivity in the conceptus versus the maternal plasma was less 
than one. The amount of radioactivity in tissues declined in a time-dependent 
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Figure Vll.l . Distribution of radioactivity in pregnant hamsters following oral 
administration of 100 )Jg/kg [3H]-Ro 13-7410. Tissues were sampled 4 (•). 24 
(Z:Z), and 96 h (EI) after dosing. Disintegrations per minute (DPM) were 
converted to pmol equivalents/ gram tissue. Bars represent S.E.M. 
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fashion with the most radioactivity remaining in the liver at 96 h (400 pmol 
eq./g tissue) (Fig. VII. !). Ninety-six h after dosing with 100 pg/ kg [3H]-Ro 
13-7410, the liver contained at least 15-fold more radioactivity than any other 
sampled tissue. 
The distribution of radioactivity in liver, conceptus, placenta, and uterus, 
following administration of either 100 or 1000 )lg/ kg [3H]-Ro 13-7410, is shown 
in figure VII.2. As was the case of a 100 ,ug/ kg dose, the liver contained the 
most radioactivity 24 h after a 1000 pg/ kg dose , having at least 36 times as 
much radioactivity as the conceptus , placenta, or uterus (Fig. VII.2). 
Pharmacokinetics 
Pharmacokinetic parameters of Ro 13-7410 (Table V11.1 ), following a 1000 
)Jg/ kg oral dose, were generated as described in chapter V. The retinoid 
accumulated in the plasma, reaching peak circulating concentrations at 3.37 h 
(Fig. VII.3) . Elimination proceeded biexponentially with elimination half-lives 
of 1.52 and 2.45 h, corresponding to the rapid and slow elimination phases. 
The AUC was 1634.4 pmol.h/ g. An unknown more polar metabolite (based on its 
retentivity) was present at 0.5 h. This metabolite reached its peak at 12 h, 
comprising 92% of the total radioactivity present in the plasma. 
DISCUSSION 
Distribution 
Arotinoids are at least 750-fold more potent teratogens than all-trans-RA 
in hamsters (Flanagan et a!., 1987). If pharmacokinetics alone are responsible 
for the increased teratogenic potency, at least a 750-fold increase in the 
concentration of arotinoids in the embryo would be required; however, this was 
not observed based on radioactivity (Figure VII. I). The increased teratogenic 
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TABLE VII.! 
PHARMACOKINETIC PARAMETERS OF ROIJ-7410 
FOLLOWING A 1000 pg/ kg DOSE 
Animal Number 
Parameter 2 
tt ; 2" 2.11 1.79 
B 
tl / 2 2.1 I 1.79 
Time to peak 
concentration (h) 3.18 5.00 
AUC (pmol.h/ g) 1698.34 1712.14 
t1 ; 2 "=Half-life for rapid elimination phase 
tt;/= Half-life for slow elimination phase 
0.65 
3.45 
1.93 
1492.84 
AUC =Total area under plasma concentration vs. time curve 
Mean± SD 
1.52 ± 0.77 
2.45 ± 0.88 
3.37 ± 1.54 
1634.44 ± 122 .8 
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Figure Vll.3. Plasma concentration of Ro 13-7410 following oral administration 
of 1000 pg/kg [3H)-Ro 13-7410 to day-eight pregnant hamsters. Plasma was 
assayed by HPLC and 0.5 ml fractions were collected and counted for 
radioactivity corresponding to the retention time of Ro 13-7410 <-!. Total 
radioactivity in plasma following a single oral dose of 100 ~or 1000 (~ 
}Jg/kg [3H)-Ro 13-7410. Disintegrations per minute (DPM) were converted to 
pmol or pmol equivalents/ gram plasma. 
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potency of arotinoids must be, in part, dependent on the retinoid's affinity for 
its receptor. Creech-Kraft et al. (1987) have demonstrated that all - trans-RA 
accumulates more than 13-ill-RA versus the maternal plasma, thus providing an 
explanation of the more potent teratogenic activity of all-trans-RA. Nau and 
Scott (1986) hypothesized that this concentration phenomenon is due to pH 
differences in embryo and maternal plasma. The pH of the embryo was found 
to be 0.4 pH units higher in the embryo thereby trapping weak acids . In the 
hamster, all-trans-RA is twice as potent a teratogen as 13-ill-RA (Willhite and 
Shealy, 1984). Pharmacokinetic differences may play a role in their differing 
potencies. However, in the mouse limb bud (Kwarta et al. , 1985) and in chick 
wing buds (Maden and Summerbell, 1986) all-!Ill.!ll-RA serves as a better ligand 
for cellular retinoic acid-binding protein (cRABP) than 13-cis-RA. In the 
mouse limb bud, all-trans-RA had a 315-fold greater affinity for cRABP than 
13-cis-RA (Kwarta et al., 1985). The in vivo accumulation of all -~-RA in 
mouse neural tissues is saturable and competitive, indicating the accumulation 
is dependent upon a receptor (Dencker et al., 1987). It must be recognized 
that much of the radioactivity in circulation was in forms other than the 
parent compound and recognizable metabolites at the time of tissue sampling. 
It may be assumed that only a small fraction of radioactivity in tissues 
represents active chemicals . 
Pharmacokinetics 
Pharmacokinetic reports of arotinoids are scarce, because very low doses 
(0.05-0.1 mg) are required for biologic activity and because the techniques for 
identifying low (pg) concentrations of arotinoids have not been developed . 
One man dosed with 0.1 mg Ro 13-6298 had circulating levels of 807 and 630 
pg/ ml after 3 and 4 h, respectively (Lambert et al., 1985). Even though 
128 
comparisons based on one observation may mean little, this compares to a peak 
circulating level of 69.7 ng/g plasma in the hamster following a I mg/kg dose. 
The elimination half-times for Ro 13-7410 were 1.52 and 2.45 h for the 
rapid and slower phases, respectively. These t 1 ; 2s are shorter than those 
observed for either 13-ill-RA or all-1TI!.!li-4-oxo-RA (chapter V) or for either 
retinamide (chapter VI). The appearance and persistence of a more polar 
metabolite in the plasma is consistent with the metabolic patterns observed for 
all-1TI!.!li-RA and 13-ffi-RA (chapter V). The extent to which this unidentified 
metabolite may contribute to the teratogenic potency of Ro 13-7410 is 
unknown. The pharmacokinetic disposition and distribution patterns of Ro 13-
7410 may not account for its high teratogenicity, as compared with all-1TI!.!li-RA. 
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CHAPTER VIII 
CORRELATION OF BINDING AFFINITIES OF RETINOIDS TO cRABP 
AND THEIR TERATOGENIC POTENCY IN HAMSTERS 
INTRODUCTION 
Cellular retinoic acid-binding protein (cRABP) has been identified in all 
fetal rat tissues (except serum, where all-lill.M-retinoic acid [all-lill.M-RA] is 
transported bound to plasma albumin), in the intestine, brain , and kidney of 
the fe tal rabbit , in limb buds of the mouse, and in embryonic chick skin 
(Chytil and Ong, 1983; Rainier et al., 1983; K warta et al. , 1985; Sani and Hill , 
1974). In the mouse limb bud, all-lill.M-RA has a 315-fold greater affinit y 
with cRABP than 13-cis-retinoic acid (13-ffi-RA) (Kwarta et al., 1985). 
However, it is unknown if bind ing with cRABP is obligatory for teratogenic 
ac ti vity . 
Retinoids vary over several orders of magnitude in their abilities to 
induce teratogenesis in hamsters (Howard and Willhite, 1986; Howard et al. , 
1987; chapter IV.) To assess the role of cellular retinoic acid-binding protein 
(cRABP) in retinoid-induced teratogenesis , the ability of these retinoids to 
displace high-specific activity [3H]- all-trans-retinoic acid from cRABP was 
investigated. 
MATERIALS AND METHODS 
Chemicals 
The retinoid all-lill.M-retinoic acid (all-trans-RA) was purchased from 
Sigma (St. Louis, MO). lsotretinoin (13-ffi-retinoic acid, 13-ffi-RA) was 
purchased from Kodak (Rochester, NY). The retinoids Ro 12-4824 , Ro 10-1670, 
Ro 13 -7410, Ro 15-0778, Ro 8-8717, Ro 10-9359, and Ro 11-1430 were gifts of 
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Hoffmann-LaRoche (Nutley, NJ). The retinoids SRI 5631-96, SRI 4657-47, and 
SRI 7167-67 were obtained from SRI International (Menlo Park, CA). The 
retinoids N-ethyl-all-trans-retinamide (NERA) and N-ethyl-13-ill-retinamide 
(CNERA) were obtained from SoRI (Birmingham, AL). 
greater than 95% pure by reversed phase HPLC. 
All retinoids were 
Bovine serum albumin (BSA) and myoglobin were purchased from Sigma. 
Norit charcoal and HPLC grade water were obtained from Fisher Scientific 
(Pittsburgh, PA). Dextran T -70 was purchased from Pharmacia (Uppsala, 
Sweden). Radioactive all-ll:l!lli.-RA ([3H]-all-ll:l!lli.-RA, 11,12-3H2-retinoic acid; 
52.5 Ci/ mmole; 98.8%) was purchased from NEN Research Products (Boston, 
MA). The 3-(N-morpholino)-propanesulfonic acid (Mops) was purchased from 
Sigma. 
Preparation of Cytosol 
Timed-pregnant hamsters were purchased from the Charles River Breeding 
Laboratories (Wilmington, MA). Animals were killed in excess C02. Whole 
day-12 hamster fetuses or day-eight hamster embryos were collected and placed 
in a centrifuge tube containing an equal volume of ice cold buffer ( 10 mM 
Mops, 10 mM KCl, 2 mM 2-mercaptoethanol, 1 mM EDTA, pH 7.5). Tissues 
were homogenized on ice for 1 min using a Tissue Tearor tissue homogenizer 
(Biospec Products, Bartlesville, OK) on setting 4. The homogenate was 
centrifuged at 10,000 x g (4°C) for 0.5 h, and the supernatant was 
subsequently centrifuged for one h at 105,000 x g in an ultracentrifuge 
(Beckman SW 41 Ti rotor). The protein concentration of the supernatant was 
determined using the Pierce protein assay reagent (Pierce, Rockford, IL) using 
BSA as the standard. Cytosol was frozen at -80° C until use. 
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Labeling of Cellular Retinoic 
Acid-Binding Protein 
Frozen cytosol was thawed at 4° C overnight. The cytosol was diluted 
with fresh tissue homogenization buffer to a final protein concentration of 1.04 
mg/ ml. An aliquot of 480 )II of diluted cytosol was pipetted into incubation 
tubes. Ten ,ul of [3H]-all-trans-RA (100 nM, 2.63 ..uCi) were added to each 
tube. An additional 10 ..ut of ethanol were added with or without a 200-fold 
molar excess of aii-~-RA to individual tubes. The retinoid-protein mixture 
was incubated for 12 h overnight at 4° C in the dark. The incubation was 
stopped by the addition of 100 ..ul of dextran-coated charcoal (2.5% charcoal , 
0.25% dextran). The mixture was vortexed immediately and at 2 min intervals 
for 10 min . The charcoal was sedimented at 1000 x g for 10 min and the 
supernatant subsequently filtered through a 0.45-).lm filter to remove all traces 
of charcoal prior to chromatography. Handling of all retinoid solutions was 
done under yellow light. 
High Performance Size Exclusion Chromatography 
Methods for high performance size exclusion chromatography (HPSEC) are 
described by Rainier et a!. {1983). A Varian Model 5000 liquid chromatograph 
equipped with a SOTAPhase GF-200 , 20 nm, 10 ,um, 7.1 X 300 mm column and a 
SOTAPhase GF-200, 7.1 X 75 mm guard column (Rainin, Emeryville, CA) was 
used. The elution buffer contained 10 mM Mops, 2 mM 2-mercaptoethanol, 20 
mM potassium acetate, I mM EDTA, pH 7.5 . The buffer was filtered through a 
0.2-,um filter prior to use. Buffer was prepared fresh daily. The eluent was 
pumped at a flow rate of 1.0 ml/min and monitored at 280 nm using a Varian 
Varichrom UV /Visible spectrophotometer. Two hundred .ul of filtered 
supernatant were injected onto the column. Myoglobin and BSA were used to 
as standards. The elution position of [3H]-RA-cRABP was determined by 
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collecting 0.5-ml fractions of the eluent. Fractions were counted in 4 ml of 
scintillation cocktail in a Beckman LS 3801 liquid scintillation counter. DPMs 
were quantified via an external standard mode. 
Saturation Analysis 
Day-12 hamster fetus cytosol (500 ug protein in 480 ul) was incubated in 
the dark at 4° C for 12 h with 10 ul [3H]-all-~-RA (1-465 nM in 95% 
ethanol) and I 0 ul of ethanol. The incubation was terminated with the 
addition of I 00 ul ice-cold dextran-coated charcoal (2.5% charcoal, 0.25% 
dextran). Samples were centrifuged and filtered as described above. One-half 
ml fractions were collected and counted as described above. Specific binding 
was calculated by the amount of radioactivity in the 10-11 ml fraction (Fig. 
VIII.I ), and a Scatchard analysis (Scatchard, 1949) was performed. 
Competitive Binding Assay 
Competition studies were performed by incubating protein samples (500 ug 
protein in 480 ul fresh homogenization buffer) at 4° C for 12 h with 100 nM 
[3H]-all -~-RA (2.63 uCi) in 10 ul ethanol and 10 ul ethanol containing from 
0.1 to 200-fold molar excess of unlabeled retinoid analogs . The incubation 
mixtures were treated with dextran-coated charcoal, centrifuged, filtered , 
chromatographed, and counted as described above. 
RESULTS 
Presence of cRABP 
The presence of cRABP was identified first in day-eight hamster embryos. 
The amount of cRABP present was 2.2 ± 0.05 pmoles/ mg protein . Day-12 
hamster fetuses contained 8.9 pmolesj mg protein. When incubated with 100 nM 
[3H]-all-~-RA and separated by HPSEC, peaks of radioactivity were 
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Figure VIII.!. High performance size exclusion chromatographic analysis of day-
12 hamster fetus cRABP. Day-12 hamster fetus cytosol was incubated with 100 
nM [3H]-all-1.!:i!.!!§.-RA in the absence (G) or presence (+) of a 200-fold molar 
excess of unlabeled all-l.!:i!.!!§.-RA. The arrow indicates the elution volume of 
myoglobin . Aliquots (200 ul) of dextran-treated charcoal assay mixtures were 
analyzed. 
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observed (Fig. VIII.l ). The first peak of radioactivity was not displaced by 
incubation with 200-fold molar excess unlabeled all-trans-RA. The peak that 
eluted at the same elution volume as myoglobin (molecular mass=l7 ,000) was 
abolished by incubating with 200-fold molar excess cRABP (Fig. VIII.l ). This 
is evidence for the presence of a specific binding protein for retinoic acid. 
Saturation Analysis 
Scatchard plots of one set of data from day-12 hamster fetus cRABP 
yielded an apparent dissociation constant (Kd) of 12.7 nM, and the total 
specific binding capacity was estimated to be II pmoles cRABP I mg protein 
(Fig. VIII .2). 
Comoetitive Binding Assay 
The relative binding affinities of various retinoids to day-12 hamster 
fetus cRABP were determined in competition experiments. First, the cytosol 
was incubated with 100 nM (3H]-all-!!l!ru.-RA and 200-fold excess of each of 
the 14 retinoids (Table VIII.l). Etretinate (Ro 10-9359), NERA, CNERA , 
motretinid (Ro 11-1430), SRI 7167-67, Ro 8-8717, and Ro 15-0778 did not 
displace any [3H]-all-trans-RA from cRABP. Slight competition was noted for 
SRI 4657-47 at 200-fold molar excess. The retinoids Ro 13-7410, Ro 10-1670 
(the free acid of etretinate), Ro 12-4824 (all-lJ:ID!j-4-oxo-retinoic acid), 13-ffi-
RA, and SRI 5631-96 displaced [3H]-all-!!l!ru.-RA. Varying the amount of free 
ligand (competitor) to the assay displaced different amounts of (3H]-all-!!l!ru.-
RA, and concentration to displace 50% of the label from the protein (DCsol 
was calculated (Fig. VIII.3 and VIII.4). The calculated DCso for each retinoid 
is shown in table VIII. I. 
The retinoids may be ranked according to their ability to displace [ 3H]-
all-trans-RA from cRABP: all-!!l!ru.-RA = Ro 12-4824 > Ro 13-7410 >SRI 5631-
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TABLE VIII.l 
MOLECULAR STRUCTURES AND BINDING AFFINITIES OF RETINOIDS 
Slli.UC11JRE = oc,.cMJ 
~co,H olll·t!:!!!!·RA 4.7.tl0"1 
~O,H 13-£1!-RA 2.6.tl0• 
~CO,H Roi2-4S24 J.•b]()"l 
0 
~CO,H Rol0.1670 6.4xhl' 
CH~O 
~co,H 
SRl5<i31·96 2.2.dO" 
WWCO,H 
Ro!J-7410 6.2..1.10"1 
~~·· Rois-<m8 NC SR146.S7-47 NC 
~CO,H Ro3-8717 NC 
~co,c,H, Ro!0-9359 NC 
CH30 
~CONHC,H, Roll-1430 NC 
CH30 
~CONHC,H, NERA NC 
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Figure Vlll .3 . Competition of retinoid analogs w1th day-12 hamster fe tus 
cRABP. The d isp lacement of [3H]-all-!rl!.M-RA occurred with increasing 
concentratio ns of all - trans- RA <•l. Ro 13-74 10 (til , or 13-cis-RA Ill). 
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Figure VIII.4. Competition of retinoid analogs with day-12 hamster fetus 
cRABP. The displacement of [3H]-all-trans-RA occurred w1th tnc1easing 
concentrations of SRI 5631-96 (S ), Ro 12-4824 (D) , or Ro 10-1670 <•>· 
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96 > 13-cis-RA > Ro 10-1670. Those with little or no affinity include SRI 
4657-47, SRI 7167-67, NERA, CNERA, Ro 15-0778, Ro 8-8717 , Ro 11-1430, and 
Ro 10-9359. 
DISCUSSION 
Cellular retinoic acid-binding protein (cRABP) exists in the embryonic 
day-eight hamster, as well as in the day-12 hamster fetus. The protein has a 
high degree of specificity for all-.t!l!ill.-RA. The saturation analysis plot was 
linear which is indicative of the exsistence of a single receptor site . This was 
also the conclusion reached by Kwarta et al. (1985) and Maden and Summerbell 
(1986). 
From competition study data, binding with cRABP was dependent on a 
free acid at position CIS. Retinoids without a polar terminus (Ro 15-0778) or 
those retinoids that contain ester or amide substitutions at C 15 failed to 
displace [3H]-all-.t!l!ill.-RA. This is consistent with reports of cRABP isolated 
from chick wing buds (Maden and Summerbell, 1986) and from hamster tissues 
(Brandes et al., 1983). A 15-fold difference in the binding affinities of various 
retinoids occurred. Ro 13-7410 had approximately 2-fold lower affinity with 
cRABP than all-.t!l!ill.-RA. However, Ro 13-7410 is at least 750 times more 
teratogenic in the hamster than all-.t!l!ill.-RA. The ethyl ester congener of 
etretin is twice as potent a teratogen in the hamster as all-trans-RA (Williams 
et al., 1984). Etretin served as the poorest ligand with cRABP. The primary 
metabolite of all-trans-RA in hamsters is all-.t!l!ill.-4-oxoretinoic acid (Ro 12-
4824) (Frolik et al., 1979; 1980; Frolik, 1981). It bound with cRABP just as 
well as all-trans-RA, and it is as teratogenic as all-.t!l!ill.-RA (chapter IV). 
lsotretinoin (13-lli-RA) bound to cRABP with approximately 10-fold lower 
affinity than all-.t!l!ill.-RA, and it is one-half as teratogenic in hamsters as all-
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trans-RA (Willhite and Shealy, 1984). This compares with the data of Maden 
and Summerbell (1986), who found that in the chick wing bud, Ro 13-7410 has 
2-fold greater affinity with cRABP than all-!.!:l!.!1l.-RA, and 13-lli-RA had a 6-
fold greater affinity with cRABP. Etretin (Ro 10-1670) was the poorest ligand 
for cRABP, having an 18 - fold lower affinity with cRABP. The present results 
contrast with those of Kwarta et al. (1985), who demonstrated that, in the 
mouse limb bud cRABP, all-!.!:l!.!1l.-RA had a 315-fold greater affinity than 13-
cis-RA. 
A structure-activity relationship resulted, such that retinoids which bound 
with cRABP were teratogenic, and retinoids which failed to bind with cRABP 
were teratogenically inactive (unless they are esters). However, no apparent 
correlation emerged between in vivo teratogenic potency and the observed 
oc5o· 
Petkovich et al. (1987) have recently demonstrated that a nuclear receptor 
for retinoic acid exists and that it belongs to a family of nuclear receptors 
similar to steroid receptors. It has been shown that [3H]-all-trans-RA is 
translocated into the nucleus (Chytil and Ong, 1979) prior to differentiation. 
Retinoids may be modifying gene expression with a mechanism analogous to 
steroid receptor interactions (Pratt, 1984), whereby retinoic acid binds to 
cRABP, and the cRABP-retinoic acid complex subsequently is transported into 
the nucleus, where it can modify gene expression (Sporn and Roberts, 1983 ). 
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CHAPTER IX 
SUMMARY AND CONCLUSIONS 
Retinoids possess a high degree of biologic activity both in vivo and in 
vitro. Orally administered retinoids induce toxic side-effects, the worst of 
which is the severe terata that can occur if retinoid treatments occur during 
the first trimester of gestation. In an attempt to broaden the therapeutic 
index of retinoids, many investigators have synthesized several thousand 
retinoid analogs. From this research, I have demonstrated that consistent 
patterns of retinoid biologic activity emerge between cultured cell, cell-free 
assay systems, the hamster tracheal organ culture , and teratogenic potency. 
Thus, it appears that retinoids that possess therapeutic value also possess 
teratogenic activity. 
The teratogenicity of retinoids containing either tetramethylated tetralin 
(Ro 13-6307 or Ro 13-2389) or tetramethylated indane (Ro 13-4306) ring 
systems substitutions was compared with the teratogenic potency of all-l!:llm-
retinoic acid. Single oral doses, administered to Syrian Golden hamsters at 
10:00 a.m. on day 8 of gestation, induced a syndrome of malformations identical 
to that induced by treatment with all-lJ:llm-retinoic acid. These retinoids 
failed to induce signs of maternal hypervitaminosis A at doses associated with 
a significant teratogenic response. The tetramethylated tetralin retinoids and 
indane retinoid were 18 and 2.4 times as embryotoxic on a molar basis, 
respectively, as all-l@M-retinoic acid. 
the side-chain restricted polyene 
hydrophobic plane of the chain. 
Introduction of a supplementary ring in 
chain flexibility and maintained the 
The present results are consistent with 
previous studies showing that the presence of or biotransformation to a free 
acid congener was necessary for retinoid teratogenic activity in hamsters and 
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that increasing conformational restriction of acidic retinoids increased 
teratogenic activity. 
The teratogenic potency of congeners of all-lrn!li-retinoic acid (all-
lrn!li-RA) containing modifications or substitution of the naturally occurring 
8-cyclogeranylidene ring was determined in Golden hamsters and compared to 
that of all-lrn!li-RA. 
phenyl (Ro S-S717), 
The following ring-modified retinoids were evaluated: 
fury! (Ro S-9750) , 4-methoxy-2,3,6-trimethylphenyl (Ro 
21-6667), which also has a thiomethylene group in place of the lrn!li-S ,9 
double bond of the etretin side-chain, 4-hydroxy- 2,3,6-trimethylphenyl (Ro ll-
476S), 2-chloro-3,6-dimethyl-4-methoxyphenyl (Ro 12-0995), 2-(1-
methoxyethyl)-5,5-dimethyl-1-cyclopentenyl (Ro 10-1770), 2-acetyl-5 ,5-
dimethyl-1-cyclopentenyl (Ro S-7699), and I 0, 11-epoxy- I I ,11-dimethyl (juvenile 
hormone III), which also has the bonds saturated, corresponding to the 7 ,S-
and I 1,12- double bonds of the retino id skeleton. The retinoids Ro 12-4S24 , 
Ro 12-4S25, SRI 2712-24 had C4-keto, CIS-hydroxyl, and CIS-methyl 
substituents, respectively. Motretinid (Ro 11-1430) had both 4-methoxy-2,3,6-
trimethylphenyl ring and ethyl amide polar group modifications. Single oral 
retinoid doses administered to pregnant dams at 10:00 A.M. on day eight 
neither induced signs of hypervitaminosis A nor induced weight loss in any of 
the treated groups. Teratogenically active retinoids induced a malformation 
syndrome identical to that induced by all-lrn!li-RA. At retinoid doses that 
were associated with malformations in all of the fetuses, embryolethality 
remained near that of vehicle-treated controls. The phenyl retinoid Ro S-
S717 was embryolethal but was not teratogenic. The ethyl amide derivative of 
the human and animal teratogen etretinate, motretinid, was teratogenic only 
at the highest dose administered, 350 mg/kg . The retinoids Ro 12-4S24, Ro 
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at the highest dose administered, 350 mg/ kg. The retinoids Ro 12-4824, Ro 
12-4825, Ro 8-7699, and SRI 2712-24 were as potent as all-!!:i!M-RA. The 
chlorine-substituted retinoid, Ro 12-0995, was 6-fold more teratogenic than all-
!!:i!M-RA, and the cyclopentene retinoid, Ro 10-1770, was 19 times more potent 
than all-!!:i!M-RA. The retinoids with fury! or epoxy group substitution for 
the cyclohexenyl ring were devoid of teratogenic activity up to equimolar doses 
of 75 mg/ kg of all-!!:i!M-RA, and Ro 21-6667 was teratogenically inactive at a 
dose equivalent to 150 mg/ kg of all-~-RA . Major modifications of the 
e-cyclogeranylidene ring can be made without altering teratogenic activity. The 
ring need not be six-membered and can have decreased lipophilicity through 
the incorporation of polar groups compared to retinoic acid but must have 
sufficient lipophilic substituents to provide the necessary mass for interaction 
with the retinoid receptor. The present results indicate that those ring-
modified retinoids having cell differentiating activity also show teratogenic 
activity. 
Additionally, have investigated several aspects (pharmacokinetics and 
retinoid affinity with cellular retinoic acid-binding protein, cRABP) in an 
attempt to explain the large variation of retinoid-induced teratogenic potency. 
In distribution studies with all-!!:i!M-RA, 13-ill-RA, all-!!:i!M-4-oxo-RA, 9-ill-
retinal, retinyl acetate, CNERA, NERA, and Ro 13-7410, the radiolabel 
associated with each retinoid crossed the placenta and entered the conceptus. 
These retinoids, or a metabolite of these retinoids, is present in the conceptus. 
Thus, the teratogenically inactive CNERA and NERA (and/or their metabolites) 
reach the target tissue, but fail to induce a teratogenic response . 
The pharmacokinetic disposition and distribution properties of all-!!:i!M-
RA, 13-ill-retinoic acid, all-!!:i!M-4-oxoretinoic acid, 9-ill-retinal, and retinyl 
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acetate were determined in pregnant hamsters. The retinoid all-trans-RA was 
eliminated rapidly from the maternal blood (elimination t1 ; 2 = 0.5 h) and was 
metabolized to its isomer, 13-cis_-retinoic acid, and to all-trans-4-oxoretinoic 
acid , both of which persisted in higher amounts and for longer periods of time. 
Isotretinoin (13-ill-retinoic acid) exhibited a longer elimination half -life of 
4.41 h; it was metabolized to the ~ isomer and also to 13-cis-4-oxoretinoic 
acid . The all-trans-4-oxoretinoic acid persisted in the maternal plasma for 24 
h and had an elimination half -life of 5.57 h. No amount of parent compound 
of either 9-cis_-retinal or retinyl acetate was detected in the maternal plasma. 
The free acid retinoids were distributed to all sampled tissues; the lowest 
amount of radioactivity was found in the perirenal fat . The aldehyde and 
acetate ester congeners were distributed primarily to the lung and li ver with 
lesser amounts present in remaining tissues sampled. 
The pharmacokinetic parameters of ~-ethyl- I 3-cis_-retinamide (CNERA) and 
~-ethyl-all-trans-retinamide (NERA) were determined in pregnant hamsters. 
CNERA was eliminated from the maternal plasma following two separate 
constants; whereas, NERA was .eliminated exponentially. Both CNERA and 
NERA were biotransformed to NERA and CNERA, respectively, but neither was 
metabolized to a free acid in appreciable amounts. The bioavailability of the 
retinamides was 10-fold lower than for free-acid retinoids. The retinamides 
are teratogenically inactive, apparently because they are not biotransformed to 
a free acid at CIS. 
Arotinoid Ro 13-7410 was investigated to determine its in vivo 
pharmacokinetic profile in pregnant hamsters . The arotinoid exhibited two 
elimination half -times of 1.52 and 2.45 h, corresponding to the rapid and 
slower elimination phases, respectively. Ro 13-7410 was distributed to all 
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sampled tissues by 4 h with the highest concentrations occurring in hepatic 
tissues. Peak concentrations of 200 pmol/g plasma were observed 3.5 h 
following a dose of 1000 ug/ kg. A polar metabolite appeared at 0.5 h and 
reached peak circulating concentrations at 12 h after dosing. The 
pharmacokinetic disposition of Ro 13-7410 may not account for its high 
teratogenic potency. 
All-lrl!.rn.-RA is twice as potent a teratogen as 13-l:ii-RA; however, all-
lrl!.rn.-RA's elimination half-life, area under the curve, and peak plasma 
concentration were less than or equal to the same parameters observed with 
13-cis-RA. No amount of parent 9-cis-retinal was detected in the maternal 
plasma, yet it is one-half as teratogenic as all-lrl!.rn.-RA. The retinoid Ro 13-
7410 had elimination half-lives similar to those observed for the retinoids 13-
ill-RA and all-tmM-4-oxo-RA, yet it is 1000-fold more potent teratogen than 
all-!mru.-RA. Therefore, an obvious correlation between teratogenic potency . 
peak plasma concentration, area under the curve, or elimination half -life was 
not observed. 
The binding affinities of 14 retinoid analogs were determined with day-12 
hamster fetus cellular retinoic acid-binding protein (cRABP) by utilization of 
high-specific activity [3H]-all-lrl!.rn.-RA. High performance size exclusion 
chromatography (HPSEC) was employed for isolation of cRABP. Retinoids that 
failed to compete with (3H]-all-!mru.-RA were also teratogenically inactive, 
with the exception of the ethyl ester of etretin, etretinate, which does 
compete. Of retinoids that did compete, all-.l.rllill.-RA = Ro 12-4824 < Ro 13-
7410 < SRI 5631-96 < 13-ill-RA < etretin. Binding with cRABP may be 
essential for teratogenic activity, but binding affinities of retinoids with 
cRABP do not correlate with their in vivo teratogenic potency. 
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A putative intracellular receptor for retinoids is cellular retinoic acid-
binding protein (cRABP). If cRABP is the ultimate receptor that mediates 
retinoid-induced teratogenicity, a structure-activity relationship should exist 
between retinoid binding affinities with cRABP and the retinoids' in vivo 
teratogenic potency. I determined the binding affinity of a series of retinoids 
with cRABP. Retinoids that were teratogenically inactive (i.e., amides, 
retinoids lacking a polar terminus, or retinoids without sufficient ring 
substituents) failed to bind with cRABP. Retinoids that bound with cRABP 
were also found to exhibit teratogenic activity. However, the binding affinities 
of retinoids that bound with cRABP varied by 15-fold, compared with a 2,000-
fold variation for teratogenic activity. Subsequently, retinoid binding with 
cRABP may be an obligatory step in retinoid-induced teratogenesis. 
In view of the fact that retinoids are metabolized (i.e., isomerized and/or 
oxidized) to other teratogenic forms, the total amount of active retinoid 
present in the target tissue needs to be assessed. Further studies evaluating 
this aspect of retinoid-induced teratogenicity should be initiated. Additionally, 
in vivo competition studies utilizing displacement of radiolabelled all-!.rJ!.M-RA 
from target tissues with other teratogenically active retinoids may provide this 
important structure-activity relationship. This information would enable 
researchers to determine if retinoid-induced teratogenicity is receptor-mediated. 
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APPENDIX 
MOLECULAR STRUCTURES OF RETINOIDS USED IN 
CHAPTERS V, VI, AND VII 
3 [10,11- H2]-all-trans-
retinoic acid 
3 [11- H ]-13-~-
retinoic acid 
3 [ 11- H ]-all-trans-
4-oxo-retinoic acid 
[11- 3H]-9-cis-retinal 
[10,11 - 3H2]-retinyl 
acetate 
[11- 3H]-~-ethyl-all-
trans-retinamide 
[11 - 3H]-~-ethyl-13-
cis- ret inarnid e 
~COOH ~ " 
0 
'H~COOH 
'H~--
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